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ABSTRACT 
Lei Miao: The Role of Tumor Desmoplasia in Nanoparticle Delivery of Drugs and Genes 
(Under the direction of Leaf Huang) 
In desmoplastic tumors, stroma cells capture nanoparticles (NPs), preventing them from 
reaching tumor cells, resulting in compromised anti-tumor efficacy. This dissertation focuses on 
understanding the basis role of tumor associated fibroblasts (TAFs), one of the major stroma cells 
constituting desmoplasia, in NP delivery and tumor resistance, as well as proposing strategies to 
overcome the TAF-elicited barriers and improve efficacy.  
While the capture of therapeutic NPs in TAFs interferes tumor-stroma crosstalk and inhibits 
tumor progression, we found that the chronic exposure of NPs paradoxically induced the secretion of 
survival factors (e.g., Wnt16) from the damaged TAFs, facilitating tumor proliferation and metastasis. 
Therefore, we proposed the delivery of siRNA against Wnt16 to TAFs via the off-target capture, to 
downregulate this survival factor. The priming of damaged fibroblasts could synergize with a 
nanoformulation of cisplatin, and benefit the treatment of a desmoplastic bladder cancer xenograft 
(UMUC3/3T3). Since the off-target delivery of NPs have been verified, we further utilized the same 
rationale to generate a group of tumor-suppressive TAFs through transfecting TAFs with a plasmid 
encoding highly secretable TNF-related apoptosis-inducing ligand (sTRAIL). The production of 
sTRAIL from TAFs bypassed the stroma barrier and resulted in efficient killing of tumor cells.
Furthermore, we also proposed a stroma depletion method via combination therapy of 
cisplatin NPs and gemcitabine NPs. This combination was not only detrimental to tumor cells, but 
induced superior apoptosis in TAFs of the UMUC3/3T3 model. To ensure the sufficient synergy, we 
further designed a nano-formulation with ratiometric co-loading and co-delivery of these two 
regimens. The design of converting these two drugs with totally different physicochemical properties 
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into nano-cores with similar hydrophobic surface and particle size, allows for their simultaneously 
and ratiometric loading in a single PLGA NPs. This combinatory NPs showed potent anti-cancer 
efficacy compared to each regimens in separate NPs. 
In summary, the stroma modulating strategies proposed in the current dissertation provide 
new paradigms for the treatment of desmoplastic tumors. Combined with cancer immunology, a more 
prolonged and efficient outcome can be anticipated. The ratiometric combination nano-platform also 
provides a promising approach for encapsulating agents with different physicochemical properties.  
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 CHAPTER 1: STROMAL BARRIERS AND STRATEGIES FOR THE DELIVERY OF 
NANOMEDICINE TO DESMOPLASTIC TUMORS1 
1.1 Summary 
Nanoparticles (NPs) based delivery formulations have become a leading delivery strategy for cancer 
imaging and therapy. The success of NP-based therapy relies heavily on their ability to utilize the 
enhanced permeability and retention (EPR) effect and active targeting moieties to their advantage. 
However, these methods often fail to enable a uniform NP distribution across the tumor, and lead to 
insufficient local concentrations of drugs. Oftentimes, this heterogeneous drug distribution is one of 
the primary reasons for suboptimal treatment efficacy in NPs delivery platforms. Herein, we seek to 
examine the biophysical causes of heterogeneous NPs distribution in stroma-rich desmoplastic tumors; 
namely the abnormal tumor vasculature, deregulated extracellular matrix and high interstitial 
hypertension associated with these tumors, and also the off-target depletion of NPs in non-tumor 
stroma cells. It is suggested that these factors help explain the discrepancy between promising 
outlooks for many NPs formulations in preclinical studies, but suboptimal clinical outcomes for most 
FDA approved nanoformulations. Furthermore, examination into the role of the physicochemical 
properties of NPs on successful drug delivery was conducted in this chapter. In light of the many 
formidable barriers against successful NP drug delivery, we provided possible approaches to mitigate 
delivery issues from the perspective of stromal remodeling and NPs design.
                                                   
1This chapter previously appeared as a review article in Journal of Controlled Release. The original 
citation is as follows: Lei Miao, C. Michael Lin, Leaf Huang, Stromal barriers and strategies for the 
delivery of nanomedicine to desmoplastic tumors, Journal of Controlled Release, 2015, 219 (10):192-
204. 
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In all, this chapter seeks to provide guidelines for optimizing nanoparticle-based cancer drug 
delivery through both modified nanoparticle design and alleviation of biological barriers to successful 
therapy.    
1.2 Introduction 
The field of nanomedicine has recently attracted tremendous attention, particularly for 
applications in cancer drug delivery. Owing to the advancements in material science and new 
manufacturing methods, NP-mediated drug delivery platforms can now be fabricated to an almost 
unlimited number of configurations with respect to size, shape, and payload, allowing for versatile 
applications for the detection, prevention and treatment in oncology. Nanotherapeutics such as 
liposomes, polymeric micelles and inorganic NPs possess a distinct functional advantage over 
conventional small molecule chemotherapy regimens by overcoming severe systemic toxicities that 
limit the clinical application of most chemotherapy drugs [1]. Furthermore, NP drug delivery 
platforms permit significantly prolonged circulation when compared to small molecule drugs alone. 
Most importantly, the leakiness of vessels established during angiogenesis and the impairment of 
lymphatic drainage, constituting the so called EPR effect, provides the primary driving force for the 
extravasation of NPs, improving the intratumoral accumulation and distribution and resulting in 
enhanced therapeutic outcome [2]. Examples of applications include both the preclinically 
investigated nanoformulation (i.e. liposomes, polymeric micelles) and FDA approved NPs of 
liposomal doxorubicin (Doxil®) and albumin-bound paclitaxel (Abraxane®). Despite demonstrating 
outstanding antitumor efficacy in preclinical studies and promising outlooks for multifunctional use 
in clinical trials, nanoparticulate anti-cancer therapeutics have only provided modest survival benefits 
overall [3]. Factors such as the fundamental design of the NPs, abnormal tumor microenvironment, 
and the heterogeneity across tumors can compromise the EPR effect. This serves to explain the 
discrepancies between the promising results obtained from preclinical studies, and the subpar 
performance in clinical trials. The tortuous tumor vasculature and abnormal basement membrane limit 
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both the trans-vascular and interstitial transport of NPs. Furthermore, the high level of extracellular 
molecules, increased solid stress and high interstitial pressure act as another set of barriers to 
successful NPs extravasation. Consequently, the limited NPs perfusion directly inhibits the 
therapeutic efficacy of the nanocarriers. The heterogeneity of the tumor stroma microenvironment 
underlines the importance of intratumoral off-target distribution of NPs to non-tumor stroma cells, 
since their disparate response towards treatment may be another major mechanisms behind 
chemotherapeutic resistance and compromised clinical outcomes [4].  
Herein, we first present mathematical models for intratumoral NPs transport to achieve a better 
understanding of this complex process. We then discuss the key physiological barriers for NPs 
transport, and analyze the design of NPs for enhanced intratumoral transport. Finally, we summarize 
the strategies to overcome delivery barriers through remodeling the tumor microenvironment and 
designing the tumor microenvironment-responsive NPs.  
1.3 Mathematical Modeling and In Vitro Models of NP Intratumoral Distribution 
The intratumoral delivery of macromolecules and NPs requires several steps in transport, 
including vascular transport, transvascular transport, interstitial transport, cellular binding, 
internalization and metabolism (Figure 1.1) [1]. All these steps are generally limited by 
pathophysiology of tumors. To better understand the biophysical underpinnings of these transport 
barriers, Jain and his colleagues have developed several mathematical models to simulate the 
intratumoral behaviors of NPs [5-7]. 
For the modeling of vessel and trans-vasculature transport, the tumor vasculature was 
represented by a two-dimensional percolation network with one inlet and one outlet that resembles 
the vascular structure and function of tumors [8]. Vessel transport is mainly dominated by convection 
(flow rate governed by pressure gradient) and is quantified based on the perfusion rate of blood flow 
(Q). Poiseuilles’s law was used to simulate vessel transport, suggesting that blood flow is 
proportional to the vascular pressure gradient and blood viscosity [8]. The transvascular flow was set 
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proportional to hydraulic conductivity of the vessel wall, the surface area of the vessel and also the 
influence of interstitial fluid pressure. All parameters can be measured using standard intravital 
microscopy, multiphoton microscopy and optical frequency domain imaging [1, 9-12]. This modeling 
formula emphasizes the potential influence of blood vessel area, pore size and interstitial fluid 
pressure (IFP) on NPs transport.  
Interstitial transport, mainly indicating the diffusion of NPs through the extracellular matrix 
(ECM) toward tumor cell targets, is another significant step in determining NPs diffusion and 
penetration. Interstitial transport follows the Darcy’s theory, which requires calculation of the 
diffusion coefficients (Deff) of NPs in the ECM [8, 13]. Diffusivity of NPs in the ECM was modeled 
in vitro using matrigel or collagen confined diffusion chamber models. Diffusion coefficients were 
determined using these in vitro ECM models by non-linear fits of intensity gradients to a diffusion 
model (e.g. Fickian model) [3, 13, 14]. Diffusion coefficients of macromolecules and liposomes can 
also be quantified in vivo using either single-photon fluorescence recovery after photobleaching or 
two photon fluorescence correlation microscopy. These measurements are more clinically relevant, 
but limited by equipment requirements and cost [14, 15]. 
For the majority of the aforementioned short time scale transvascular transport models or 
long-term NPs penetration models, neither the binding of NPs to cancer cells, nor cell uptake was 
included [16]. However, these two factors play a substantial role in the process of NPs transport. In 
light of this, Mok et al. are credited for the development of mathematical models considering rapid 
cell surface binding, internalization and degradation through an intratumorally infused Herpes 
Simplex Virus (HSV). In addition to diffusion coefficient, second-order binding rate constants, first-
order dissociation constants and internalization constants were included in the differential equation to 
distinguish the free interstitial virus, bound virus and internalized virus respectively [16, 17]. Using a 
similar mathematical model, Kim et al discriminated the interstitial diffusion, cellular uptake and 
intracellular release of fluorescein-labelled gold NPs (6 nm overall with ligand) on a three-
dimensional multicellular tumor cylindroid model [18]. The intracellular release kinetics of 
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fluorescein from NPs were further included into the differential equation. However, these 
mathematical equations are all confined to in vitro 3D tumor models or intratumoral injection of NPs, 
and do not consider the effect of vascular transport and plasma clearance. In another study, Schmidt 
et al. modeled the cellular binding affinity of the targeted molecules along with the dynamic plasma 
clearance of macromolecules into the mechanistic compartmental model, and avidly studied the effect 
of molecular size and binding affinity on tumor targeting [19]. 
Although, most of the mathematical and in vitro models are based on assumptions and 
limitations, the overall modeling of intratumoral transport of NPs still provides a semi-quantitative 
method for the extrapolation of parameters such as NPs physicochemical properties and tumoral 
barriers on NPs transport. This can then be extended so as to predict dynamics of NPs transport and 
the therapeutic outcomes of NPs delivering chemotherapy and gene therapy. 
1.4 Enhanced Permeability and Retention Effect and Anti-cancer NPs in the Clinical Trials 
The mathematical models discussed in the previous section emphasize the importance of the 
tumor vasculature on vascular and transvasculature transport of NPs. New vessels formed during 
angiogenesis are known to have a leaky and tortuous morphology, permitting NPs extravasation [20]. 
On a different note, rapid unconstrained proliferation is coupled to an IFP and solid stress, which 
results in the compression of lymphatic vessels and impairs NPs clearance [21]. Together, these 
characteristics comprise the EPR effect. The EPR effect describes how the leaky vasculature of 
tumors permits enhanced NPs permeability, while the lack of a functioning lymphatic network 
promotes NPs retention in the tumor. The EPR effect states perhaps one of the most fundamental 
advantages for NPs-based drug delivery. Clinically, NPs have been applied to treat a broad range of 
cancers. Abraxane is an albumin-stabilized NPs designed for the delivery of paclitaxel [22]. Along 
with other platforms such as a PEGylated liposome based doxorubicin delivery system (Doxil®), 
both share the ability to exhibit enhanced tumor localization through the EPR effect.  
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1.5 Tumor Microenvironment Barriers for Intratumoral NPs Diffusion and Distribution 
Ironically enough, the mechanistic basis for the EPR effect also comprises one of the primary 
barriers to NPs delivery. Namely, the elevated IFP [23] and increased solid stress act to inhibit 
successful NPs extravasation into the tumor. This paradoxical observation explains the discrepancy 
between promising preclinical research and the subpar clinical outcomes for NPs application. 
Therefore, successful NPs drug delivery relies heavily on the balance of these two competing aims 
(Table 1.1). 
1.5.1 Abnormal Tumor Vasculature Plays Paradoxical Roles in NPs-based Delivery 
When compared with non-cancerous tissues, tumor vessels are known to be heterogeneous, 
leaky and dilated, leaving avascular spaces of various sizes. In addition, abnormal vessel-wall 
structures with heterogeneous basement membranes, wide inter-endothelial junctions and large pore 
sizes contribute to the irregularity of the tumor vasculature [2, 24-27]. These factors therefore 
compromise NPs transport and undermines the efficacy of therapeutic agents.    
Genetic and epigenetic changes drive tumor and mesenchymal cells to produce pro-
angiogenic factors, such as vascular endothelial growth factor (VEGF) [28]. Due to over-activation of 
these pro-angiogenic pathways, tumor vessels become tortuous and leaky. As mentioned in the 
previous section, leaky vasculature then facilitates transient NPs extravasation through the EPR effect. 
However, the mechanistic basis behind the EPR effect also contributes to excessive fluid 
extravasation, inducing increased IFP, fluid viscosity and therefore impairs NPs vascular transport 
[29]. The tortuous nature of tumor vessels further contributes to these elevated geometric resistance 
through decreased blood flow [20, 30]. Meanwhile, solid stress resulting from unconstrained tumor 
growth and an abnormal ECM, further compresses vessels, blocking blood flow and leading to vessel 
collapse [20]. The decrease in blood flow, in turn, has a great effect on the viscous resistance of the 
blood. Slow blood-flow rates and high blood viscosities govern the vascular and transvascular 
transport of small molecules, macromolecules and NPs. Furthermore, unlike normal tissues, blood 
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velocity in tumors is independent of vessel diameter and unevenly distributed. The poorly perfused or 
even unperfused blood supply leads to hypoxia and acidic conditions, which bolsters drug resistance 
and further limits NPs diffusion [2]. Aside from blood vessel constriction, the lymphatic vessels in 
the tumor are also compressed by proliferating cancer cells, causing collapse. The inefficient drainage 
of fluid from the tumor center coupled with fluid leakage from tumor vessels contributes to interstitial 
hypertension, which further limits NPs perfusion deep into the tumor core [4]. 
1.5.2 Acidic and Hypoxia Limit Nanotherapeutic Approaches to Necrotic Areas 
Acidic and hypoxic conditions are distinctive features of most solid tumors. Acidification of 
tumor microenvironments primarily arises from the Warburg effect, which describes the tumor’s shift 
in energy metabolism from pyruvate oxidation to glycolysis. The excess lactic acid produced through 
this pathway remains in the tumor due to poor lymphatic drainage as described previously, a 
characteristic of most solid tumors [31]. Acidic conditions lead to the ionization of weakly basic 
drugs and compounds, limiting their ability to diffuse in the ECM [32]. On the other hand, hypoxic 
conditions primarily arise due to unconstrained cell proliferation that outgrows the blood supply in 
the tumor. As a result, it is well documented that hypoxic regions most commonly surround the 
necrotic center of the tumor [33]. Due to the altered blood-flow in hypoxic regions, particles often fail 
to localize in regions of hypoxia [34]. Even if delivery of NPs is successful to hypoxic regions, cells 
deficient of oxygen show surprising resilience to chemotherapy. As hypoxia reduces cell proliferation, 
chemotherapy drugs targeting rapidly proliferating cells are rendered useless in these regions [35]. 
Furthermore, hypoxic regions are hotspots of hypoxia-inducible factor (HIF) production. The 
stabilization of HIF-1A, a normally labile transcription factor, is known to induce drug resistance 
through up-regulation of genes such as MDR1 [35] [36]. Therefore, hypoxic and acidic environments 
are a barrier to nanoparticle-based chemotherapy options from both a delivery and therapeutic 
standpoint.  However, many novel treatment regimens seek hypoxic and acidic environments as a 
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tumor drug target. Specifically, some treatments use the acidic environment to induce drug release 
from polymeric nanoparticles [37]. 
1.5.3 High Interstitial Fluid Pressure Limits NPs Convection and Accumulation 
Another notable contradiction that arises when discussing the mechanism behind the EPR 
effect is the elevated IFP. The balance between elevated IFP and the increased NPs uptake via EPR 
effect influences successful NPs delivery. High IFP is known to be the result of a variety of factors. 
Firstly, the dense surrounding collagen matrix of the tumor microenvironment is rich in tumor 
associated fibroblasts (TAFs), which contract and tighten the collagen network by secreting ECM 
associated molecules and integrin dependent binding [23, 38]. This first barrier physically limits the 
expansion of the tumor cavity in response to growth. Continuous unregulated tumor proliferation in 
this enclosed space then compresses blood and lymphatic vessels due to growth induced solid stress, 
which in turn prevents the efficient discharge both NPs and interstitial fluid from the tumor [20, 39, 
40]. An elevated IFP is known to be particularly detrimental for large molecule/nanoparticle delivery, 
which rely primarily on convection for their extravasation [26]. High IFP acts against convection and 
force NPs to enter via passive diffusion, a kinetically slower process. Furthermore, IFP induced vessel 
constriction has been shown to cause tumor hypoxia, where the increased precedent of angiogenic and 
growth factors contribute to lymph node metastasis and drug resistance. These secreted factors are 
then relocated from the tumor periphery toward the outer invasive front due to the IFP gradient where 
they communicate with fibroblasts to induce resistance and metastasis [41-43]. A high IFP therefore 
obstructs the therapeutic efficacy of NPs and leads to heterogeneous drug distribution in the tumor 
stroma. 
1.5.4 Abnormal Extracellular Matrix Interferes with NP-based Drug Delivery 
The tumor extracellular matrix (ECM) is a key element for regulation of cell proliferation and 
differentiation [43]. Particularly, the high cellularity of tumors compresses the interconnected 
collagen network and space-filling hydrogel-like glycosaminoglycans (GAG) of the ECM. The 
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compressed network in turn results in the accumulation of solid stress and dictates interstitial 
transport [44]. At the cellular level, ECM is localized at two different intratumoral sites, the basement 
membrane (BM) and the interstitial matrix. 
The BM functions as a scaffold for endothelial and mural cells. In particular, the matrix of the 
BM contains highly compact, sheet-like dispositions formed from fibronectin, laminin and type IV 
collagen, linked via nidogen and heparin sulfates [45, 46]. More than 99% of non-cancerous blood 
vessels are covered by a thin layer of BM, which regulates vessel development through paracrine 
secretion of pro-inflammatory and pro-angiogenic cytokines. Specifically, cytokines such as 
transforming growth factor beta (TGF-β) and tumor necrosis factor alpha (TNFα) support the 
homogenic architecture of the blood vessels; whereas the BM of tumor microvessels are primarily 
continuous but conspicuously abnormal [47]. Heterogeneous BM morphologies were observed in 
different tumors or different regions of the same tumor. MCa-IV breast carcinomas and 4T1 breast 
cancer are characterized by a lesser amount of collagen in the vessel wall, which are loosely 
associated with the underlying endothelia [48]. Separately, breast cancer 3LLL and pancreatic cancer 
BXPC3 are characterized by a second type of BM, with a distribution of brighter collagen nodules are 
more condensed and overlapped with the capillary. The BM does not induce the elevation of IFP, yet 
functions as a sieve to modulate extravasation of free drug and NP from capillaries into the tumor 
microenvironment. Free DOX, FITC-tagged dextran and 80 nm PEGylated, DOX loaded liposomes 
were used as tracers to evaluate the extravasation of small molecules and large NPs into the tumor 
microenvironment. Yokoi et al’s study showed that the extravasation pattern of small molecules in the 
type I BM model 3LLL and type II BM Model 4T1 were comparable [48]. However, the 
extravasation of NPs from the same two tumor types was very different, as suggested by their in vivo 
NPs diffusion model and in vitro collagen-sleeve model. Diffusion based transport of NPs was 
severely hindered by the thickness of collagen fibers, fiber mesh pore size and fiber density. 
Moreover, the BM is not static, but dynamic as angiogenesis of blood vessels requires degradation of 
collagen IV by matrix metalloproteases MMP2 and MMP9 [49, 50]. Therefore, degradation of 
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collagen IV provides a transient niche with leaky tumor vasculature, low and thin BM, a very 
beneficial window for NPs delivery. Besides the collagen meshwork, some earlier works also 
proposed that the extensively charged heparin sulfate chain, which is attached to the laminin/collagen 
IV network, is essential for the microscopic filtering of positive charged particles. Simultaneously, 
the nidogen molecules and the protein core of the perlecan complex geometrically hinder the 
negatively charged particles [51]. Overall, BM characteristics such as the matrix density, presence of 
proteoglycans and angiogenesis mediated BM remodeling limit the extravasation of NPs from blood 
vessels into the interstitium of tumors.  
While the interstitium is also rich with ECM, it limits NPs penetration differently from the 
BM in three ways. Firstly, high stromal fraction and large matrix molecules are restricted to a limited 
interstitial volume, compressing the matrix into a dense network with increased IFP; limiting 
convection of NPs. Secondly, fibrillar structure, mesh size and collagen thickness directly limit the 
diffusion of NPs. Since the molecular components of interstitial ECM are more confluent than BM, 
the interactions between these parameters are both more pronounced and more complicated. The 
tortuous nature of the interstitial space is the third primary barrier for NPs since it elongates the 
diffusion path of both NPs and macromolecules from blood vessels to target cells. In tumors with a 
lower amount of interstitial matrix, such as melanoma and colorectal cancers, NPs can easily diffuse 
across the interstitial barrier, access tumor cells and therefore induce growth inhibition [52]. However, 
this process proves more difficult for tumors with a thick interstitial matrix. Collagen content is the 
major determinant of interstitial transport [2]. Unlike BM, collagen I rather than collagen V is the 
major component of the collagen matrix [53]. Fibril or collagen orientation can also influence particle 
diffusion rates. During cancer development, collagen-remodeling enzymes convert the orientation of 
collagen scaffolds from thin and relaxed collagens (curly fibrils) to thick, aligned fibrils. 
Stylianopoulos et al. established a mathematical model to evaluate particle diffusion across collagen 
fibers with varying degrees of alignments, suggesting that alignment of the collagen matrix stiffens 
the ECM, which thereafter not only elicits diverse effects on cellular migration and differentiation, 
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but also [54]narrows the inter-fiber spacing, retarding the movement of particles [55]. The collagen 
organization pattern also causes disparate NPs diffusion. Crosslinking of collagen via lysyl oxidase 
(LOX), regulated by fibronectin and organized by SPARC (secreted protein acidic and rich in 
cysteine), resulted in the stiffness of collagen fibers [55, 56]. These molecules are therefore used as 
interesting target candidates to inhibit stromal stiffness. With this aim, Kanapathipillai et al. designed 
a PLGA loaded LOX inhibitory antibodies to decrease collagen crosslinking and improve therapy 
[57]. 
The contribution of GAGs toward macromolecular diffusion is controversial. As one of the 
major non-sulfated GAG, hyaluronan is a linear polysaccharide with repeating disaccharide units of 
β-d-glucuronic acid and N-acetyl-β-D-glucosamine [54]. In most cases, the elimination of hyaluronan 
negatively affected nanoparticle transport, opposite to the effect of eliminating collagen [15]. The 
polymerization of HA has been shown to partition the collagen matrix into aqueous and viscous 
compartments. Hyaluronidase treatment increased the proportion of slow-diffusing compartments and 
shifted the slow diffusion coefficient to smaller values [58, 59]. On the other hand, for certain tumors 
such as pancreatic cancer, in which more than 70% ECM consists of HA, the degradation of HA 
resulted in increased drug diffusion [60]. The sulfated glycosaminoglycan, similar to that in the BM, 
carries a highly negative charge, which can inhibit the transport of macromolecules or NPs by 
forming aggregates [2, 61]. 
1.5.5 Stromal Cells Regulate the Interstitial Distribution of NPs  
In contrast to features of the non-cancerous ECM, tumor stroma contains modified ECM 
attached to multifaceted stromal cells, including fibroblasts/myofibroblasts (carcinoma-associated 
fibroblasts), mesenchymal cells such as pericytes/mural cells, endothelial cells and immune cells [4, 
20]. The high cellularity of tumors works in two distinct ways to limit NPs penetration and 
internalization. Firstly, solid stress induced by unconstrained proliferation of stromal and tumor cells 
compress the matrix into a disorganized network. Secondly, the stromal cells nonspecifically deplete 
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NPs, which extravasate from adjacent microvessels, compromising the internalization of therapeutic 
NPs in cancer cells and in turn, the overall therapeutic effect.  
In the modified tumor ECM, pericytes play an important role, as they are a ubiquitous part of 
the tumor microenvironment. Pericytes are primarily characterized as periendothelial mesenchymal 
cells embedded within the vascular basement membrane[62], which can be identified by pericyte 
markers such as alpha smooth muscle actin (αSMA), PDGFR-β, NG2, RGS5 and XlacZ4 [63]. The 
establishment of pericytes starts with recruitment, which is primarily mediated by endothelial cells 
through PDGF-β /PDGFR-β signaling during physiological angiogenesis [62]. On the other hand, 
VEGF-α acts as a negative regulator of pericyte function and vessel maturation [64, 65]. The structure 
of newly established pericytes is loosely associated with the endothelial cells, and has cytoplasmic 
processes that penetrate deep into the tumor parenchyma. However, heterogeneity of tumors 
determines the spatial arrangement pericytes. Work by Kano et al recently classified cancers into two 
categories based on pericytes coverage: those with less coverage of tumor neovasculature (e.g. colon 
cancer, CT26) by pericytes and those with more (e.g. pancreatic cancer and diffuse-type gastric 
cancer) [66]. Pericytes regulate blood flow and control the stabilization and maturation of tumor 
vasculature. Neither leaky, immature blood vessels with little coverage, nor over-matured vessels 
with abundant pericyte coverage are suitable for NPs delivery and should be optimized for better NPs 
perfusion [67]. For example, NPs extravasation was severely impeded in the high pericyte coverage 
(BxPC3) model. Yet, treatment by TGF-β inhibitors or PDGF-β inhibitors could slow down pericyte 
recruitment, inhibit endothelial pericyte associations and therefore, improve NPs extravasation. While 
the low pericyte subtype showed better NPs perfusion, modulation of the pericytes still offered an 
improvement in NPs perfusion with respect to the unmodified group. Specifically, through 
diminishing non-functional microvessels with low pericyte coverage while increasing pericyte 
coverage in the normalized tumor vasculature [67]. For example, the VEGF inhibitor, Sorafenib, 
which negatively controls the regulations of pericytes, increased extravasation of 2 MDa dextran in 
the CT26 model [68].  
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TAFs are another major player of tumor fibrosis. TAFs inhibit the interstitial transport of NPs 
via the secretion of ECM, construction and stiffening the fibrillar structure and also secretion of 
paracrine growth factors for tumor resistance and metastasis. For example, lysyl oxidase (LOX) 
synthesized by TAFs could be stimulated via the TGF-β signaling pathway and contributed to 
increased stromal stiffness through crosslinked collagen fibers [69]. As a major stromal cellular 
component, TAFs also nonspecifically internalize therapeutic NPs and compromise NPs’ association 
with tumor cells; resulting in sub-optimal clinical outcomes [70]. The ratio of off-target NPs 
distribution into fibroblasts is regulated by the spatial distribution of blood vessels in relation to 
tumor cells and other stromal components (i.e. fibroblasts) [71]. Two dominant phenotypes based on 
tumor stromal architecture delineate tumor types into either a tumor vessel phenotype (with vessels 
embedded throughout tumor cells) or a stromal vessel phenotype (vessels distributed in proximity to 
fibroblasts). While the tumor vessel phenotype is commonly applied in xenograft models, the stroma 
vessels are more clinically relevant and seen in orthotopic tumors (4T1 breast cancer or pancreatic 
cancer) and other primary cancers. Off-target distribution of NPs into TAFs is in fact, more prominent 
in the stromal vessel type. This was demonstrated in an experiment with 120 nm Docetaxel-
conjugated NPs could distribute to fibroblasts in 4T1 and MDA-MB-231 orthotopic breast cancer and 
deplete TAFs content by 70% [72]. Given that the tumor-fibroblast transition is one major source of 
TAFs, surface receptors that are highly expressed in tumor cells are not surprisingly also found on 
respective fibroblasts [73]. Because of the increased binding affinity between fibroblasts and targeted 
NPs, the binding site barrier of TAFs is stronger for the targeted NPs, rendering off-target distribution 
more likely. Although therapeutic NPs that were delivered off-target to fibroblasts could deplete 
fibroblasts, and synergize with chemotherapy in some tumor models [74], the therapeutic effect of 
anti-cancer therapies are also likely to significantly deviate from initial predictions in TAFs, due to 
the different sensitivities and resistance mechanisms of benign fibroblasts and tumor cells [71]. For 
example, TAFs attacked with chemotherapy could secrete survival factors such as Wnt16 that 
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induced the formation of resistant phenotypes of prostate cancer [70]. Overall, the off-target delivery 
of NPs in TAF severely hinders NPs penetration and induced convoluted anti-tumor efficacy.  
Immune cells, including B cells, T cells, granulocytes, dendritic cells, myeloid derived 
suppressor cells and macrophages, are indispensable constituents of the tumor microenvironment that 
modulate the intra-tumoral immune response [75, 76]. Owing to the partial peri-vasculature 
localization of infiltrated immune cells (other immune cells are likely to distribute in inflammatory 
hypoxia and necrosis area) [77] and phagocytic properties of some of the immune cells (e.g. 
macrophages) [78], off-target internalization of NPs is inevitable. Using an orthotopic model of 
melanoma and fluorescently labeled PRINT nanoparticles, Roode et al demonstrated that association 
between tumor-associated macrophages (TAM) and NPs were 4-fold greater than that of cancer cells 
despite TAM constituting only 1% of all cells in tumors [79]. In another study, the correlation 
between increased delivery and release of CKD-602 from S-CKD602 liposomes, and increased 
expression of CD11c-positive dendritic cells in a SKOV3 ovarian xenograft suggested that the NPs 
disposition may be associated with the phagocytic cells (i.e. DC and TAM) [80, 81]. Although, the 
off-target association of NPs in leukocytes and the general immune compartment may modulate the 
immune pathway (i.e. Stat-3, ERK) and modify the suppressive tumor microenvironment to 
synergistically improve cancer vaccines (data not shown), direct phagocytosis of NPs by phagocytic 
cells may deplete the NPs and limits accumulation into the tumor. Overall, the cellular components of 
the tumor stroma deplete NPs through multiple mechanisms and interfere with the therapeutic 
outcome of anti-cancer agents.  
1.6 Physicochemical Properties of NPs influences NPs transport in Stroma-rich Tumors 
Though the biophysical properties of tumors present prominent barriers for successful NPs 
delivery, the physicochemical properties of NPs govern the extent and limitations of such barriers. 
Steric small particles (with size <50 nm), such as PEGylated NPs (i.e. polymeric micelles, gold 
nanoparticles or quantum dots), can penetrate poorly permeable hypovascular tumors such as BxPC3, 
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better than the larger NPs (> 50 nm) [52]. The inverse relationship between diffusion rate and NPs 
size was also observed in vitro on the multicellular spheroid models [82]. One potential explanation is 
that the vascular pore size and the cross-linked collagen fiber mesh form pores that are in between the 
size of the large and small particles. Therefore, both transvascular and interstitial transport of smaller 
NPs occur rapidly [83]. However, one should note that NPs smaller than 10 nm are likely to be 
excreted from the kidney, at least partially. Therefore, NPs below the 10 nm limit exhibit 
compromised pharmacokinetic profiles and an increase in collateral damage toward normal organs. 
Increasing the size of NPs will provide selectivity, but at the cost of limiting extravasation and 
diffusion.  
Aside from particle size, surface charge also affects intratumoral transport by regulating NPs’ 
diffusive mobility in the ECM. Both PEGylated NPs and neutrally charged liposomes exhibit quasi-
free diffusive motion in ECM hydrogel and have the advantage of deep penetration into tumors. 
Cationic NPs (e.g. DOTAP liposomes), on the other hand, were entrapped in the hydrogel [51]. 
However, cationic NPs have been shown to exhibit optimized transvascular transport by preferential 
targeting to the tumor endothelial cells and electrostatic attraction with the negatively-charged vessel 
pores [84, 85]. Furthermore, positively charged NPs are more likely to be taken up by proliferating 
cells (e.g. tumor cells) compared to neutral and negatively charged NPs, which is an additional 
advantage for effective drug delivery [18]. 
As far as the shape of NPs is concerned, research has shown that NPs or macromolecules 
with linear, rod-like semi-flexible configurations diffuse and penetrate more efficiently into the 
interstitial matrix compared with solid spherical particles of similar size. The shape of therapeutic 
NPs also affects their circulation time in the blood stream. For example, rod-shaped micelles have a 
circulation lifetime ten times longer than their spherical counterparts [2, 5, 86].  
Surface modification of NPs with targeting ligands is another concern for enhancing NPs 
intra-tumoral transport. High binding affinities between NPs and the target site are generally seen as 
an advantage by increasing the internalization of NPs. However, the use of targeted NPs with high 
 16 
 
binding affinity may elicit a binding site barrier. This regards a phenomenon where NPs binding to 
target cells paradoxically reduces diffusion deep into tumors. The binding site barrier was first 
observed during antibody delivery into tumors and later found to be present for NPs based delivery as 
well. High avidity may also comprise the selectivity, since particles may also inadvertently bind to 
non-tumor cells expressing low levels of tumor specific determinant and depleted accordingly. After 
all, targeting ligands exclusive to tumor cells are unlikely to exist [87, 88]. 
Though surface charges and targeting moieties modulated intra-tumoral NPs distribution, 
growing evidence suggested that nanomaterials that interact with biological fluids (e.g. plasma) are 
likely to adopt a “new” identity through acquiring a surface corona of biomolecules (such as lipid and 
proteins), a phenomenon that, in turn, may comprise the influence of surface properties and dictate 
the in vivo biodistribution of NPs. The composition of this corona is dynamic, reflects the 
nanomaterial-intrinsic properties, e.g., size, surface curvature and hydrophobicity. Among the 
identified compositions, opsonins (including immunoglubin (IgG), complementary factors and 
fibrinogen) were reported to promote receptor mediated phagocytosis, leading to rapid clearance and 
limited tumor accumulation of NPs. The attachment of antifouling polymers, in particular PEGylation, 
has widely been used to prevent protein binding, and consequently module the pharmacokinetic 
profiles of NPs. On the other hand, strongly bound monolayer bio-corona could be taken advantage of 
to prolong the NPs circulation. For example, albumin was said to complex with negative charged NPs 
and promote prolonged circulation times. Abraxane™, the FDA approved albumin-bound form of 
paclitaxel, is a good example of using albumin as a drug carrier for efficient anti-tumor therapy. 
Furthermore, one may consider exploit the bio-corona phenomenon for targeting purposes. Kim et al 
found that preadsorption of apolipoprotein E (ApoE) onto PEG-polyhexadecylcyanoacrylate NPs 
shown efficient delivery across the BBB into the brain. Other examples include specific adsorption of 
transferrin onto NPs for targeting purposes. Above study focused on bio-corona formed in plasma and 
discussed the pros and cons of this bio-corona for NPs delivery. However, considering the ultimate 
fate of NPs as to approach tumor cells through dense stroma, therefore, how the bio-corona coated 
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NPs interact with stroma, or whether the covered biomolecules will exchange with stroma and 
dynamically reform a new bio-corona are also influential for NPs disposition and need more detailed 
investigation. 
Overall, the physiological properties of NPs greatly influence the pharmacokinetics, 
transvascular transport, intratumoral penetration and cellular internalization in paradoxical manners. 
This helps to explain the inconsistency between preclinical animal studies and clinical outcomes and 
therefore, physicochemical properties of NPs need to be optimized for each tumor. 
1.7 Strategies to Improve NPs extravasation and Penetration 
Examination of the barriers that hinder NPs delivery has opened doors for new treatment 
regimens that seek to mediate these factors. Generally, these approaches involve restoring the 
abnormal tumor vasculature and interstitial stress towards that of normal tissue, and modifying NPs 
with environmentally responsive modifications to enhance delivery (Table 1.1). 
1.7.1 Normalization of Tumor Vasculature Benefits NPs Extravasation 
To counter the detrimental effects of abnormal tumor vasculature on NPs transport, strategies 
to restore normal vasculature have been proposed [66, 88]. Since irregular BM and pericyte coverage 
hinders the maturation of tumor vasculatures, promoting BM and pericyte recruitment has been 
proposed to normalize blood vessels [66] Collagen IV, the major constituent of BM, have been shown 
to be degraded by MMPs. Therefore, the application of MMP inhibitors such as the peptide inhibitor 
TIMP-1, or a non-peptide inhibitor, AG3340, could inhibit BM remodeling and is considered a 
promising method for vessel normalization [89]. Another method involves the knockdown of the 
VEGF signaling pathway. VEGF receptor-2 blocking antibody DC101 can prune immature vessels 
and recruit pericytes. Proangiogenic molecules, including VEGF, fibroblast growth factor (FGF) and 
PDGF are overexpressed in tumors and favor angiogenesis [2]. Therefore, VEGF inhibitors can also 
be applied as an anti-angiogenic agent to revert the vasculature toward a more normal phenotype. A 
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variety of monoclonal antibodies (mAb) against VEGF and other angiogenic signaling factors have 
been designed. For example, bevacizumab (Avastin), the first approved anti-angiogenic mAb, and its 
derivative, ranibizumab have been applied in the treatment of metastatic colorectal cancer. 
Furthermore, the inhibition of heparanase, which plays a major role in angiogenesis, has also been 
considered as a promising tumor priming strategy [90]. The resulting modifications reduced size of 
pores in the vessel walls and decreased IFP, allowing NPs extravasation to occur through convection 
rather than diffusion, a much faster process for free molecules and small NPs (<12 nm) [8]. 
Despite these improvements, the smaller vessel pores established through normalization may 
compromise the advantages gained from enhanced convection for large NPs, since the increased 
steric and hydrodynamic hindrance inhibit the extravasation process [6, 8]. As an additional 
consideration, the anticancer agents should be administered during the window of normalization to 
obtain improved delivery, since vascular normalization is a transient process. Furthermore, this 
strategy may not lead to desirable results against cancer with compressed and less permeable tumors 
as seen in the case of pancreatic tumor BXPC3 and breast cancer 4T1. Owing to the thick pericyte 
coverage that limits diffusion of NPs in these compressed hypovasculature tumor models, strategies 
to inhibit angiogenesis may lead to diminished NPs accumulation. While somewhat counterintuitive, 
tumors of the hypovasculature phenotype should be remodeled to improve the leakiness of blood 
vessels by decreasing pericyte coverage and BM thickness. TGF-β receptor antagonists are the most 
frequently used therapeutic agents, since low dose TGF-β inhibitor inhibits pericyte recruitment 
without affecting the function of tumor cells and endothelial cells. Consistent with this finding, 
various types of TGF-β inhibitors, including small kinase inhibitor and its nano-formulation in 
addition to siRNA and antibodies, have been used to improve the intratumoral penetration of sub-100 
nm NPs, such as liposomes, polymeric micelles and PEI-PEG-coated MSNPs in hypovasculature 
tumor models [67, 91, 92]. Another approach to improve NPs penetration in the hypovascular models 
involves the administration of vasoactive agents such as thrombin, lipopolysaccharide endoxin, to 
initiate a cascade of cellular events that lead to the disruption of endothelial cell junction and increase 
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vascular permeability. Transiently raising the systemic pressure by infusing vasoconstrictors (e.g., 
angiotensin II) can also increase the vascular permeability and consequently increase NPs 
extravasation. A combined treatment might also beneficial for hypovasculature model, with one 
treatment to alleviate solid stress through depletion of stromal cells or extracellular matrix, and a 
subsequent or concurrent vascular normalization treatment to improve perfusion [93]. Overall, the 
approaches for remodeling tumor vasculatures to improve NPs delivery vary with regards to 
vasculature contents and abnormalities, as well as the size of the therapeutic NPs. One should be 
cautious when choosing strategies and agents since the efficacy of treatment depends largely on the 
nature of each specific tumor [67]. 
1.7.2 Normalization of the Extracellular Matrix Improves NPs Penetration 
Apart from activation of chemical signaling, interstitial stromal barriers in desmoplastic 
tumors physically restrict diffusion of macromolecules and nanotherapeutics within the tumor 
parenchyma. Attesting to this, Dellian et al observed heterogeneous distribution of stealth liposomal-
clusters in the perivascular ECM of a xenograft tumor, indicating the role of ECM in limiting the 
particle diffusion [94].  In another study, Eikenes et al. showed that the degradation of the structural 
collagen network is more important than the degradation of the GAG and hyaluronan when 
attempting to increase diffusion of NPs and macromolecules [58]. Jain and his colleagues further 
confirmed this finding [15, 95, 96]. Based on these findings, numerous studies have focused on the 
subsequent or concurrent delivery of collagenase alongside nanotherapeutics to enhance the 
intratumoral transport of NPs. For example, co-intratumoral injection of oncolytic HSV vector along 
with bacterial collagenase increased the viral vector distribution by nearly a 3-fold difference in a 
human melanoma xenograft [97]. In another example, intravenous injection of collagenase-I resulted 
in higher gene expression of lipoplex in xenograft tumors, further confirming the usefulness of 
collagen degradation in improving NPs distribution [98]. Enhanced diffusion after modification of 
collagen production was also demonstrated by the use of hormone relaxin, which was reported to both 
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stimulate collagenase synthesis and down-regulate collagen production [99, 100]. Additionally, 
relaxin is safer compared with bacterial collagenase for in vivo application and proposed for long term 
use [20]. 
Similar to collagen, GAG are also key matrix element that induces vascular collapse; among 
which, hyaluronan (HA) is a major component [96]. HA polymerizes into cage-like structures, 
partitioning the interstitial space into aqueous and viscous compartments as previously investigated. 
The use of hyaluronidase to improve the tumor permeability is controversial. High doses of 
hyaluronidase collapse the HA-based water swelling cage, increase the ECM viscosity and thereby 
reduces the diffusion coefficient of NPs [101]. Notably, elevated expression of tumor-derived 
hyaluronidase has been used as a diagnostic cue for high-grade bladder cancer and limited perfusion, 
suggesting the negative outcome of combining hyaluronidase with therapeutic NPs [59, 102]. 
However, in pancreatic ductal carcinoma (PDAC), with HA overpowering collagen and constituting 
70% of the ECM, the opposite is observed [54]. In a genetically engineered mouse model of PDAC, 
PEG-PH20, a PEGylated recombinant human PH20 hyaluronidase, can effectively improve vascular 
perfusion of doxorubicin and gemcitabine [54].  Intratumoral administration of bovine hyaluronidases 
has also shown promise in several xenograft models [103, 104]. A recent study in a human 
osteosarcoma xenograft model indicated that hyaluronidase induced a 4-fold increase in the 
distribution of liposomal doxorubicin [60]. Therefore, the application of HA is not limited to small 
molecules and can also be a promising combinatory component to improve the delivery of NPs with 
larger particle size [54]. 
However, the aforementioned ECM modifiers may produce collateral damage in healthy 
tissues (e.g., bacterial collagenase) or increase the risk of tumor progression (e.g., relaxin, matrix 
metalloproteinases, and hyaluronidase) [105]. Therefore, rather than systemic delivery of these 
modifiers, site-specific degradation of ECM was preferred and conducted by coating NPs with 
specific ECM enzymes [106, 107]. Goodman et al indicated that collagenase coated 100 nm gold NPs 
showed a 4-fold increase in the number of particles delivered to the spheroid core compared with 
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normal stealth particles [106]. The major concern for enzyme coated NPs is maintaining the 
enzymatic activity during, and after conjugation with the NPs. Also, the pharmacokinetic profile of 
the coated NPs proves important as well.  Recent work by Ji et al examined these major concerns with 
enzyme coated NPs platforms and confirmed the applicability of the design for improved NPs 
diffusion [108].  
1.7.3 Disruption of Stromal Cells Improves the Intratumoral NPs Delivery 
In addition to high ECM concentrations, desmoplastic tumors are usually characterized with 
high levels of stromal cell density. This abundance of stromal cells synthesizes and secretes 
interstitial matrix molecules (i.e. collagen, fibronectin, etc.) that constituent the high interstitial solid 
stress. Simultaneously, they act as strong binding site barriers for interstitial NPs delivery. TAFs have 
been considered to be the major component of tumor stroma. The dense ECM associated with TAFs 
also obstructs the intratumoral vasculature, preventing small molecule and NPs delivery. These 
findings suggest that TAF represents a potential target for both therapeutic efficacy and NPs delivery. 
Directly eliminating fibroblasts from the tumor can increase the interstitial transport and distribution 
of nanotherapeutics by decreasing the tortuosity of the interstitium. For example, off-target 
distribution of therapeutic NPs through platforms such as cisplatin NPs and Docetaxel conjugates 
greatly improved the outcome of stroma rich bladder and breast cancer models through depletion of 
fibroblasts [72, 74]. To improve the therapeutic outcome, targeted depletion of fibroblasts was 
investigated in detail. One example is the oral DNA vaccine that targets fibroblast activation protein 
(FAP), which is commonly overexpressed on TAFs [109]. The DNA vaccine specifically depleted 
fibroblasts and improved the delivery of the therapeutic agents [109]. Later on, TAF-targeted NPs, 
such as FAP antibody conjugated immuno-liposomes and FAP substrate conjugated drugs, were 
designed to specifically deplete TAFs [110, 111]. Though depletion of TAFs undoubtedly induced an 
increased vessel perfusion and enhanced NPs diffusion, two recent studies also suggest that 
eliminating stroma by targeted deletion of fibroblasts results in undifferentiated progression of 
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aggressive pancreatic cancer, suggesting the paradoxical effect of TAF depletion [112]. One 
explanation for the paradox is that these depletion strategies run the risk of eliminating key stromal 
components needed for tissue homeostasis. Furthermore, the off-target distribution of chemotherapy 
in fibroblasts may induce senescence in TAFs, a procedure that will induce the growth and resistance 
of neighboring tumor cells and ultimately stiffen ECM, limiting NPs perfusion in the long run [113]. 
To prevent this paradox, alternative approaches were adopted to remodel fibroblasts and ECM. Note 
that resting fibroblasts (normal fibroblasts) can be transdifferentiated into TAFs in response to 
cytokines (i.e. TGF-β, PDGF and sonic hedgehog (SHH) [114-116]), growth factors, oxidative or 
metabolic stress, and synthesize abundant ECM proteins to support tumor proliferation. Therefore, the 
pharmacological means to reprogram TAFs back to this quiescent state would be a promising strategy 
to inhibit tumor growth and improve NPs delivery [117, 118]. Recent studies by Diop-Frimpong et al 
indicated the downregulation of TGF-β signaling in TAFs by an angiotensin receptor inhibitor, 
Losartan, could reprogram and reduce the activity of TAFs, decreasing the synthesis of collagen I and 
thus improving the intratumoral penetration of NPs [105]. Success from this formulation has led to a 
phase II clinical trial of Losartan along with FOLFIRINOX in patients [88, 119]. Vitamin D Receptor 
(VDR) has also been shown to be overexpressed in the pancreatic stellate cells (PSC), an activated 
form of TAFs in PDAC. Sherman et al suggested that the VDR ligand acts as a master transcriptional 
regulator of PSC to reprise the quiescent stroma, reduce the fibrotic content and increase intratumoral 
vasculatures; which is promising for enhancing NPs delivery [117]. Evidence presented above 
emphasizes the advantages of stromal cell reprogramming over depletion. Despite diluting the ECM 
components for increased NPs perfusion in the reprogramming strategy, high cell densities still act as 
a binding site barrier for NPs with high cell binding affinity, which limits the outcome of this 
strategy. Considering the spatial intratumoral distribution of TAFs and blood vessels as discussed in 
the earlier sections, fibroblasts are a more likely target for NPs and regarded as a therapeutic target. 
Instead of depletion and transdifferentiation back to noncancerous fibroblasts, TAFs can be 
reprogrammed into killer cells that secrete toxins or other factors that inhibit the proliferation of 
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neighboring tumor cells. Fibroblasts can be engineered into macrophage like cells, providing us hope 
for in situ engineering using NPs delivered agents to convert fibroblasts into natural killers [120]. 
1.7.4 Design of Extracellular Matrix Targeted NPs 
Specific characteristics of the TME can either be utilized, or modified for improving NPs 
drug delivery (Table 1.2). Both strategies can be divided into two categories. These methods are 
primarily based on the notion that the EPR effect allows improves NPs accumulation in tumors over 
free drugs. In terms of the first strategy, stimuli-responsive NPs can be designed to release the free 
drug in the tumor interstitium. This method is advantageous as it overcomes the limitation of barriers 
in the ECM for large sized NPs. Stable hydrophobic drugs with membrane permeability could be used 
as candidate drugs, for example, doxorubicin (DOX). The hydrophobic drug could be directly 
conjugated to a hydrophilic polymer through an ECM cleavable linkage, or the segments of block 
copolymers could be connected by stimuli-cleavable linkers and further assembled into micellar NPs 
[121]. Another strategy is based on the premise that the binding site barrier hindered NPs distribution. 
To improve the penetration, stealth materials, such as PEG, were linked to the NPs with stimuli-
responsive linkers as a shielding layer. The degradation and cleavage of this shield triggered by the 
TME resulted in the exposure of targeting ligands, which lead to the efficient internalization by 
neighboring cells [122]. The aforementioned ECM stimuli, distinct from intracellular stimuli, are 
usually referred to as extracellular stimuli, including temperature, acidic pH and enzymes. When 
designing the responsive structure, the structure should be smart enough to distinguish the 
extracellular signals from intracellular signals, and thus achieve the original designed purposes. 
Temperature Responsive NPs. Temperature is originally considered as an external stimuli (e.g. 
magnetic field), generated by using external forces [123]. Temperature responsive materials was first 
found during hyperthermia treatment of tumors, dated back to 1970s, and lately became a major 
constituent of chemotherapy and used as a complementary strategy for hyperthermia treatment [123, 
124]. However, in early 1990s, studies revealed that the core temperature of breast cancer was higher 
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than the peripheral tissues, suggesting that temperature is not only applied as an external force but 
also an internal physicochemical feature of the ECM [125]. Abnormal temperature gradients were 
also observed later in brain tumors and melanoma [126, 127]. It is suspected that the elevated 
temperature in tumor regions is due to glycolysis degradation and reaction, energy exhaustion [128]. 
Temperature dependent response is usually governed by a sharp nonlinear change in the conformation 
and physicochemical properties of at least one component of the nanoformulations across their phase 
transition temperature. The sharp response triggers the release of free drugs from the cargos. Ideally, 
materials exhibiting relatively sharp thermal phase transitions around body temperature would be 
utilized to form the thermo-response NPs [123]. The commonly used chemicals are summarized in 
figure, among which the thermo-responsive polymer, including poly(N-isopropylacrylamide) 
(PNIPAM), poly(vinyl chloride) (PVC) and their derivatives were most widely investigated. Thermo-
responsive NPs were designed according to the aforementioned two strategies. Besides polymer 
micelles, liposome and peptide conjugates were also designed with thermal responsive components 
[129]. For liposomes, temperature responsiveness usually arises from a phase transition of the 
constituent lipids and the associated conformational variations in the lipid bilayers [123].  However, 
since the tumor temperature is hard to detect, most of the studies in this field focus on the in vitro 
characterization.  
Tumor acidity Due to the production of lactic acid converted from glucose during the aerobic 
glycolysis (also known as the Warburg effect, the hallmark of tumors), the extracellular pH of most 
tumor tissues is mildly acidic in the range of 6.5-6.8, which is in between that of blood (7.4) and 
lysosome pH (6.4) [130, 131]. pH variations between pathological situations and the normal tissues 
have been exploited to trigger the release of therapeutic drugs and imaging agents [121]. Notably, pH-
dependent delivery systems designed on the basis of this subtle pH difference require that the systems 
possesses ultrasensitive pH-responsiveness [132]. In the past decades, pH sensitive polymers that are 
synthesized to meet the requirement include tertiary amine-containing methacrylate copolymers, 
poly(β-amino ester) (PAE) and poly(sulfadimethoxine) (PSD), as well as those containing pH-
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sensitive chemical bonds (e.g., imidazole functionality of histidine, 2,3-dimethylmaleic anhydride 
(DMMA) modified amine moieties) [121].  Accordingly, designs of nanoformulations can be 
classified into two categories. One is the use of polyacids or polybase with ionizable groups that 
undergo conformational changes in response to environmental pH variations; the other is the design 
of polymeric systems with acid-sensitive bounds whose cleavage enables the release of molecules 
anchored at the polymer backbone. For example, a series of micellar NPs possessing ultrasensitive 
pH-activatable fluorescence emission were formulated by Gao’s group [132, 133]. The pH-activatable 
nano-probe was composed of a PEG conjugated poly(2-(hexamethyleneimino)ethyl methacrylate) 
copolymer and showed a micellization-disintegration transition within a narrow pH range of 0.25 
units. The release of fluorescent dye from micelles in response to extracellular pH can nonlinearly 
amplify tumor microenvironment specific signals for imaging purposes [132]. 
Extracellular Enzymes In the tumor tissue microenvironment, specific enzymes, including MMPs, 
phospholipases, glycosidases and esterases, etc., are present with high concentrations and abnormally 
high activity [121]. Therefore, they have been extensively exploited to modulate targeted drug 
delivery and release. The first approach is the direct conjugation of lipophilic drugs to a hydrophilic 
polymer via enzyme cleavable linkage, and further self-assembled into micelles for both anti-tumor 
drug delivery and tumor imaging. One such linker is the MMPs specific cleavable peptide Gly-Pro-
Leu-Gly-Val (GPLGV) [134]. The PEG-peptide-DOX micelle formulation improves the release and 
delivery of DOX both in vitro and in vivo [134, 135]. The second approach is to use the enzyme-
cleavable linkers to link segments of polymers or to use enzyme-degradable materials to loaded 
chemotherapeutic drugs or imaging agents and release them via enzyme degradation. Enzyme-
cleavable linkers crosslinked with hydrogel is among one of the most commonly used formulations. 
For example, cisplatin was loaded in PEG-diacrylate hydrogel wafers linked with an MMP substrate. 
The controlled release of cisplatin from the hydrogel upon MMP degradation improved the 
therapeutic outcome for the treatment of Glioblastoma multiform (GBM) [136, 137]. Gelatin is 
another frequently used nanocarrier that can be degraded by MMP-2, which is overexpressed in the 
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ECM. A recent study by Wong et al. indicated that a multistage NPs composed of 100 nm gelatin 
core covered with 10 nm quantum dots showed deep tumor diffusion. The triggered release of smaller 
NPs upon MMP degradation lowered the diffusional hindrance in the interstitial matrix compared to 
larger NPs. In the meantime, the lymphatic clearance rate for 10 nm NPs was significantly lower in 
comparison with free small molecular drugs [3, 16].   
1.8 Conclusions and Future Perspectives 
The treatment of tumors requires efficient delivery of therapeutic agents to the target cells 
through a series of transport steps, including vascular transport, transvascular transport and interstitial 
transport. The dense ECM structure and aberrant tumor vasculature constitute the physiological 
barriers that hinder the transport of NPs through these steps, and subsequently limit therapeutic 
outcome. In this review, we summarized the barriers and provided strategies to overcome these 
barriers for improved NPs delivery. However, penetration alone is not the only criteria to evaluate 
therapeutic response. Firstly, the approaches to remodel the TME for enhanced NPs transport may 
controversially promote tumor cells migration and metastasis, compromising or even reversing the 
therapeutic effects. As seen, degradation of collagen improves the NPs diffusion, but also increases 
the risk of tumor cell migration by eliminating barriers that usually prevent it. Using cell-based 
delivery systems such as stem cells with homing properties, may overcome the delivery barriers 
without adversely changing the TME. Secondly, heterogeneous distribution of NPs in the interstitium 
and disparate internalization of NPs to stromal cells may result in acquired resistance from TME and 
eventually lead to the treatment failure. Therefore, the current challenge is to design multifunctional 
NPs to target both tumor and stroma cells, blocking the resistant tumor-stroma crosstalk [138]. The 
heterogeneity of the TME also differs across different cancers or even individuals. So the optimal 
design of NPs is likely to be specific to each case. This is a formidable task, especially considering 
the differences between one type of tumor and another. However, this review emphasizes the 
heterogeneity as a potential reason for the discrepancy between the successes of many formulations in 
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preclinical studies but later failure in clinical trials. Further, we hope to provide guidance for the 
possibility of individual therapy.  
Thirdly, in addition to delivering therapeutic and diagnostic NPs to solid tumors, the delivery 
of NPs to metastatic sites for cancer therapy is even more difficult considering the difference in TME 
between primary tumors and the metastatic niche. Recently, Swami et al. approached this challenge 
by formulating NPs to target myeloma and the bone metastatic microenvironments [139]. 
Furthermore, a recent study on the relationship of melanoma-derived exosomes, which induce 
vascular leakiness at pre-metastatic sites, may provide a means of passively targeting NPs to 
metastatic sites [140]. More systemic cancer treatments may require the combination of immune 
therapy, and other methods.  
Overall, the advancement of NPs mediated cancer drug delivery has been fueled by 
discoveries in material science. These advances allow the development of nanotherapeutics that can 
cater to a seemingly endless number of situations. As examined, this versatility is crucial considering 
the differences between each tumor and across different patients. As each specific case demands its 
own specific treatment approach, the diversity of investigated and available nanotherapeutics proves 
promising to the advancement of cancer treatment.   
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Table 1.1 Summary of stromal barriers and strategies 
Major 
Barriers 
Type Barriers 
Constituent 
Barriers 
Mechanism 
Strategy 
Mechanisms 
Strategy 
Agents 
Applied 
Tumor 
Models 
Ref 
Vascula
ture 
 Angiogenesis
; 
Tortuosity; 
Low blood 
flow;  
High 
viscosity 
IFP 
increase; 
Solid stress 
Increase; 
EPR effect 
decrease 
Normalizatio
n 
DC101 (VEGF-R 
mAb); 
bevacizumab, 
ranibizumab 
(VEGF mAb); 
SST0001 
(Heparanase 
inhibitor); 
Trastuzumab 
(HER2-R mAb) 
Hypervasc
ulature: 
colon 
carcinoma, 
myeloma, 
melanoma 
[2, 
20, 
67, 
90] 
Leakiness  
Improvement 
Imatinib (PDGF 
antagonist);   
LY364947 (TGF-
β inhibitor); 
Thrombin 
(vasoactive 
agents)   
Angiotensin II 
(transient vessels 
pressure raising 
agent) 
Hypovascu
lature:  
pancreatic, 
lung and 
breast 
carcinoma 
 
[52, 
67, 
68] 
Stroma BM Collagen IV Thickness, 
mesh size, 
orientation, 
and density 
limit NP 
penetration  
Degradation Collagenase; 
MMPs 
Lung and 
breast 
carcinoma 
[48] 
Nidogen  Crosslinkin
g Collagen 
Network, 
and hinder 
the anionic 
NP 
- Modulating the 
surface charge 
and antifouling 
effect of NP  
- [2, 
51, 
58] 
Perlecan 
GAG Trap the 
cationic NP 
- - 
ECM Collagen I Same as 
Collagen 
IV 
Degradation Collagenase; 
Relaxin 
Lung 
carcinoma, 
melanoma 
[97-
99] 
 HA Partitioning 
collagen 
matrix into 
aqueous 
and viscous 
compartme
nts 
Degradation  
(Paradox) 
Hyaluronidase; 
PEGPH20 
Osteosarco
ma, PDAC 
[54, 
60] 
Stromal 
Cells 
TAFs  Secrete 
ECM 
molecules,  
stiffen 
ECM  
Reprogram to 
Normal 
Fibroblasts 
Losartan (inhibit 
collagen 
synthesis); VDR 
inhibitor (inhibit 
TAFs activation) 
Breast 
carcinoma, 
PDAC 
[105
, 
117] 
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Off target 
depletion 
NP 
TAF 
Depletion 
(Paradox) 
cisplatin NP and 
Doxectaxel 
conjugates; pFAP 
(anti-FAP 
vaccine); FAP 
substrate-drug 
Conjugates; FAP 
targeted 
liposomes 
Stroma 
Rich 
Bladder 
Cancer; 
4T1 breast 
cancer; 
colon 
[72, 
74, 
110, 
111] 
Peric
ytes 
 Regulate 
vasculature 
maturation 
and limit 
NP 
penetration 
 TGF beta 
inhibitors 
PDGF-β 
inhibitors 
VEGF inhibitors 
Pancreatic 
and breast 
carcinoma 
[66, 
68, 
92] 
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Table 1.2 Design of ECM targeted NP2 
Stimuli 
Factors 
Major 
Stimuli 
Structure 
Formulati
on 
Materials Stimuli 
Criteria 
Disease Model 
(Cell line) 
Drug In 
Vitro& 
In Vivo 
Ref
. 
Thermo 
Sensitiv
e 
PNIPAA
m 
Polymeric 
Micelle 
PNIPAAm-
b-PLA 
LCST 
36°~40° 
- Dox in vitro [14
1] 
P(NIPAAm
-co-
NDAPM)-
b-PCL 
LCST 
36.5° 
- Prednisone 
Acetate 
in vitro [14
2] 
PNAS-b-
PNIPAAm-
b-PCL 
LCST 
36.5° 
Hela Dox in vitro [14
3] 
DHBCS, 
PEG-b-
PNIPAM 
LCST 
32.0° 
PKH26 Dox in vitro [12
1] 
PNVCL Chitosan-g-
PNVCL 
LCST 
38.0° 
L929, MCF7, 
PC3, KB  
Curcumin in vitro [14
4, 
145
] 
P(mNVCL)
-co-
PNVCL 
LCST1 
20~24°; 
LCST2 
30~42° 
B16-F10 
melanoma 
Dox  in vitro 
 
[14
6] 
DPPC, 
DSPC 
Liposome DPPC, 
DSPC, 
CHOL, 
DSPE-
PEG2000 
Tm 41° SK-BR-
3,MDA-MB-
435 breast 
cancer; U87-
MG glioma; 
B16F10  
Dox in vivo 
& in 
vitro 
(externa
l) 
[14
7, 
148
] 
Leucine 
Zipper 
Peptide 
Lipid-
peptide 
NP 
Leucine 
zipper 
peptide;DP
PC, 
DSPC,MSP
C, HSPC 
Tm 40° 
 
B16F10, 
SW480 
 
Dox 
 
in vivo  
& in 
vitro 
[14
9] 
Elastin 
& 
Elastin 
mimetic 
NP Elastin/DN
A 
aggregation 
Tm 50-
60° 
- - - [15
0] 
pH 
Sensitiv
e 
PHis Micelle 
 
PEG-PHis-
PLL or 
PLL-b-
PEG and 
PHis-b-
PEG Mixed 
pKa 
~6.5; 
dissemb
ling 
 
4T1 breast 
cancer 
Dox in vivo [14
2, 
151
, 
152
] 
PHEMA-b- HCT116 Dox in vivo [15
                                                   
2PNIPAAm, poly(N-isopropylacrylamide); NDAPM, N-(3-(dimethylamino)propyl)methacrylamide; 
PNAS, poly(N-acroyloxysuccinimide); PNVCL, poly(N-vinylcaprolactam); DPPC, 1,2-dipalmitoyl-
sn-glycero-3-phosphocholine; DSPC, 1. 1,2-distearoyl-sn-glycero-3-phosphocholine; PAE, 
polyacrylic ester; PSD, polysulfonamide   
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PHis human colon & in 
vitro 
3] 
PAE PEG-b-
(PLA-co-
PAE) 
pKa 
~7.0 
HepG2 Dox in vitro [15
4] 
PEG-PAE BT-20, 
B16F10 
melanoma 
Paclitaxel in vitro [15
5] 
PC7A PEG-b-
PC7A 
pKa 
~6.9 
A549 Fluorescen
ce 
in vivo [13
2, 
133
, 
156
] 
PSD Polyplex PEG-
PSD/PEI 
NP 
pKa 
~7.0 
A2780, human 
ovarian 
carcinoma 
Gene  in vitro [15
7] 
Chitosan NP Chitosan-
silica 
nanosphere
s 
pKa~6.
3; 
swelling 
MCF-7 Breast 
cancer 
TNFα in vitro 
& in 
vivo 
[15
8] 
Enzyme 
Sensitiv
e 
MMP2- 
cleavabl
e 
octapept
ide 
liposome PEG-MMP 
cleavable 
peptide-PE 
(Gly-Pro-
Leu-Gly-
Ile-Ala-
Gly-Gln) 
MMP 4T1 breast 
cancer 
Fluorescent 
probes 
in vitro 
& in 
vivo 
[15
9] 
gelatin NP gelatin-
gold/quant
um dots 
fabricated 
multistage 
NP 
C6 glioma 
cells 
Gold NP, 
quantum 
dots 
in vitro  
& in 
vivo 
[3, 
160
] 
GPA 
peptide 
sequence 
Drug 
Conjugate 
Peptide-
FAP 
cleavable 
substrate-
promelittin 
protoxin 
FAP MCF7 breast 
cancer 
promelittin 
protoxin 
in vitro 
& in 
vivo 
[11
0] 
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Figure 1.1 Scheme of desmoplastic tumors 
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 CHAPTER 2: THE BINDING SITE BARRIER ELICITED BY THE TUMOR 
ASSOCIATED FIBROBLASTS INTERFERES DISPOSITION OF NANOPARTICLES 
IN THE STROMA-VESSEL TYPE DESMOPLASTIC3 
2.1 Summary 
The binding site barrier (BSB) was originally described decades ago that binding of antibody to 
cells near the vessel prevents it from deep penetration into the tumor. It is revisited herein with 
respect to the intratumoral cellular disposition of nanoparticles (NPs). Specifically, BSB limits NP 
diffusion and results in unintended internalizations of NPs by stroma cells localized near the blood 
vessels. This not only limits the therapeutic outcome, but also poses the danger of off-target adverse 
effects. In the current study, we showed that tumor associated fibroblasts (TAFs) are the major 
component of the BSB, particularly in desmoplastic tumors with a stroma-vessel architecture where 
TAFs align with the blood vessels. Specifically, TAFs’ distance to blood vessels, expression of 
receptor proteins, and binding affinity affect the intensity of BSB. The physical barrier elicited by 
extracellular matrix also prolongs the retention of NPs in stroma, potentially contributing to BSB. The 
influence of particle sizes on the BSB was also investigated. The highest BSB was found with small 
(~18 nm) NPs targeted with the anisamide ligand. The uptake of these NPs by TAFs was about 7-fold 
higher than that of the other cells 16 h post intravenous injection. This was because TAFs also 
expressed the sigma receptor under the influence of TGF-β secreted by the tumor cells. Overall, the 
current study underscores the importance of BSB in the delivery of nanotherapeutics and provide 
rationale of exploiting BSB to target TAFs. 
                                                   
3This chapter previously appeared as a manuscript soon to be submitted  
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2.2 Introduction 
The BSB hypothesis was originally proposed by Weinstein to explain the non-uniform 
distribution of monoclonal antibodies in tumor nodules [161, 162]. Specifically, he proposed that cell 
populations localized near the blood vessels with high antigen density and binding affinity are likely 
to elicit strong BSB [161, 162]. Beyond affecting antibodies, the BSB may be extended to the 
intratumoral dispositions of NPs [87]. Unintended binding of NPs to cells in vicinity of the blood 
vessels may significantly decrease the number NPs available for penetration into the tumor matrix 
[73]. Considering the heterogeneous stromal cell populations around the blood vessels, unintended 
uptake of NPs into these cells constitutes the basis of the off-target effect [81, 87].   
Stromal desmoplasia, in conjunction with tumor associated fibroblasts (TAFs), localize near 
blood vessels in multiple solid tumor systems such as pancreatic adenocarcinoma (PDAC), non-small 
cell lung cancer (NSCLC), aggressive urothelial carcinoma and breast cancer, suggesting TAF’s 
potential as major component of the BSB [68, 71, 163-166]. Previous studies conclude that TAFs can 
enhance cancer cell proliferation, invasion, and contribute to immune suppression [167]. Resultantly, 
destruction of TAFs through off-target distribution of therapeutic NPs has emerged as a promising 
therapeutic approach. The depletion of fibroblasts then decreases the synthesis of ECM proteins, 
downplaying mechanical barriers and facilitating targeting to tumor cells [72, 74]. However, recent 
studies paradoxically indicated the role that TAFs play in constraining tumor growth. Specifically, the 
transgenic depletion of FAP positive fibroblasts facilitated tumor growth and metastasis in a PDAC 
model [112, 168]. Furthermore, off-targeted distribution of therapeutic agents to TAFs may elicit 
paracrine secretion of survival factors such as Wnt16, promoting neighboring tumor cells’ drug 
resistance [169]. Moreover, the response of tumor cells and TAFs toward therapeutic agents is 
inconsistent across different models, leading to discrepancy in treatment outcomes [71]. Collectively, 
the investigation of fibroblasts as BSB is of great significance in understanding and solving off-target 
effects for the dilemma at hand.  
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Herein, the function of fibroblasts as BSB for NPs uptake was quantitatively investigated using 
lipid coated calcium phosphate nanoparticles (LCP NPs). LCP NPs possessed a steric surface with 
brush PEG coating and cationic lipid shell for enhanced uptake and release. In addition, LCP NPs 
demonstrated stable delivery of several modalities including macro-biomolecules and small 
phosphorylated drugs [170, 171]. Therefore, LCP NPs were used to evaluate tumor perfusion and 
predict therapeutic outcomes. By tuning the surfactant ratio, LCP NPs could also be prepared with 
variable sizes [172]. The influence of particle sizes on the BSB uptake was also investigated. 
Anisamide (AA), a model targeting ligand, was added on the surface of LCP NPs to evaluate the role 
of targeting ligands in dictating intratumoral cellular association of NPs [173]. To investigate 
fibroblasts’ role on BSB, their distance to blood vessels, expression of receptor proteins, and binding 
affinity were quantified. An in vitro tumor spheroid model was also established to evaluate the BSB. 
Based on the spheroid model, a mathematical model was created to assay the influence of each 
independent parameter. Overall, this study emphasizes the role of the BSB in dictating NPs delivery. 
Considering the large population of stromal cells, this study also investigates a platform to 
quantitatively evaluate the effect of the BSB on other stromal cell populations, providing guidance for 
NP-mediated treatment of desmoplastic tumors. 
2.3 Methods and Materials 
2.3.1 Materials 
Dioleoylphosphatydic acid (DOPA) and 1,2-dioleoyl-3-trimethylammonium-propane 
chloride salt (DOTAP) were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL). 1,2-
distearoryl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethyleneglycol-2000) ammonium 
salt (DSPE-PEG2000) and 1,2-distearoryl-sn-glycero-3-phosphoethanolamine-N-[amine 
(polyethyleneglycol-2000) ammonium salt (DSPE-PEG2000) were obtained from NOF America 
Corporation. The hydrophobic dye, 1,1’-Dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine 
perchlorate (DiI) was purchased from Thermo Fisher Scientific, Inc. (Carlsbad, CA). Double-strand 
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oligo DNA (sense sequence, 5’-CAAGGGACTGGAAGGCTGGG-3’) and Texas-Red labeled sense-
strand oligo DNA (sequence: 5’-[TxRd]CAAGGGACTGGAAGGCTGGG-3’) were both synthesized 
by Sigma Aldrich (St. Louis, MO). Cholesterol, 4-methoxybenzoyl chloride, 2-bromoethylamine 
hydrobromide, N,N-diisopropylethylamine (DIPEA) , dichloromethane, triton X-100, Igepal CO-520 
and cyclohexane were purchased from Sigma-Aldrich (St Louis, MO) without further purification. 
2.3.2 Cell Culture and Animals 
The human bladder transitional cell line (UMUC3) was provided by Dr. William Kim 
(University of North Carolina at Chapel Hill, NC). The mouse melanoma cell line D4M was a gift 
from Dr. Constance E. Brinckerhoff (Geisel School of Medicine at Dartmouth, NH). The mouse 
embryonic fibroblast cell line (NIH3T3), mouse breast cancer 4T1, human melanoma cell line A375lu, 
and human non-small cell lung cancer H460 were obtained from UNC Tissue Culture Facility. These 
cell lines were cultured in Dulbecco’s Modified Eagle’s Media (DMEM) (Invitrogen, Carlsbad, CA) 
(for UMUC3, A375lu, H460), Advanced MEM Media (For D4M), RMPI1640 (For 4T1) 
supplemented with streptomycin (100 μg/ mL) (Invitrogen), penicillin (100 U/mL), and 10% fetal 
bovine serum (Sigma, St. Louis, MO) respectively. NIH3T3 was cultured in DMEM supplemented 
with 10% Bovine calf serum (Hyclone, Logan, Utah). Cells were cultured in a humidified incubator at 
37 °C with 5% CO2.  
Female athymic nude mice used in all studies weighed between 22–28 g and were 6–8 weeks 
of age. They were provided by the University of North Carolina animal facility. Animals were cared 
for in the Center for Experimental Animals (an AAALAC accredited experimental animal facility) at 
the University of North Carolina. Experimental animal handling procedures were performed 
following the protocols conformed to the Guide for the Care and Use of Laboratory Animals and 
approved by the University of North Carolina Institutional Animal Care and Use Committee.  
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2.3.3 Synthesis of DSPE-PEG2000-AA 
The synthesis was performed according to the previous synthetic protocol with some 
modifications [173]. Firstly, an aqueous solution of 2-bromoethylamine hydrobromide (1.32g, 6.4 
mmol) was mixed with 4-methyoxybenzoyl chloride (1g, 5.8 mmol) in 50 mL of warm benzene to 
synthesize the N-(2-bromoethyl)-4-methoxy-benzamide. The mixture was shaken and cooled under 
running water. At the meantime, a 5% aqueous solution of sodium hydroxide was added dropwise to 
the mixed emulsion. The precipitate was solidified out of the reaction mixture within a few minutes to 
form an amorphous mass. The mixture was continued stirred for 1h. And then, the sold amide was 
filtered with suction and washed once with benzene and air dried for 2-3h [174]. Then, the 
synthesized N-(2-bromoethyl)-4-methoxy-benzamide (100 mg, 0.4 mmol) was reacted with DSPE-
PEG-NH2 (100 mg, 23.3 μmol) in acetonitrile (5 mL) in the presence of DIPEA (30 μL, 0.2 mmol) at 
65-70 °C for 16h. After removing the solvent by rotary evaporation, 5 mL of methanol was added to 
dissolve the pellet followed by precipitating with excess ether (50 ml). The mixture was then kept at -
80 °C overnight. Afterwards, the precipitate was collected by centrifugation and recrystallized twice. 
The overall yield was 70%. The product was characterized by NMR and TLC as reported elsewhere 
[173].  
2.3.4 Preparation of LCP NPs with Tunable Size 
Briefly, one hundred μL of 500 mM CaCl2 was dispersed in 8 mL of oil phase containing 
Igepal CO-520/cyclohexane (29:71, V:V). The other emulsion was prepared by adding 100 μL of 100 
mM pH9.0 Na2HPO3 into a separate oil phase. Another 185 μL of 37.5 mM DOPA was added to the 
phosphate phase before mixing of the two separate emulsions. The mixed emulsion was then stirred 
for 45min, and 16 mL of ethanol was added and the mixture, which was centrifuged at 10,000 g for 
15 min to remove the surfactants and cyclohexane. After being washed with ethanol twice, the pellets 
were re-dispersed in 250 μL of chloroform for storage.  To label the LCP core, 16 μL of 2 mg/mL 
Texas Red labeled oligonucleotide was added to the CaCl2 phase and the LCP core was prepared with 
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the same method as mentioned above. To tune the LCP core size, a Trition surfactant system 
(cyclohexane/hexanol/Trion X-100=75/0/15, v/v/v) was mixed with the original Igepal surfactant 
system. As the portion of the Triton surfactant system increased (from 1:0, to 1:7, as Igepal:Triton 
surfactant), the size of LCP core could be enlarged from 8~10 nm to ~50 nm. To create the outer 
leaflet coating, 100 μL of 20 mM DOTAP, 100 μL of 20 mM cholesterol and 50 μL of 20 mM of 
DSPE-PEG2000 (all in chloroform) were mixed with the LCP cores. After the removal of chloroform, 
the precipitate was suspended in a small volume of pre-warmed THF and ethanol, and then dispersed 
in water. As expected, when the cores size increased to 50nm, the final LCP enlarged to around 65nm 
in diameter. To create the AA targeted LCP NPs, 20 μL of 20mM DSPE-PEG2000-AA was mixed with 
30 μL of 20mM DSPE-PEG2000 and added to the outer leaflet lipid mixture followed by the same 
preparation method.  
Particle size and zeta potential of purified LCP NPs were measured using a Malvern 
ZetaSizer Nano series (Westborough, MA).  The morphology of LCP cores and LCP NPs were 
determined by TEM microscopy (JEOL 100 CS II). The final LCP NPs were negatively stained with 
2% uranyl acetate.  
2.3.5 Preparation of Fluorescence-labeled LCP NPs 
The LCP NPs was prepared using a previously described method with some adjustments. 
Additional details of NPs manipulation are provided in the Supplementary Methods.  To label the 
final LCP NPs, 0.5% DiI (mole/mole) was mixed with the outer leaflet lipid solution before the 
solvent was removed. Sucrose gradient centrifugation was performed to remove the excess lipid. 
Briefly, LCP NPs were loaded into a tube containing a sucrose density gradient ranging from 0% to 
60% (w/w). After ultra-centrifugation at 40,000 g for 3 h, excess lipids in the upper part of the 
gradient were separated from the dense LCP, which formed a sharp band around the 10~30% layer in 
the gradient. The morphology from each layer was confirmed by TEM.  
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2.3.6 GFP/RFP Lentivirus Transduction in NIH3T3 Fibroblast and UMUC3  
Lentiviral agents with RFP and GFP were generously provided by Dr Shawn Hingtgen 
(University of North Carolina at Chapel Hill, NC). The virus particles were assembled via 
transfecting 293FT packaging cells. The virus-containing culture medium was harvested and filtered 
through 0.45-μm syringe filters 48 to 96 hours post-transfection. NIH3T3 fibroblasts and UMUC3 
cells were then infected by exposure to virus-containing medium for 48 hours, maintained in the 
complete medium, followed by selection in puromycin.    
2.3.7 Sigma Receptor Silencing with Small Hairpin RNA (shRNA) in NIH3T3 Cell Lines 
Sigma R shRNA lentivirus particles and control shRNA lentiviral particles were purchased 
from Santa Cruz. The transduction process were performed followed the protocols provided by the 
manufacturer. In brief, the NIH3T3 and GFP transfected NIH3T3 cells were infected by exposure to 
virus-containing medium for 12 to 16h, maintained in the NIH3T3 complete medium, followed by 
selection in puromycin. The interference of Sigma R was confirmed by western blot with pretreating 
the cells with TGFβ (10 ng/mL, 24h). 
2.3.8 Preparation of Tumor Models 
Female nude mice (18~22 g) were inoculated subcutaneously with a combination of NIH3T3 
(2.5×106 cells) and UMUC3 (5×106 cells), or with H460 (5×106 cells, 100 μL) to form the stroma-
vessel phenotype tumor model, or with A375lu (5×106 cells, 100 μL) to form the tumor vessel 
phenotype tumor model. The 4T1 cells (5×105 cells, 50 μL) were orthotopically inoculated into the 
breast fat pads of the BALb/c mice and the D4M. 7A cells were injected intradermally (3×105 cells, 
50 μL) into C57/B6 mice to form the stroma-vessel and tumor-vessel type models, respectively, in the 
syngeneic host.   
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2.3.9 Plasma Clearance 
Tumors were allowed to grow until reaching a diameter of 4–8 mm (2–3 weeks post-
inoculation) for in vivo pharmacokinetics and biodistribution studies. Mice were injected 
intravenously via the tail vein with 3H labeled LCP NPs with similar 3H levels. At 5 min, 15 min, 30 
min, 1, 2, 4, 8, 12, 24, 48, and 72 h post-injection, blood samples were collected from the saphenous 
vein using a heparinized capillary tube. The amounts of radioactivity in the blood and tissue samples 
were determined by liquid scintillation.  
2.3.10 Intratumoral Distribution of LCP NPs.  
3H (3H-chesterolester) -labeled LCP NPs were intravenously administered into nude mice 
bearing UMUC3/3T3 GFP (300 mm3) (n = 4). At determined time points, mice were euthanized. 
Tumor tissues were transferred to a dish and dissociated with tumor cell digestion solution (1 mg/ml 
collagenase A, 0.1 mg/mL HAse, 0.2 mg/mL DNAse), followed by incubation at 37°C for 40 min. 
Dissociated tumor cells were then collected by centrifugation. Extracellular radioactivity was 
collected from the supernatant. This method was validated previously to produce highly pure 
cytoplasmic fractions. Dissociation of the tissue samples likely leads to a certain degree of cell 
rupture: therefore, the amount of 3H-LCP NPs measured in the intracellular fractions may be an 
underestimate. However, it should be noted that all tumors harvested from each treatment groups 
were homogenized in the same manner. In this way, the data afforded relative comparisons with no 
preferential bias towards mice treated with either method.  
2.3.11 Measurement of Binding Affinity of L-LCP NPs for UMUC3 and Activated NIH3T3.  
A modification of the method reported by Zhou et al. (2007) was performed to determine the 
binding affinity of LCP NPs to Sigma R expressing cells. Briefly, 2×105 UMUC3 cells, NIH3T3 cells 
(activated with TGF-β 10ng/mL, overnight), or GFP-positive fibroblasts sorted from the tumor tissues 
were incubated with various dilutions of DiI labeled L-LCP NPs (+/- AA) at 4 °C for 40min 
(concentration of NPs ranges from 0.31-2.5 nM) in FACs buffer. Considering the similar surface 
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properties of LCP to liposomes, the concentration of LCP NPs was roughly converted from the 
concentration of phospholipid on the basis of the approximate number of phospholipid molecules per 
120 nm liposome (80,000).  Then the reaction was stopped by washing twice with FACs buffer. 
Afterwards, the amount of cell-bound NPs was quantified by flow cytometry in BD FACs Machine. 
Kd values were determined by the following equation: 
MFI = MFImin + MFImax( ), 
where MFI=mean fluorescence intensity, MFImin=background fluorescence, MFImax was calculated 
from the plot. The term [NP] has been substituted for [NP-NPbound], the unbound NP concentration, 
based on the assumption that the concentration of bound NPs is much less than total NPs.    
2.3.12 Flow Cytometry Analysis.  
To study the kinetics of the intratumoral cell populations that took up NPs, DiI-labeled LCP 
NPs (S/L, +/- AA) at a dose of 300 µg/kg DiI were intravenously administered into nude mice bearing 
UMUC3/GFP-3T3 xenograft (tumor volume, 400~600 mm3, n=3~6 for each group). The mice were 
euthanized at determined time points and tumor tissues were collected. Fresh tumor tissues were 
dissociated with the digestion solution to generate a single cell suspension. After red blood cell lysis, 
cells were washed with PBS and subjected to flow cytometry analysis.  To study the non-target LCPs 
NP (S/L) dispositions in 4T1, H460, D4M, A375Lu at early time point, the same dose of DiI-LCP 
NPs was intravenously injected into mice bearing different tumors. Mice were sacrificed 8 h post 
injection and subjected to the same treatment as mentioned above. After obtaining single cell 
suspensions, cells were fixed with 2 % paraformaldehyde. For the staining of fibroblasts with 
PDGFRα, the fixed cells (5*106 cells/mL) were stained with APC anti-mouse PDGFRa antibody (BD 
bioscience, San Jose, CA) and processed following the manufacturer’s instruction. For the staining of 
intracellular fibroblasts marker, αSMA, the cells from the tissues were penetrated with penetration 
buffer (BD, Franklin Lakes, NJ) following the manufacturer’s instructions. The anti-mouse αSMA 
(Abcam, Cambridge, MA) and isotype control were then applied, followed by extensive washing and 
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Fluor 647 conjugated anti-rabbit secondary (Abcam, Cambridge, MA) staining. All staining 
procedures were carefully compensated by flow cytometry. To analyze the expression of Sigma R in 
tumor cells and fibroblasts, and to evaluate how the expression levels correlated with the DiI-LCP 
NPs’ distribution, cells were stained with an anti-Sigma R antibody (Santa Cruz biotechnology, Inc.) 
following the same staining protocol. The UMUC3 cells were pre-transfected with red fluorescence 
protein (RFP) and fibroblasts were pre-transfected with green fluorescence protein (GFP) to define 
the cell populations (n=3~6). The flow cytometry data were analyzed using FlowJo 7.6.1 (FLOWJO, 
Ashland, OR). The % of DiI-positive cells per cell population was calculated according to the 
following equation: 
 % of DiI positive cells per cell population
= % of ("#$
%&'' ()(*'+,#)-) of the parent cells
% of  ("#$ %&'' ()('*'+,#)- + "#$/%&'' ()(*'+,#)-∓)of the parent cells 
Cell population indicates either GFP-3T3, RFP-UMUC3, Sigma R+ or CD45+ cell populations. 
2.3.13 In vitro NP Penetration in a Core-Shell Tumor Spheroid Model.  
 For evaluating the effects of the binding site barrier elicited by fibroblasts in vitro, an ex vivo 
multicellular Core-Shell 3D tumor spheroids mimicking the single tumor nest surrounded by 
fibroblasts were developed using the lipid overlay system with some adjustments. This models was 
used to study the penetration behavior of LCP NP after extravagating from the blood vessel. In brief, 
1×104 UMUC3 cells were seeded into each well (using complete medium) of the ultra-low 
attachment round bottom 96 well plates (Costar, Corning, NY), followed by slight centrifugation at 
900 rpm for 2min to cluster the cells to the bottom of the wells, and incubated at 37°C for 4 days. The 
culture medium was changed every 2 days. On the fourth days, 1×104 GFP-NIH3T3 cells were added 
into each well, followed by continuous gentle rotation (200 rpm, 37°C) for 6h. And then the formed 
core-shell tumor spheroid was incubated overnight. The structure of the core-shell spheroid was 
confirmed using a Zeiss LSM700 confocal microscope. Briefly, the spheroid was carefully transferred 
to a chambered coverslips and scanned from the bottom. Each scanning layer was 15 mm in thickness, 
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and the total scanning was 90 mm in depth. Only the ones with uniform and compact core-shell 
structure were selected for the follow-up studies (approximatedly 20 out of the 96 well-plate). For the 
time-lapse assay, fluorescent images were acquired at fixed focus at determined time points. Radial 
fluorescence intensity profiles in the spheroids were generated using a customized script in ImageJ. 
Average fluorescence intensity were determined for two annular regions; the tumor region (non-
fluorescence) and the fibroblast region (fluorescence region). The treated spheroids were also washed 
with PBS, and dissociated with collagenase and trpsinase. The DiI positive cell populations in both 
fibroblasts and tumor cells were quantified by Flow Cytometry.  
2.3.14 Mathematical Modeling of the 3D spheroid 
We model the tumor spheroids as perfect spheres (radius 1 = 50045 ) with radially 
symmetric NP concentrations (parameters shown in Table 2.2). The Stokes-Einstein diffusion 
coefficient in water for a particle of radius 18-5  is "8 = 4.9 × 10=45>/hour . We expect the 
effective diffusion coefficient of NPs within the spheroid to be less than the Stokes-Einstein diffusion 
coefficient due to the porous ECM. We also consider that the diffusion coefficient within the 
fibroblast layer may be less than regions of the spheroid containing tumor cells. The equation for the 
extracellular concentration of NPs within the spheroid is 
@A
@, = "B>A(C, ,) − FA(C, ,),  0 < C < 1, 
where F is the NP absorption rate. Initially, there are no NPs within the spheroid, so we set 
A(C, 0) = 0,  0 < C < 1. 
Each spheroid is in a solution with a fixed concentration %IJ  of NPs. Covering each sphere is a 
permeable barrier, possibly due to ECM, restricting the diffusive flux of NPs into the spheroid. This 
is modeled by imposing a boundary condition at the spheroid edge: 
" @@C A(1, ,) =
1K
3 %IJ − A(1, ,), 
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where K is the rate at which NPs enter the spheroid. Based on NP distribution within the spheroids, 
we find that %IJK = 2.34 ± 0.097, which did not vary significantly between spheroids or between 
targeted and non-targeted NPs. The averaged concentration absorbed into cells is 
%PQRSTQUV(,) = 3F1W X C>
Y
Z
A(C, ,)[C. 
The total concentration of NPs (both absorbed and extracellular) within the spheroid is  
A\(C, ,) =  A(C, ,) + F X A(C, ])[].
^
Z
 
To determine the diffusivity and the NP absorption rate, we first examine the data set for the S-LCP 
spheroid. We define the diffusion time _` = 1>/(4") as the time it takes for a concentration starting 
at the spheroid edge to diffuse inward so that the concentration at the center is roughly 80% of the 
value at the edge. Because the concentration is distributed relatively evenly within the tumor, we can 
conclude that NPs have time to diffuse throughout the spheroid before they get absorbed; in other 
words _` < 1/F . We find that " = 3.1 × 10=45>/hour  and F = 0.25(hour/a)  provides a 
reasonable match between the model and the data. 
We next examine how the NP distribution within the UMUC3-only spheroid changes for AA 
S-LCP NPs. Because the AA S-LCP NPs have roughly the same hydrodynamic radius as the S-LCP 
NPs, we assume they have the same diffusion coefficient. The AA S-LCP NPs have a higher uptake 
rate than the S-LCP NPs. The distribution of NPs within the UMUC3-only spheroid is shifted toward 
the edge because more NPs are absorbed before they have time to diffuse very far into the spheroid. 
We find that a four-fold increase in the uptake rate for AA-S LCP provides a reasonable match 
between our model and the data. 
In the UMUC3-3T3 spheroid, the outer layer is comprised of fibroblasts. Based on Figure 
2.9C and D), we assume that the uptake rate by fibroblasts is the same as tumor cells. Because the 
ECM excreted by fibroblasts has smaller average pore size, the diffusion coefficient in the outer 
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stroma layer is reduced. The model prediction of the NP distribution with a 65% reduction of the 
diffusion coefficient in the stroma matches well with experimental data. 
The mathematical model provides qualitative guidance and reasonable quantitative accuracy. 
Improved accuracy can be achieved by expanding the model to account for non spherical shape of 
tumor spheroids, heterogeneity within the spheroid, and variations in the diffusivity due to ECM and 
cell density. However, based on the qualitative behavior and observed timescales of absorption and 
diffusion, we conclude that an increased absorption rate acts as a barrier to NP penetration into the 
spheroid center when the average absorption time becomes less than the diffusion time (i.e., 1/F <
_`), and that this effect is amplified when the diffusion coefficient is reduced in the fibroblast layer at 
the edge of the tumor. 
2.3.15 Western-blot Analysis 
For the analysis of Sigma Receptor expression levels in different cell lines. Cultured UMUC3, 
activated NIH3T3 (treated with 10 ng/mL TGF-β for 0, 24, 48h respectively), and other normal 
fibroblast cell lines including MRC5, PA319, WI-38, were collected and lysed using 
radioimmunoprecipitation assay (RIPA) buffer (Sigma). After incubation on ice for 30 min, the 
concentration of total protein in each cell lysates was quantified using bicinchoninic acid (BCA) 
protein assay reagent following the manufacturer’s instruction (Thermo, Rockford, IL). Then, 
identical amounts of protein samples were diluted with 4×sample buffer containing a reducing agent 
and heated at 95 ºC for 5 min, 40 μg of protein per lane was separated by 4–12% SDS-PAGE 
electrophoresis (Invitrogen, Grand Island, NY). After gel separation, the proteins were transferred to 
polyvinylidene difluoride (PVDF) membranes (Millipore, Billerica, MA). The protein loaded 
membranes were blocked with 5% skim milk for 1 h and incubated overnight at 4 ºC with anti-Sigma 
Receptor primary antibody and the loading control GAPDH antibody (1:4000 dilution; Santa Cruz 
biotechnology, Inc.), respectively. On the second day, the membranes were washed three times and 
then incubated in horseradish peroxidase-conjugated secondary antibodies (1:4000 dilution; Santa 
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Cruz biotechnology, Inc.) at room temperature for 1 h. Finally, the membranes were washed four 
times and detected using the Pierce ECL Western Blotting Substrate following the manufacturer’s 
instructions (Thermo Fisher Scientific).  
2.3.16 Immunofluorescence Staining 
For the frozen tissue sections, mice bearing different tumors, were intravenously injected 
with DiI-labeled LCP NP, or Texas Red labeled LCP NPs, at determined time points, mice were 
sacrificed and tumor tissues were collected. Tissues were fixed with 4% paraformaldehyde overnight, 
and dehydrated with sucrose gradient. Then, fixed tissues were frozen in OCT (Tissue-Tek, Dublin, 
OH) on dry ice. After the generation of 5 µm thick cryosections, the tissue sections were then 
mounted on Superfrost Plus slides (Fisher Scientific Co., Houston, TX). After the brief rinse with 
PBS, some of the tissue sections were mounted with ProLong Gold antifade reagent with DAPI 
(Invitrogen). Other slides were blocked with 1% bovne serum albumin at room temperature for 1h, 
followed by anti-CD31 (Abcam, Cambridge, MA) primary antibody staining overnight at 4C. On the 
second day, after being washed three times, tissue sections were stained with Fluor 647 conjugated 
anti-rabbit secondary antibody (Abcam, Cambridge, MA), and then mounted with mounting solution 
containing DAPI. For paraffin embedded sections, paraffin embedded tissues were prepared by the 
UNC Tissue Procurement Core and the slices were deparaffinized, antigen retrieved, permeabilized 
and fixed if necessary and blocked with 1% BSA at room temperature for 1h. Cell markers (including 
αSMA, Sigma Receptor, CD31) were detected with primary antibodies followed by visualization 
using Fluoro conjugated secondary antibodies. All antibodies were diluted after optimization. Images 
were taken using fluorescence microscope (Nikon, Tokyo, Japan). Three randomly selected 
microscopic fields were quantitatively analyzed using Image J software.   
2.3.17 Cellular Uptake Study in single cell layers  
UMUC3 cells and pre-activated fibroblasts were seeded into a 48-well plate (1.5 x105 
cells/well) containing 1 ml of media. Twenty-four hours later, 500 µL of DiI labeled LCP NPs were 
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incubated with cells in a serum-free medium. At determined time points, cells were dissociated, the 
mean DiI intensity in each cell line was analyzed by flow cytometry.   
2.3.18 Statistical Analysis.  
Data are presented as Mean ± SD (standard deviation). A two-tailed Student’s t-test or a one-
way analysis of variance (ANOVA) were performed when comparing two groups or larger than two 
groups, respectively. Statistical significance was defined as the P value less than 0.05. Statistical 
analysis was performed using Prism Software.   
2.4 Results 
2.4.1 Characterization of LCP NPs  
LCP NPs were prepared according to established protocols [172]. By adjusting the 
composition of the surfactant system, LCP core sizes could be tuned between 6 to ~50 nm. The 
hydrophobic DOPA-cores were further self-assembled with outer leaflet lipids to form the 
asymmetric lipid-bilayer NPs (Figure 2.1A-D). Sucrose-gradient centrifugation was used to purify 
LCP NPs. Approximately 0.5% DiI was incorporated into the outer leaflet to monitor the purification 
process. LCP NPs containing dense CaP cores localized at the interface between the 10% and 20% 
sucrose layers. TEM imaging confirmed successful purification of LCP NPs (data not shown). 
Particle size and surface modifications had minimal effect on purification efficacy as approximately 
85% of DiI labeled NPs were consistently recovered (Table 2.1). 
Large LCP NPs (diameter ~65 nm and PDI ~ 0.3) are termed L-LCP NPs. Smaller LCP NPs 
(diameter ~18 nm and PDI ~ 0.2) are termed S-LCP NPs (Table 2.1). All NPs demonstrated a clear 
core/membrane structure as determined by TEM and presented similar positive zeta potentials 
ranging from 18~20 mV due to cationic DOTAP (Figure 2.1 and Table 2.1). Structure and zeta 
potential were independent of particle size and particles maintained their diameters over 96 h (Figure 
2.1E). NPs showed similar plasma clearance rates independent of size or the presence of targeting 
ligands (Figure 2.1F), consistent with studies using other NPs of different sizes and targeting motifs 
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[52, 175]. To confirm that outer leaflet lipids containing DiI served as a feasible tracker, the integrity 
of NPs before cellular internalization was determined in vivo. A hydrophilic Texas Red oligo was 
encapsulated into the CaP core along with hydrophobic DiI in the outer leaflet of L-LCP NPs. The 
fluorescence intensity of each dye remained similar when loaded alone or simultaneously into the 
NPs, suggesting low to no intermolecular Főrster resonance energy transfer (FRET) between two 
fluorophores interfering with the fluorescence measurement (Figure 2.2). Therefore, co-expression of 
Texas Oligo and DiI in an individual tumor cell after systemic circulation is an indication of NP 
integrity. Flow cytometry analysis indicated that ~15% of cells in the tumor tissue co-expressed the 
aforementioned two fluorophores within 16 h after injection of the double labeled NPs (Figure 2.1G), 
accounting for ~70 % of all the fluorescence positive cells. Dissociated single-dye positive cells were 
observed 28 h post injection, probably due to dissociation of NPs trapped in the extracellular matrix 
(ECM) or intracellular degradation of released fluorophores. Data herein suggests that DiI localized 
in the outer leaflet remains associated with the inner core within 16 h during systemic delivery. The 
co-localization of these two fluorophores was also visualized by confocal microscopy (Figure 2.1H). 
Majority of these dyes were distributed in the GFP positive stromal area, only a small portion was 
observed in other cells. Thus, size tunable DiI-labeled LCP NPs were suitable for the evaluation of 
NP size or surface properties on intra-tumoral cellular distribution.   
2.4.2 Binding Site Featured by TAFs within the Stroma-vessel Type Tumors Affects the 
Intratumoral Dispositions of Non-targeted NPs at Early Time Point 
The role of stromal patterns on the intratumoral distribution of NP was investigated. 
According to the criteria proposed by Smith et al., malignant solid tumors are categorized into two 
phenotypes based on the stromal architecture [71]. In stroma-vessel phenotype tumors, e.g. breast 
cancer 4T1 and NSCLC H460, immunofluorescence (IF) indicated the formation of tumor nests 
surrounded by well-developed stroma structures containing the majority of CD31-positive vessels and 
αSMA-positive fibroblasts. Whereas, in melanoma tumors such as D4M and A375lu, the tumor 
vessels are embedded throughout the tumor cell mass, revealing a tumor-vessel phenotype, 
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represented in Figure 2.3A. The influence of stromal architecture on NP dispositions would be best 
visualized in animals bearing two tumor phenotypes and treated with highly permeable NPs with 
minimal selective cellular binding. Further, the difference should be magnified at earlier time points 
[162]. Therefore, D4M and H460 were used as model tumors in animals treated with non-targeted S-
LCP NPs and examined 8 h after injection. The representative images are shown in Figure 2.3B. 
Since these two tumors vary in blood vessel perfusions and interstitial fluid pressures (IFP), the 
results should be interpreted with caution. Yet, the percolation of S-LCP NPs from blood vessels into 
both αSMA positive stroma and the negative area was observed in the tumor-vessel phenotype tumor, 
D4M. Meanwhile, the majority of DiI-positive S-LCP NPs were trapped in the stroma of H460, a 
stroma-vessel type tumor. Therefore, proximity of stromal components to blood vessels likely dictates 
the distribution of non-targeted NPs in regions of dense stroma in stroma-vessel type tumors.  
Mechanical barriers such as tight junctions, ECM or elevated IFP can trap non-targeted NPs 
in the non-cellular stroma [161]. The binding and internalization of NPs in the cellular compartment 
of the stroma (BSB) also depletes the NPs. To examine role of BSB in stromal cells, the association 
of DiI-labeled NPs with major stromal cells (fibroblasts) was investigated. Individual cells were 
collected after tumor tissue digestion and labeled with anti –αSMA, commonly used for TAFs [176]. 
After staining, samples were studied with flow cytometry and results were shown in Figure 2.3C. In 
stroma-vessel type tumors (both H460 and 4T1), association of DiI NPs (S/L) with αSMA positive 
was ~2- to 3-fold higher than those delivered to the tumor nests. Stroma densities vary among tumors 
(i.e., 4T1 has higher amount of stroma than H460), but the preferential distribution of NPs in stroma 
remains constant. Consistent with previous findings, smaller NPs demonstrated higher association 
with total cells, but the association ratio between fibroblasts and other cells (mainly tumor cells) was 
independent of size. However, the trend was reversed in the tumor vessel models (D4M and A375lu) 
where tumor cells favored DiI NPs’ accumulation. The data suggests that the binding site 
characteristic of fibroblasts was independent of particle size and stroma density, but was strongly 
dependent on whether the blood vessels are associated with the stroma.  
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To minimize the interference of heterogeneity in fibroblasts and the non-specific staining 
using antibodies, a xenograft model consisting of the GFP transfected NIH3T3 fibroblasts (GFP-3T3) 
and human bladder cancer UMUC3 was established. It was found that this bladder tumor mainly 
adopted a tumor-vessel structure when smaller than 200 mm3. The tumor then transitioned to a 
stroma-vessel structure when larger than 400 mm3 (Figure 2.4A). Consistent with the previous results, 
NPs specifically favor fibroblasts in large tumors, independent of the size of the NPs tested (Figure 
2.4B). This observation was also paralleled in a patient derived xenograft bladder cancer model 
(Figure 2.4C), suggesting the artificial UMUC3/3T3 model can recapitulate the NP disposition 
features in the patient tumors. All data herein demonstrates that the binding site characteristics of 
fibroblasts in stroma-vessel tumors affect the initial distribution of non-targeted NPs. Since stroma-
vessel tumors often indicate poor patient prognosis, further studies on these tumor subtypes were 
conducted using UMUC3/3T3 (> 400 mm3, ~30% fibroblasts) as a standard model.  
 
2.4.3 Fibroblast induced BSB was Intensified and Prolonged for Targeted NPs in the Stroma-
vessel Type Tumor Models 
AA has been exploited for targeted delivery of NPs to many epithelial cancers over-
expressing the sigma receptor (Sigma R) [170, 173, 177]. To assess whether AA could increase 
binding affinity of LCP NPs to tumor cells and overcome the fibroblast-mediated BSB, the 
intratumoral dispositions of NPs (+/-AA) were examined. Eight % of AA (40 % of total DSPE-PEG) 
was coated onto the surface of NPs to ensure enhanced cellular uptake while maintaining the same 
physicochemical properties (Figure 2.1and Table 2.1). The time-dependent disposition of NPs in 
GFP positive fibroblasts and other cell populations were further measured by flow cytometry and 
compared. As expected, non-targeted NPs gradually extravasated from the stromal layer for binding 
and internalization by tumor cells, despite the presence of BSB. Consistent with other studies, S-LCP 
NPs were preferentially internalized by tumor cells over L-LCP NPs. Sixteen h after injection, over 
40 % of cells containing S-LCP NPs were tumor cells and over 30 % of tumor cells were DiI-positive. 
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Surprisingly, the addition of AA did not increase the ratio of DiI-positive tumor cells. Rather, the 
initial association ratio of NPs (S/L) with fibroblasts increased almost two-fold over non-targeted NPs 
and was plateaued over 16 h (Figure 2.5A). The preferential association of NP with stroma was 
further confirmed by fluorescence imaging (Figure 2.5B). After 4 h, NPs were localized within the 
GFP-positive stroma. The S-LCP NPs demonstrated a disperse distribution pattern compared to L-
LCP NPs. Perhaps, either uneven blood vessel permeabilization or differences in ECM composition 
may have limited the distribution of large NPs. However, at 16 h post injection, non-targeted S-LCP 
NPs in particular, expanded across the stroma and penetrated deeper into the tumor core (arrows in 
Figure 2.5B). In contrast, the stromal matrix was populated with targeted NPs, leaving minimal 
distribution in the GFP negative area (Figure 2.5B). Therefore, the fibroblast-mediated BSB was 
intensified and prolonged when NPs were modified with AA.   
2.4.4 Increased Expression of Sigma Receptor in TAFs Resulted in the Enhanced BSB for 
Targeted NPs 
The distribution of Sigma R was then evaluated by co-immunostaining Sigma R with GFP-
positive fibroblasts, CD31 or αSMA. Results in Figure 2.6A demonstrate a heterogeneous Sigma R 
distribution. Tumor cell-rich areas were primarily Sigma R-positive, whereas, CD31-positive 
endothelial cells were not. However, the distribution of Sigma R was uneven among GFP-fibroblasts 
(Figure 2.6C). Primarily, the expression of Sigma R was greater in αSMA-positive fibroblasts than 
αSMA-low fibroblasts (Figure 2.6B and C). Consistently, other tumor models, 4T1, A375lu and 
H460 (Figure 2.6D-F) expressed different levels of Sigma R in the αSMA-positive activated 
fibroblasts, suggesting that the expression of Sigma R positive fibroblasts was not unique to the 
mixed bladder cancer xenografts. Furthermore, western blot analysis indicated that under normal 
conditions, the expression level of Sigma R in fibroblasts (e.g., NIH3T3, MRC5, WI-38) was 
constantly low compared to tumor cells, which was consistent with previous findings (Figure 2.6G). 
This was actually the rationale of utilizing AA coated NP for specific tumor targeting. However, 
fibroblasts activated by TGF-β (TAFs) showed increased both αSMA and Sigma R expressions with 
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time (Figure 2.6H), and consistently a higher uptake efficiency for the targeted, but not the 
untargeted NPs compared to un-activated fibroblasts (data not shown). Therefore, activated TAFs 
expressing higher levels of Sigma R induced enhanced uptake of NPs and led to an intensified BSB. 
To confirm the aforementioned hypothesis, individual cells in tumor tissues were collected 8 
h post NP injection for Sigma R staining and flow cytometry. To exclude interference from other 
stromal cells, the tumor cells were pre-transfected with fluorescent RFP. As shown in Figure 2.7A-E, 
the association of NPs with cells increased with the expression of Sigma R. Consistent with previous 
findings, the fibroblasts were categorized based on the expression level of Sigma R, into Sigma R (-), 
Sigma R low (L) and Sigma R high (H) (Figure 2.7C and Figure 2.8). Next, a fibroblast cell strain 
expressing shRNA specific to Sigma R to block induction of Sigma R expression was generated 
(Figure 2.7F). NIH3T3-GFP (shRNA Sigma R) cells were mixed with UMUC3 and inoculated, low 
to no level of Sigma R expression of fibroblasts in the knockout model was confirmed (data not 
shown). As expected, the disposition of IV administered AA-targeted NPs in Sigma R knockout 
fibroblasts was significantly decreased, while association of NPs with tumor cells increased compared 
to standard NIH3T3/UMUC3 model (Figure 2.7G). Thus, specific AA-Sigma R interactions 
facilitated BSB in fibroblasts for targeted NPs.   
2.4.5 High Binding Affinity Explains the Intensified BSB for Targeted NPs 
The binding affinity of NPs to fibroblasts and tumors is a direct indicator of the BSB strength. 
As described above, fibroblasts possess a heterogeneous expression of Sigma R in vivo. Thereby, to 
relate the NPs binding properties in activated NIH3T3 in vitro with the average behavior of the in 
vivo TAFs, GFP-positive fibroblasts were sorted from the tumor tissue by MoXlo Flow. The binding 
affinity of AA LCP NPs was determined with these sorted fibroblasts, and was identical to NIH3T3 
activated with TGFβ for 24 h in vitro (Figure 2.9A). The binding constant (KD) of both non-targeted 
and targeted NPs were then compared in vitro on this activated NIH3T3 and UMUC3 cells. As shown 
in Figure 2.9B, both UMUC3 and NIH3T3 did not bind with any non-targeted NPs. Yet, AA-
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modified NPs bound strongly with both UMUC3 and activated NIH3T3 at low concentrations. 
Binding plateaued as the particle number increased. The apparent KD of AA L-LCP NPs for UMUC3 
and activated NIH3T3 was 11.13 and 10.11 nM, respectively. Low and comparable dissociation 
constants suggested strong and similar binding affinities for both types of cells. The binding capacity 
of UMUC3, indicated by the surface saturation level, was higher compared to activated NIH3T3. This 
finding is consistent with the fact that higher levels of Sigma R are present on UMUC3 over majority 
of the activated fibroblasts even though the sigma receptor was upregulated in TAFs (Figure 2.9B). 
In most cases, NPs entered the cells following binding to the cell surface. Thereby, the uptake 
process including adhesion and internalization was further evaluated on both fibroblasts and tumors. 
To mimic the unsaturated conditions in vivo, approximately 0.1 nM NP were given to a single layer of 
cells. As expected, the targeted NPs entered cells more rapidly regardless of size compared to non-
targeted NPs, most likely due to the facilitated ligand-receptor interaction process. Consistent with the 
previous hypothesis of involving a wrapping time of the membrane, larger NPs with required stronger 
driving forces and additional energy for successful cellular internalization [178, 179]. Therefore, 
cellular uptake quantities of NPs decreased with increasing particle size. Additionally, similar linear 
uptake profiles were observed between the two cell types (Figure 2.9C and D). The uptake rates for 
the targeted NPs in these two cell lines were almost identical. While, for the non-targeted NP, the 
uptake rate was slightly higher in UMUC3 than in the activated fibroblasts (Figure 2.9D). Altogether, 
observations herein demonstrated that targeted NPs with high avidity can bind rapidly to and be taken 
up by non-tumor cells expressing lower levels of Sigma R. Subsequently uptake is sufficient to elicit 
a BSB. 
2.4.6 In vitro Tumor Spheroid Modeling of the BSB 
To quantify the BSB in vitro, a spheroid model was generated in which tumor cells (UMUC3) 
were enclosed by fibroblasts (GFP-NIH3T3) to simulate the in vivo condition. The core-shell 
structure was confirmed by confocal Z-stack scanning from the bottom to the center of the spheroid 
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with each layer measuring 15 µm in thickness (Figure 2.10A). Images indicated that the overall 
diameter and the fibroblast-shell thickness increased as the amount of added fibroblasts increased 
(Figure 2.10C). The core-shell 3D model (35% fibroblasts) closely mimicked the in vivo condition of 
the UMUC3/3T3 model where a single tumor nest was surrounded by a thin layer of stroma cells 
(Figure 2.10B). Thereby, this model was used to analyze the real-time disposition of NP into tumor 
nests after their extravasation from blood vessels.  
An excess of DiI labeled LCP NPs (S/L, +/- AA) was incubated with the 3D spheroids in 
37°C under frequent stirring. The spheroids were imaged at determined time points approximately 
150 µm from the bottom of the spheroid (Figure 2.11A). Background fluorescence was corrected by 
subtracting the fluorescence at 0 h. Consistent with the in vivo study, the use of targeting ligands had 
a pronounced effect on the penetration of NPs in the spheroid. DiI labeled AA S-LCP NPs and L-LCP 
NPs bound rapidly to the surface of fibroblasts within 30 min after incubation. Upon binding, the 
fluorescence intensity of targeted NPs in the fibroblast region increased with time. However, 
penetration into the tumor nest required nearly 6 h post incubation before a notable amount was 
observed. On the other hand, non-targeted NPs required longer incubations before initial binding. Yet, 
fluorescence penetrated rapidly into the tumor nest upon binding, resulting in the illumination of the 
entire nest soon afterwards. These dynamics were further observed by averaging the intensities in the 
fibroblast (Figure 2.11B and C, grey bar) and tumor cell regions. For targeted NPs, the fluorescence 
intensity in the fibroblast region was approximately 4 times higher than that in the tumor region, 
demonstrating lower penetration of targeted NPs. Time dependent accumulation of non-targeted NPs 
in the fibroblasts region of the spheroid was notably similar to targeted NP except for the delayed 
binding. However, the behavior was different in the tumor region, in which the fluorescence intensity 
increased monotonically and eventually matched to the intensity in the fibroblasts region. Together, 
these observations are consistent with the in vivo observation and demonstrate that the fibroblasts 
served as the primary barrier for NPs penetration, especially for targeted NPs. The distribution of 
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large NPs was similar to the small NPs but significantly smaller in signal strength, suggesting the role 
of particle size in tumor penetration.   
2.4.7 Mathematical Model: Mechanical Barrier Strengthen the BSB 
A descriptive mathematical model was developed to examine the coupled effects of 
extracellular diffusion and cellular uptake on the distribution of AA S-LCP NPs in the 
aforementioned 3D spheroid model. For simplicity, several assumptions were made. Firstly, tumor 
spheroids were modeled as perfect spheres with radius R = 500 μm and NP distribution was assumed 
to possess radial symmetry. The thickness of the fibroblast shell was estimated as 80 μm based on the 
measurement of ex-vivo 3D spheroids and the volume fraction of fibroblasts in the UMUC3/3T3 
xenografts. Furthermore, the diffusion of NPs in the ECM was assumed to follow the Stokes-Einstein 
relationship, similar to the proposed movement of NPs in the gel-like cervicovaginal mucus (CVM) 
[180, 181]. Lastly, no pressure-mediated convection was considered in the scope of the current study 
[83]. The diffusivity (D) and uptake rate (k) for non-targeted S-LCP NPs were derived from a 
spheroid model of only UMUC3 cells (UMUC3 only spheroid). UMUC3-GFP constitutes the 
spheroid shell, with the same thickness to the UMUC3/3T3-GFP spheroid model (Figure 2.12). 
Assuming the D is constant within this single-cell-population spheroid, modeling results fit the 
experimental data when D=3.1x104 µm2/h and k=0.25 h-1(Figure 2.14A and Table 2.2). The 
calculated D and k are comparable with those of 10 nm cationic quantum dots or 15 nm PEGylated 
polymeric NPs reported elsewhere [18, 83]. This match was therefore considered reasonable. Both the 
modeling results and experimental images demonstrate the diffusion time of S LCP NPs as evidently 
faster than the uptake rate. Therefore, small NPs have ample time to diffuse throughout the spheroid 
before absorption. To illustrate the impact of the uptake rate of NPs on the distribution pattern, the 
distribution of AA S-LCP NPs in the same UMUC3 only spheroid was examined. We assumed the D 
of AA S-LCP NPs is consistent with that of the non-targeted NPs, since both NPs possess identical 
size, surface charges and PK profiles. In contrast to the uniform distribution of S-LCP NPs, the 
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localization of AA S-LCP NPs was shifted toward the GFP-edge. A 4-fold increase in the uptake rate 
for AA-S LCP NPs was predicted by the model, which was only slightly higher than the measured 
values in vitro on a single layer of UMUC3 (Figure 2.9C and D). Results therefore demonstrate a 
reasonable match between modeling and experimental data wherein cells with high affinity for NPs 
hinder the penetration of targeted NPs.  
However, this NP distribution shift was intensified and pronounced in UMUC3/NIH3T3 
spheroids when treated with AA S-LCP NPs. Preliminary studies suggest that the fibroblasts’ 
expression of Sigma R was consistent to that quantified in vivo over the course of measurement (data 
not shown). Therefore, the NP uptake rate for fibroblasts mirrored the uptake rate for UMUC3 as 
confirmed in vitro on a single cell level (Figure 2.9C). So, decreased diffusivity was proposed to fit 
the experimental data (Figure 2.14C). The cellular association of NPs was then examined based on 
the modeling data (Figure 2.14E and F). The ratio of cell associated NPs in the fibroblast shell 
versus the tumor core was found to be higher in the UMUC/3T3-GFP spheroid as opposed to the 
UMUC3 spheroid. Therefore, the increased retention of NPs in the fibroblast shell is likely due to 
decreased diffusivity, which further enhanced the cellular uptake of NPs and intensified the BSB. 
This prediction was confirmed by examining the ratio between the MFI of DiI in fibroblast layer and 
tumor layer of the two spheroid models using flow cytometry (Figure 2.13).  
The modeling results accurately replicate a number of characteristics for NPs distribution and 
provide valuable insight into the parameters responsible for limiting NP uptake. Firstly, the uptake 
rate of AA S-LCP NPs overshadowed the rate of diffusion as opposed to S-LCP NPs, retarding the 
penetration NPs. Furthermore, the decreased diffusivity in the stromal layer intensified the BSB 
elicited by fibroblasts when compared to tumor cells with less secretion of ECM proteins. 
2.5 Discussion 
In summary, a detailed investigation into the BSB elicited by TAFs and the subsequent 
effects on intratumoral deposition of sub-100 nm NPs in a stroma-vessel tumor model was conducted. 
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Results herein focus on characterization of the TAF-elicited BSB through three major qualities 
defining the BSB: the proximity of the TAFs to blood vessels, the number of Sigma R and binding 
affinity [161].  
Firstly, the close proximity of fibroblasts to blood vessels in stroma-vessel type tumors 
contributed to TAFs’ role as a binding site for NPs. Data herein suggested that NPs preferentially 
distributed to fibroblasts initially, regardless of size and targeting ligands, resulting in depletion of 
NPs available for tumor uptake. While the biological mechanism for the formation of this stroma-
vessel architecture is unknown, it is conceivable that fibroblasts infiltrate during desmoplasia and 
envelop the neoplasm, subsequently influencing the architecture [163]. Although blood vessels are 
sometimes observed in the tumor nests, the intra-nest NP extravasation is still retarded due to the 
malfunction of these intra-nest blood vessels [52].  
The number of receptors characterizes a second feature of the BSB. Overexpression of Sigma 
R is reported in several fast growing cancer cell lines. Since TAFs are highly metabolic active 
compared to the quiescent fibroblasts, increased expression of Sigma R is reasonably consistent with 
previous investigations demonstrating the up-regulation of Sigma R in rapidly dividing normal tissues 
[167, 182]. Consistently, both the up-regulation of Sigma R and its heterogeneous distribution could 
be correlated with αSMA expression and triggered by TGF-β. The overexpression of Sigma R on 
TAFs was also observed in several patient bladder cancer samples, unveiling the clinical-relevancy of 
this finding. As expected, we found that AA (ligand of Sigma R) targeting paradoxically strengthened 
the BSB elicited by fibroblasts for NPs. This off-target binding of NPs to stroma cells was not the 
only challenge for AA coupled NPs. Other targeting receptors whose expression correlates with 
metabolic rate (e.g. folate and transferrin receptors) also exist in non-tumor cells and are likely prone 
to unspecific targeting [87, 183, 184]. Since these ligands are commonly used for tumor-targeted 
therapy, evaluation of off-target distribution would be of significance for therapeutic guidance.     
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While the induced expression of Sigma R in TAFs is still somewhat lower than in cancer 
cells, a strong binding affinity of NPs to TAFs constitutes the third parameter of the BSB. Notably, 
the high avidity of targeted NPs to receptors compromise the selectivity based on the number of 
receptors per cells, as NPs can bind rapidly with fibroblasts expressing lower levels of receptors.  
Mathematical modeling simulations based on the in vitro spheroid model parallel the 
aforementioned experimental findings that enhanced binding and uptake in TAFs subsequently 
enhanced the BSB. It should be noted that the BSB is not a feature unique to TAFs and can be 
extended to various types of cells (including tumor cells) with strong binding affinity to NPs and near 
the NP pool. However, the reduced diffusivity of NPs in stroma herein tuned the balance of NP 
accumulation towards the edge of the spheroid, which mainly consist of TAFs. This observation was 
confirmed both experimentally and with mathematical modeling. Factors such as the highly packed 
extracellular proteins secreted from TAFs, the spindle shape of TAFs, the presence of tight junction 
and the raised IFP could also contribute to the decreased diffusivity in TAFs. These mechanical 
barriers contribute to the TAF-specific BSB by prolonging the retention of NPs in the stroma layer.  
 Consistent with other studies, this study suggested that non-targeted NPs demonstrated 
favorable tumor penetration over targeted NPs. The association of non-targeted NPs to tumor cells 
was actually higher than for targeted NPs over time, opposing the dogma that non-targeted NPs have 
greater penetration but lower cellular uptake. Compared to other studies using anionic NPs, cationic 
PEGylated NPs were studied herein. Previous studies demonstrated that shedding of the PEG layer on 
DOTAP coated NPs causes a subsequent shift in the PEG confirmation from brush to mushroom. 
This shift exposes cationic charges and enhances cellular uptake, offering a potential explanation for 
the observations made in the current study [185]. Since infiltrating leukocytes also constitute the 
TME, their contribution to off target effects was also investigated. Flow cytometry analysis shown 
that NP association with CD45-positive leukocytes on the tested tumor models was relatively low 
compared to that in TAFs (Figure 2.15). No significant trend was observed in terms of different 
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phenotypes and targeting ligands. This finding highlights the rule that TAFs possess as the primary 
BSB in the selected models. 
What then, is the significance of studying the TAF-elicited BSB? The TAF-elicited BSB 
depletes the number of NPs available to tumor cells, compromising therapeutic efficacy. At the 
meantime, it further induces adverse effects due to resistance of stromal cells to tumor-specific 
therapy. Examples of adverse effects can be found in a previous study, where TAF’s internalization of 
cisplatin NPs induced the secretion of Wnt16 (a survival factor) and paradoxically promotes tumor 
growth and metastasis. Despite certain limitations and assumptions, this study demonstrates the 
mechanistic basis of these off-target effects from the aspect of NP-delivery, and offers guidance for 
the development of nano-therapeutics against stroma-vessel desmoplastic type tumors. Separately, 
these findings explore the rationale of intentionally targeting fibroblasts through the BSB. This 
feature can be utilized to exploit TAFs as an in situ cytokine or cytotoxic protein producing reservoir, 
overcoming the tumor-specific delivery barrier, orchestrating the suppressive tumor 
microenvironment and improving the currently marginal anti-tumor outcome of desmoplastic tumors.  
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Table 2.1 LCP NPs characterization 
NP Diameter 
(nm) 
PDI 
 
Zeta Potential 
(mV) 
DiI Encapsulation 
(%) 
S-LCP 18.2±3.4 0.21±0.04 21.9±2.3 82.9±2.6 
AA S-LCP 18.5±2.2 0.28±0.06 20.8±1.8 85.4±3.5 
L-LCP 67.8±8.6 0.32±0.08 19.9±3.3 80.1±4.1 
AA L-LCP 71.3±4.5 0.27±0.12 18.7±2.6 84.6±3.6 
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Table 2.2 Parameters in the mathematical modeling 
Parameter Symbol Model Value  Unit Note 
radius of tumor 
nests r 
3D tumor 
spheroid ~500 µm measured 
UMUC3/3T3  ~300 µm Fig.3A 
H460 ~650 µm Fig.2A 
4T1 ~200 µm Fig.2A 
BXPC3 ~200 µm [68] 
thickness of 
fibroblasts d 
3D tumor 
spheroid ~80 µm measured 
UMUC3/3T3 ~60 µm Fig.3A 
H460 ~30 µm Fig.2A 
4T1 ~40 µm Fig.2A 
BXPC3 ~50 µm [68] 
particle diffuson 
coefficient D 
18 nm S LCP NP 
(+/-AA) 3.0×104 µm2/h measured 
11 nm quantum 
dots (anionic) 5.0×104 µm2/h [83] 
11 nm quantum 
dots (cationic) 4.0×104 µm2/h [83] 
20 nm polymeric 
NP   2.5×104 µm2/h [186, 187] 
10 nm polymeric 
NP  20×104 µm2/h [186, 187] 
cell uptake rate 
constant k 
18 nm S LCP NP 
(+/-AA)  7×10-5 /S measured 
20 nm polymeric 
NP 5×10-5 /S [93, 187] 
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Figure 2.1 Characterization of LCP NPs.  
A-B, representative TEM images of LCP cores (S/L). C-D, TEM images of final LCP NPs (S/L). E, 
in vitro stability of LCP NPs (S/L, +/- AA) in 5 % FBS, 37 ºC, over 96 h. F, PK profiles of LCP NP 
(S/L, +/-AA). G, co-association of DiI and Texas Red Oligo in the same cells within the 
UMUC3/3T3-GFP tumor models 8, 16 and 28 h after NPs injection. Data were analyzed by flow 
cytometry and the fluorescence was compensated. The red-marked population indicates the % of 
double positive cells in all fluorescence positive cells. H. Fluorescence images of DiI/ Texas Red 
Oligo labeled LCP NPs in the GFP positive fibroblasts 8 h post injection of the UMUC3/3T3-GFP 
tumors. The circled population indicates the double fluorescence (DiI and Texas Red) positive GFP-
fibroblasts (cryosection).       
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Figure 2.2 Fluorescence Intensity of DiI/Texas Red Oligo labeled NPs, in comparison with only 
DiI labeled NPs and only Texas Red Oligo labeled NPs.  
A, excitation was fixed at 488nm, B, excitation was fixed at 594 nm. 
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Figure 2.3 Stroma-vessel architecture affects the intratumoral distribution of non-targeted NPs.  
A. Immunostaining of CD31 (red, stained for blood vessel) and αSMA (green, stained for fibroblasts) 
in subcutaneous tumor models (paraffin sections) with different tumor-stroma architectures. 4T1 and 
H460 belong to the stroma-vessel phenotype. Tumor nests (T) are highlighted in the images. D4M 
and A375lu belong to tumor-vessel phenotype. B. Confocal images of DiI-labeled NP distribution in 
D4M and H460 8 h post injection (Cryosections). The fibroblasts were visualized by staining with 
αSMA. C. Flow cytometry analysis of the association of non-targeted DiI-labeled NPs with either 
αSMA-positive fibroblasts or other non-labeled cells 8 h post injection in the four different tumors (n 
= 3, * P < 0.05, ** P < 0.01, *** P < 0.001). 
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Figure 2.4 UMUC3/3T3 recapitulates NPs distribution pattern in the desmoplastic tumors.  
A tumor model established by co-inoculating UMUC3 with GFP-transfected fibroblasts NIH3T3. 
When the tumor was small, it adopted a tumor-vessel phenotype in most area. As the tumor grew, it 
adopted a stroma-vessel phenotype. B. Flow cytometry analysis of the cellular distribution of non-
targeted NPs (S-LCP NP, 18 nm; M-LCP NP, 35 nm (Characterization not shown); L-LCP NP, 75 
nm), the ratio of DiI-positive fibroblasts and other cells are calculated and shown in blue (n = 6). F. 
Flow cytometry analysis of the association of S-LCP NPs in a bladder cancer patient derived 
xenograft (PDX) model 8 h post injection (* P < 0.05, ** P < 0.01, n = 3). 
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Figure 2.5 Time dependent association of non-targeted and targeted NPs in fibroblasts and 
other cells (tumor cells).  
A. Flow cytometry analysis of the time dependent cellular distribution of NPs (S/L, +/-AA). B. 
Confocal images of the DiI NPs distribution in the tumor sections at 4 or 16 h post injection. Boxed 
areas in 16 h images are also shown as enlarged images below. Green: GFP-NIH3T3, cyan: blood 
vessel, red: DiI NPs. n = 6, **, P < 0.01.   
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Figure 2.6 Sigma Receptor is expressed in αSMA positive TAFs.                                                                               
A. IF staining of paraffin embedded tumor section from UMUC3/NIH3T3 model. Red: Sigma R; 
Green: αSMA; Cyan: CD31. Co-localization was observed partially between Sigma R and αSMA, 
appeared as orange or yellow. B. Higher magnification of the UMUC3/NIH3T3 model stained with 
Sigma R and αSMA. The sigma receptor High and Low regions in fibroblasts were marked as F-H 
and F-L. Tumor nest (T) was highly positive for Sigma R. C. Cryosection of UMUC3/NIH3T3. 
Green indicates all the GFP-positive fibroblasts. Red indicates Sigma R. D-F: co-staining of Sigma R 
(red) and αSMA (green) in 4T1, A375lu and H460. G and H. Western blot analysis of sigma receptor 
expression in vitro on different cell lines (including tumor cells UMUC3, and other mouse or human 
fibroblasts). Note that, activation of NIH3T3 with TGFβ enhances the expression of Sigma R.  
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Figure 2.7 The correlation between Sigma R level and distribution of targeted NP.  
A. Gating of UMUC3-GFP and 3T3-RFP in the dissociated tumor tissues. B and C. Gating of Sigma 
R positive populations in tumor cells and fibroblasts. Isotype controls were shown in supplementary 
figures. Most of tumor cells have high and coherent Sigma R expressions. Whereas, fibroblasts can be 
classified into Sigma R (H), Sigma R (L) and Sigma R (-) groups based on the expression of Sigma R 
levels. D and E. Quantitative flow analysis of the distribution of DiI NPs in different groups (different 
Sigma R level) of cells. F. Western blot confirmation of the shRNA knockout of Sigma R in the 
NIH3T3 fibroblasts in vitro. G. % of DiI positive cells in tumor cells and fibroblasts 8 h after 
injection of DiI NPs in the normal UMUC3/NIH3T3-GFP model or UMUC3/NIH3T3-GFP Sigma R 
knockout model (n = 6). * P < 0.05; ** P < 0.001.   
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Figure 2.8 Flow Cytometry analysis of Sigma R 
A. Gating of UMUC3-GFP and 3T3-RFP in the dissociated tumor tissues. B. Flow cytometry 
analysis of the DiI NPs distribution in Sigma R labeled cells (n=4). The upper row is the Sigma R 
and DiI distribution in the UMUC3-GFP cells. The lower row is the Sigma R and DiI distribution 
in the NIH3T3-RFP cells. The fibroblasts can be classified into Sigma R (H), Sigma R (L) and 
Sigma R (-) groups based on the expression of Sigma R levels. 
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Figure 2.9 Binding affinity and uptake rate of LCP NPs (S/L, +/-AA) in UMUC3 and activated 
fibroblasts.  
A. Binding curve of AA L-LCP NPs for activated NIH3T3 and sorted GFP-fibroblasts from the 
stroma-rich bladder tumor models. B. Binding affinity of LCP NPs (S/L, +/- AA) in UMUC3 and 
activated NIH3T3. The data points were fitted to Michaels-Menten curve, KD and Vmax were 
calculated and shown in the inserted chart. Time dependent uptake of 1 nM LCP NP (S/L, +/-AA) in 
activated NIH3T3 and UMUC3 was shown in C and D (n = 3). 
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Figure 2.10 Establishment and Characterization of the “Core-Shell” exvivo tumor spheroid 
model.  
A. Confocal Z-stack Scanning of a mixed spheroid model (mixture of 35% GFP-3T3 and 65% 
UMUC3) and the “core-shell” spheroid model. AA S-LCP NP were incubated with the spheroid, the 
penetration of DiI labeled NP were shown 4h after incubation in A. And the association of NP with 
cells were analyzed by flow cytometry and shown on right. B. The “core-shell” spheroid closely 
mimicked the tumor nest in the stroma-vessel tumor model. C. The morphology change of the 
spheroid when increasing amount of fibroblasts were added. D. The association of DII Labeled 35nm 
AA-LCP NP with spheroid with different amount of fibroblasts. The association fibroblasts with NP 
increased when the fibroblasts ratio increased. 
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Figure 2.11 Penetration, binding and internalization kinetics of LCP NP (L/S, +/- AA) in a” 
Core-Shell” ex-vivo spheroid model.  
The “Core-Shell” spheroid model was established by coating the UMUC3 spheroid with GFP-3T3 
fibroblasts. Fluorescence images were acquired after incubation with DiI labeled LCP NP for 
determined time points and shown in A. Scale bar, 500 um. The corresponding fluorescence intensity 
profiles are shown at determined time points in B. The grey rectangle indicates the position of 
fibroblasts. Change of average fluorescence intensities overtime in the tumor region and the 
fibroblasts region after incubation with DiI labeled LCP NP are shown in C. Mean value was 
presented (n = 3).   
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Figure 2.12 Time-dependent penetration of DiI labeled S-LCP NPs (+/-AA) in UMUC3 only 
spheroid. 
UMUC3-GFP constitutes the shell of the spheroid, with the similar thickness as compared to the 
UMUC3/3T3 spheroid. Upper two lanes are the AA-S-LCP NPs, bottom two lanes are the S LCP 
NPs. 
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Figure 2.13 The ratio of mean fluorescence intensity (MFI) between the GFP shell and tumor 
core at different time points. 
AA S-LCP NPs were dosed. UMUC3 only and UMUC3/3T3 spheroids were compared (n = 3, * P 
< 0.05). 
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Figure 2.14 Mathematical modeling of S-LCP NPs (+/-AA) distribution in the core-shell 
spheroid and predictions of cellular uptake of S-LCP NPs (+/-AA) 
A, B, C Fluorescence intensity profiles measured in fluorescence images of core-shell 3D spheroids 
(symbols), and those predicted by the mathematical model (solid lines). D, E, F Predictions of cellular 
associated NPs (dashed lines) and acellular NPs (solid lines). 
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Figure 2.15 Off-target distribution of NPs in infiltrating leucocytes of the desmoplastic UMUC3 
xenografts.  
A. IF staining of blood vessel (CD31, shown as cyan), Sigma R (shown as red) and CD45 (shown as 
green) positive leucocytes in the stroma vessel type tumors (4T1 and UMUC3/3T3) and tumor vessel 
type tumors (A375lu). Results indicated the CD45 positive cells were not localized near blood vessel 
in either types of tumors and most of them were not Sigma R positive. B. Flow cytometry analysis of 
the distribution of  DiI S-LCP NPs (+/- AA) in CD45 positive cells 8 h after intravenous injection (n 
= 3). The ratio of DiI-positive CD45 positive cells in all CD45 positive cells was lower compared to 
that in fibroblasts. And the % was independent of the presence of targeting ligands.
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 CHAPTER 3: PRIMING OF THE DAMAGED TUMOR ASSOCIATED FIBROBLASTS 
ENHANCES THERAPEUTIC EFFICACY OF CISPLATIN NANOPARTICLES FOR 
DESMOPLASTIC BLADDER CANCER TREATMENT4 
3.1 Summary 
The tumor microenvironment (TME) serves as a multidrug resistant center for tumors under 
the assault of chemotherapy and a physiological barrier against the penetration of therapeutic NPs. 
Previous studies have shown that TAFs, as the major stroma cells, create a binding site barrier (BSB) 
that trap almost 60% of NPs. Though, the off-target distribution of therapeutic NPs to TAFs can 
partially suppress stroma cells, contributing to improved therapeutic outcomes, a drug resistant 
phenotype gradually arises after repeated doses of chemotherapeutic NPs.  Herein, the acquisition of 
drug resistant phenotypes in the TME after repeated cisplatin NPs treatment was examined. 
Particularly, this study was aimed at investigating the effects of NP-damaged TAFs on neighboring 
cells and the alterations of stromal structure after cisplatin treatment. Findings suggested that while 
off-targeted NPs damaged TAFs and inhibited tumor growth after an initial dose, chronic exposure to 
cisplatin NPs led to elevated secretion of Wnt16 in TAFs. Wnt16 upregulation was then attributed to 
heightened tumor cell resistance and stroma reconstruction. Results attest to the efficacy of Wnt16 
knockdown using siRNA against Wnt16 in damaged TAFs as a promising combinatory strategy to 
improve efficacy of cisplatin NPs in a desmoplastic bladder cancer xenograft (UMUC3/3T3).
                                                   
4This chapter previously appeared as a research article in Journal of Controlled Release. The original 
citation is as follows: Lei Miao, Yuhua Wang, C. Michael Lin, Yang Xiong, Naihan Chen, Lu Zhang, 
William Y. Kim and Leaf Huang, nanoparticle modulation of the tumor microenvironment enhances 
therapeutic efficacy of cisplatin, Journal of Controlled Release, 2015, 217 (10):27-41. 
  
78 
 
3.2 Introduction  
Cisplatin, a front line DNA alkylating agent, is a chemotherapeutic regime used to treat basal 
type muscle invasive bladder cancer [188]. Clinical application of cisplatin is limited by adverse 
effects including neuro- and nephrotoxicity [177, 189, 190]. Herein, NPs have been designed to 
improve the pharmacokinetics, facilitate the intratumoral accumulation and subsequently reduce 
adverse effects of cisplatin-based treatment [191-193]. In previous work we developed a novel 
cisplatin nanoformulation consisting of hydrophobic solid cisplatin cores surrounded by PEGylated 
cationic lipid corona for the delivery of cisplatin (cisplatin LPC NPs, shorted as cisplatin NPs) [194, 
195]. Anisamide (AA), a ligand for the sigma receptor (Sigma R) overexpressed on the surface of 
cancerous epithelial cells and TAFs, was coated on the NPs to enhance receptor mediated endocytosis 
[173, 177, 194]. Previous results proved this novel cisplatin NPs exhibited enhanced anticancer 
activity for the treatment of aggressive bladder cancer at low doses (cisplatin 1mg/kg) compared to 
free cisplatin, which was completely ineffective at the same dose level [74].  
Despite encouraging antitumor efficacy after initial treatment, drug resistant eventually 
contributes to ultimate treatment failure [74, 196]. Efforts have been focused on combining cisplatin 
NPs with another nanoformulated therapeutic regimen to inhibit DNA repair enzymes, cisplatin 
export and subsequently reverse tumor cell autonomous resistance [195, 197, 198]. However, 
inconsistencies between the ex vivo prediction of combinatory NPs sensitivity and the in vivo 
therapeutic outcome suggests that stroma cells in the TME also play a key role in the innate resistance 
[70, 199-201]. Stromal cells in the TME, including TAFs, macrophage and endothelial cells build a 
physical barrier within tumors by crosslinking the ECM to inhibit penetration of the therapeutic NPs 
[92, 105]. They also mediate tumor cell-resistance by secreting growth inducing cytokines and growth 
factors [201-204]. Yet, the innate resistance from TME still fails to explain progressions from high 
treatment sensitivity in early stages to late stage therapeutic failure [70]. Findings suggest acquired 
resistance in stromal cells may contribute to the long-term treatment failure [70]. DNA damage 
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induced secretion of extracellular molecules was likely to explain the acquired resistance [205, 206]. 
In agreement with this theory, recent research indicates that damaged stromal cells secrete damage 
response program (DRP) molecules to promote the survival and growth of neighboring cells [70], and 
thus paracrinely influence treatment outcome [207, 208].  
Stromal cell populations damaged by cisplatin uptake control the secretion of DRP molecules. 
Therefore, intratumoral disposition, in particular the off-target distribution of NPs in stroma cells was 
hypothesized to regulate drug resistance through secretion of DRP molecules. To reverse the cisplatin 
NPs induced drug resistance, the blockade of DRP production and secretion was proposed in 
combination with cisplatin NPs as a proof of concept strategy.  
DRP molecules mainly consist of proteases and mitogenic growth factors [70, 207, 209]. 
Wingless-type MMTV integration site (Wnt) family molecules are considered one of the major 
mitogenic growth factors that constituent DRP molecules [210]. Though little information has linked 
Wnt signaling to cisplatin induced resistance, abnormal Wnt signal activation promotes tumorigenesis, 
stemness and resistance in various tumors [211, 212]. In addition, previous studies correlated Wnt16 
expression and chemotherapy-induced DNA damage in prostate and breast cancer fibroblasts [70, 
213]. So, Wnt16 plays a potentially significant role in regulating the crosstalk between neighboring 
cells during DNA damage. Herein, Wnt16 is investigated as a potential DRP molecule for cisplatin 
mediated resistance and knockdown of Wnt16 was therefore proposed to overcome cisplatin induced 
resistance. Several studies have demonstrated functional blocking of Wnt-canonical β-catenin 
pathway using monoclonal antibodies or small molecule inhibitors [214]. However, undesired off-
target effects have led to safety concerns in this approach [215, 216]. RNA interference provides an 
alternative way to maintain the aforementioned specificity while also improving safety. Liposome-
protamine-hyaluronic acid NPs (LPH-NPs) was used to encapsulate siRNA and was shown to be an 
effective delivery tool in various tumor models [217]. Therefore, based on previous claims, a 
combination therapy of cisplatin NPs and LPH-NPs delivered siRNA against Wnt16 (siWnt NPs) was 
proposed to be the optimal treatment for of aggressive bladder cancer. 
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In the current study, a desmoplastic bladder cancer xenograft (UMUC3/3T3) was established, 
similarly to the one described in the previous chapter, by co-inoculating human basal type bladder 
tumor UMUC3 with mouse NIH3T3 fibroblasts. This model resembles bladder tumor patient samples 
in the components and in the morphology of the TME [74]. In the desmoplastic UMUC3/3T3 model, 
we investigated the off-target effect of cisplatin NPs on TAF-damage, the Wnt16 secretion level and 
antitumor efficacy. We also studied the role of cytokines, such as Wnt16 in the regulation of crosstalk 
between tumor cells and the TME.  We conclude that targeting tumor-stroma regulatory cytokines in 
the TME along with NPs-delivered chemotherapy could potentially overcome intratumoral off-target 
effects and improve treatment responses.  
3.3 Materials and Methods 
3.3.1 Materials 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(methoxy(polyethyleneglycol)-2000) 
ammonium salt (DSPE-PEG2000), 1,2-dioleoyl-3-trimethylammonium-propane chloride salt 
(DOTAP), dioleoyl phosphatidic acid (DOPA) were obtained from Avanti Polar Lipids (Alabaster, 
AL). Cholesterol, hyaluronic acid (HA), protamine sulfate (fraction ×from salmon), hexanol, triton-
100, cyclohexane were obtained from Sigma-Aldrich (St Louis, MO). Cisplatin was purchased from 
Acros Organics (Fair Lawn, NJ). All the other chemicals were purchased from Sigma-Aldrich unless 
otherwise mentioned. DSPE-PEG-AA was synthesized based on the previous established protocols 
[173]. The mouse Wnt16 siRNA with sequence 5’-CCAACUACUGCGUGGAGAA-3’, the human 
Wnt16 siRNA with sequence of 5’-CCAACUACUGUGUAGAAGA-3’ and the control siRNA with 
sequence 5’ AATCTCCGAACGTGTCACGT-3’ were purchased from Sigma-Aldrich.  
3.3.2 Cell lines and Animals 
The human bladder transitional cell line UMUC3 was provided by Dr. William Kim 
(University of North Carolina at Chapel Hill, NC). The mouse embryonic fibroblast cell line NIH3T3 
and the human umbilical vein endothelial cells (HUVEC) were purchased from UNC Tissue Culture 
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Facility. UMUC3 and NIH3T3 were maintained in Dulbecco’s Modified Eagle’s Media  (Invitrogen, 
Carlsbad, CA), supplemented with 10% feta bovine serum (Sigma, St. Louis MO) or 10% bovine calf 
serum (Hyclone, Logan, Utah), penicillin (100 U/mL) (Invitrogen) and streptomycin (100 µg/mL) 
(Invitrogen). HUVECs were cultured in HuMEC basal medium (Invitrogen, Carlsbad, CA), 
supplemented with 10% fetal bovine serum (sigma, St. Louis, MO), bovine pituitary extract 
(Invitrogen, Carlsbad, CA) and HuMEC Supplement (Invitrogen, Carlsbad, CA). Female athymic 
Balb/C nude mice of 6–8 weeks old were provided by the University of North Carolina animal 
facility. All animal protocols were approved by the University of North Carolina at Chapel Hill’s 
Institutional Animal Care and Use Committee.  Antibodies used for western-blot analysis and 
immunostaining are listed in Error! Reference source not found.  
3.3.3 Preparation and Characterization of Cisplatin NPs 
Cisplatin NPs were formulated as previously described [41, 74, 154]. Briefly, 300 μL of 200 
mM cis-[Pt(NH3)2(H2O)2 ](NO3)2 and 300 μL of 800 mM KCl  aqueous solution were separately 
dispersed in a mixed oil solution cyclohexane/triton-X100/hexanol (75:15:10, V:V:V) and 
cyclohexane/Igepal CO-520 (71:29, V:V) to form a well-dispersed reversed micro-emulsion. Then, 
500 μL of DOPA (20 mM) was added to the cisplatin precursor emulsion and the mixture were stirred 
for 20 min. Afterwards, the two emulsions were mixed and reacted for another 20 min. Forty mL of 
ethanol was then added to break the micro-emulsion and particles were collected by centrifuge at 
10,000 g for at least 15 min. The pellets were washed with ethanol twice to completely remove the 
surfactants and cyclohexane, and then re-dispersed in 2.0 mL of chloroform for storage. Finally, the 
preparation of cisplatin NPss consisted of mixing 1 mL of cisplatin nanocores with 200 μL of 20 mM 
DOTAP/Cholesterol (1:1), with 20 μL of 20 mM DSPE-PEG-2000 or 20 μL of 20 mM DSPE-PEG-
2000/DSPE-PEG-AA (4:1). After evaporating the chloroform, the residual lipid was dispersed in 100 
μL of 5% glucose. The particle size of cisplatin NPs was confirmed using a Malvern ZetaSizer Nano 
series (Westborough, MA). TEM images of LPC NPs were acquired using a JEOL 100 CX II TEM 
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(JEOL, Japan). Cisplatin NPs were negatively stained with 2% uranyl acetate. The drug-loading 
capacity and platinum content were measured using Inductively Coupled Plasma-Mass Spectroscopy 
(ICP-MS, NexlONTM 300, Perkin Elmer Inc). Samples were digested in 60% HNO3 and diluted in 
water to a final acid content of 2%. Platinum concentration was determined using the 195Pt isotope. 
3.3.4 Preparation and Characterization of siWnt NPs 
siWnt NPs were prepared through a stepwise self-assembly process based on a previously 
well-established protocol [217]. Briefly, cholesterol and DOTAP (1:1, mol/mol) were dissolved in 
chloroform and solvent was removed by rotary evaporator. The lipid film was then hydrated with 
distilled water to make the final concentration of 10 mmol/l cholesterol and DOTAP. Then, the 
liposome was sequentially extruded through 400 nm, 200 nm, 100 nm, and 50 nm polycarbonate 
membranes (Millipore, Billerica, MA) to form 70–100 nm unilamellar liposomes. The siWnt NPs 
polyplexes core were formulated by mixing 140 μl of 36 μg protamine in 5% glucose with equal 
volume 24 μg siRNA and 24 μg HA in 5% glucose. The mixture solution was incubated at room 
temperature for 10 minutes and then 60 μl cholesterol/ DOTAP liposome (10 mmol/l each) was added. 
Post insertion of 15% DSPE-PEG and DSPE-PEG-AA were further performed at 50 °C for 15 
minutes. The size and surface charge of the NPs were determined by Malvern ZetaSizer Nano series 
(Westborough, MA). TEM images were acquired using a JEOL 100 CX II TEM (JEOL, Japan). 
Particles were negatively stained.  
3.3.5 GFP Lentivirus Transduction in NIH3T3 Fibroblast 
Please refer to Section 2.3.6 
3.3.6 Establishment and Evaluation of Patient Derived Xenograft (PDX) Model 
PDX tumors were obtained from human bladder cancer patients. Excess bladder tumors were 
taken at the time of the transurethral resection of the bladder tumor (TURBT). Further pathologic 
examination confirmed that the tumor was a high grade, urothelial carcinoma of the bladder. The 
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primary tumor was first processed for implantation and then sectioned. Tumor fragments were stored 
in a urine cup on ice for transport and storage. Prior to implantation, tumor fragments were washed in 
5x Pen-Strep in PBS and dipped in aliquots of Matrigel. Fragments were then surgically implanted 
into NOD-NSG-SCID mice on the flank of the animal. Typically, tumor fragment sizes were 
approximately 2 mm3. Once an appropriate size was reached, tumors were resected and passaged into 
additional mice. Passages were conducted until passage three was reached. At this point, passage 
three mice were administered a total of five doses of LPC NPs via IV every other day.    
3.3.7 Collection of Conditioned Medium 
Conditioned medium was collected as described elsewhere [207, 218]. NIH3T3 cells were 
activated by 10 ng/mL TGF beta 2h before experiments. The activated NIH3T3 cells were treated 
with siCont NPs, siWnt NPs respectively with Opti-MEM medium for 4h. Post transfection, cells 
were further treated with free cisplatin and cisplatin NPs for another 3h. After treatments, the cells 
were rinsed thrice with PBS and left overnight (in total 2 days including the treatment) in DMEM 
medium with 5% BCS. Culture medium was then collected and centrifuged at 900 rpm for 5 min, and 
then supernatant was filtered through 0.45 µm filter and collected as conditioned medium for further 
study. 
3.3.8 Cell Treatments with Cisplatin 
NIH3T3 cells were pre-activated with 10 ng/mL TGF-β and treated with10 μM free cisplatin 
or cisplatin NPs for 3h before replacing into fresh full medium, and then left overnight (in total 2 
days). After treatment, the conditioned medium (CM) was collected (Supplementary Methods) and 
cells were rinsed 3x with PBS. Both CM and cells were used for western-blot assay (Supplementary 
Methods) and ELISA assay (Supplementary Methods) to detect the expression levels of Wnt16.  
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3.3.9 In vitro Transfection of siWnt NPs 
UMUC3 cells or activated NIH3T3 cells were grown until 80% confluent in six-well plates. 
Then LPH NPs loaded with siRNA against mouse Wnt16 (siWnt NPs), human Wnt16 or control 
siRNA (siCont NPs) were added to each well in the presence of OptiMEM medium with final 
concentration of 250 nmol/L. Medium was refreshed 4h post transfection. The remaining cells were 
treated for another 3h with 10 µM cisplatin to boost the expression of Wnt16, then washed and left 
overnight. The knockdown efficiency and specificity of Wnt16 by siRNA were determined by 
western-blot analysis with GAPDH as a loading control.  
3.3.10 Non-contact Co-culture Model for Mechanistic Study 
Non-contact co-culture transwell system was established according to a previous protocol 
with little adjustment (Figure 3.1)[218]. Briefly, activated NIH3T3 were seeded into a transwell filter 
(polycarbonate membrane insert, 0.45 µm pore, Corning Inc.). Before co-culture, transwell insert 
received different types of treatments, including solo siCont NPs or siWnt NPs treatment, or LPH 
NPs (containing either siCont or siWnt) transfection followed by cisplatin (NPs) assault (namely 
siCont NPs/cisplatin (NPs) or siWnt NPs/cisplatin (NPs)). Immediately after extensive washing of the 
insert cells with PBS, the co-culture start by setting the insert in to the lower chambers pre-seeded 
with UMUC cells, HUVEC cells or naïve NIH3T3 for different experimental purpose. After 
determined time of co-culture, bottom cells were collected for western-blot analysis, β-catenin 
nucleus translocation assay, tube formation and other immunofluorescence assay (Supplementary 
Method). β-catenin nucleus translocation assay. β-catenin assay was carried out in the lower 
chamber UMUC3 cells, as a mechanistic study to determine the canonical Wnt pathway activation in 
the neighboring UMUC3 cells by Wnt16 secreted from damaged fibroblast [219]. Lower chamber 
UMUC3 cells were seeded on a coverslip (Fishier Scientific), and co-cultured with upper chamber 
NIH3T3 cells subjected to the aforementioned treatments. At indicated time points, coverslips were 
taken out, fixed, permeabilized, blocked and probed with anti-β-catenin antibody. Cells were further 
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incubated with FITC-labelled secondary antibody and then counterstained with Hoechest 33342 
(Invitrogen). Co-localization of β-catenin with cell nuclei was visualized using a confocal microscope 
(Laser Scanning. Zeiss 510 Meta). Scratch assay. The spreading and migration capabilities of 
UMUC3 cells affected by Wnt16 secreted from neighboring fibroblasts were also assessed in the 
lower chamber UMUC3 using a scratch assay [220, 221]. Upon co-culturing with treatment assaulted 
NIH3T3, a linear wound was scratched into the monolayer of UMUC3 with a sterile 200 μl pipette tip. 
The width of the wound was measured under a microscope at 0 and 20h after co-culture to assess the 
migration ability of the cells. The data were performed in duplicate and analyzed using Image J. 
Lentiviral luciferase reporter assay. The activation of Wnt pathway in the neighboring naïve 
fibroblast by damaged fibroblast was evaluated using TCF/LEF reporter assay [222]. To produce 
stable Wnt-reporter cell lines, NIH3T3 cells were transduced with the Cignal Lenti TCF/LEF 
Reporter (luc) kit for 48h. Following transduction, the cells were cultured under puromycin selection 
to generate a homogenous population of transduced cells. Activated NIH3T3 and Wnt-reporter cell 
lines were seeded on to the upper chamber and lower chamber of the non-contact co-culture system 
respectively. Four h post co-culture, bottom cells were collected and luciferase assays were performed 
using a Luciferase Assay Kit (Promega, Inc.) according to the manufacturer's instruction. Tube 
formation assay. Paracrine secretion of Wnt16 in inducing angiogenesis was evaluated by tube 
formation assay [223, 224]. The non-contact co-culture system was established with the upper 
chamber of activated NIH3T3 receiving different treatments and bottom chamber of HUVEC in a 24-
well plate. For the formation of capillary-like structures, 24-well plate were pre-coated using growth 
factor-reduced matrigel (BD biosciences, San Jose, CA, USA). HUVECs (4×104 cells/well) were 
plated on top of matrigel (280 µL/well). Four h after co-culture, HUVECs were stained by calcein 
AM (Invitrogen) and visualized under a fluorescence microscope. The number of tubes was 
quantified using Image J from 5 randomly selected microscopic fields.  
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3.3.11 In vitro Analysis of Cell Proliferation and Chemotherapy Resistance 
To assess the role of Wnt16 in inducing cisplatin resistance of cancer cells, two sets of 
experiments were designed. First, UMUC3 cells were cultured with recombinant Wnt16 protein 
(R&D systems) at different concentrations (0.03, 0.3, 3, 6, 12 µg/mL) 6 h prior to cisplatin treatment. 
Then, cisplatin at a range of concentrations bracketing cell line’s IC50 was added to the medium and 
incubated for 48 h. Cell viability was assayed by 3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide (MTT) to address the extent of resistance. Non-linear regression curves 
were plotted using GraphPad Prism. Second, chemo-resistance of bladder cancer was evaluated by 
culturing the UMUC3 with CM (Details of CM generation was described in Supplementary Method) 
generated from activated fibroblasts under different types of treatments, including siCont NPs, siWnt 
NPs, siCont NPs/cisplatin (NPs), siWnt NPs/ cisplatin (NPs)). The CM treated cells further received 
cisplatin (10 μM) for 2 days. Cell viability was then assayed, and the percentage of viable cells was 
calculated by comparing each experiment to UMUC3 treated with CM of normal activated NIH3T3 
cells. For short-term proliferation assay of fibroblast to cisplatin and siRNA treatment without 
considering the neighboring effect, 96-well plates were seeded with activated NIH3T3 of 80% 
confluence. To evaluate the pro-apoptotic property of siWnt NPs, cells were transfected with siWnt 
NPs or siCont NPs at different concentrations. To study the combo effects, free cisplatin within the 
range of concentration bracketing its IC50 were combined with fixed concentration, 250 nM, of either 
control siRNA or siRNA against Wnt16.    Forty-eight h later, cells were subject to MTT assay 
described elsewhere.    
3.3.12 Tumor Growth Inhibition  
Desmoplastic UMUC3/3T3 model was established as described in the previous chapter [74, 
195]. In brief, UMUC3 (5×106) and NIH3T3 (2.5×106) were subcutaneously co-inoculated into the 
right flank of mice with Matrigel (BD biosciences, CA) at a ratio of 1:1 (V/V). Small tumor 
treatments were initiated on the 9 th day when tumor sizes reached 150~200 mm3. Mice were then 
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randomized into 5 groups (n = 5~7 per group) as follows: Untreated group (PBS), siCont NPs, siWnt 
NPs, cisplatin NPs, siWnt NPs/ cisplatin NPs. Dosing and dose schedule of cisplatin NPs and siWnt 
NPs were optimized on mice bearing desmoplastic UMUC3/3T3 tumors. After optimization, IV 
injections were performed every other day for a total of 5 injections with siRNA dose of 0.6 mg/kg 
(equivalent to 12 µg siRNA per mice) and cisplatin dose of 1.0 mg/kg. Tumor volume was measured 
every day with a digital caliper (Thermo Fisher Scientific, Pittsburg PA) and body weight was also 
recorded. Tumor volume was calculated as (1/2*length*length*width). To monitor the dynamic 
intratumoral Wnt16 and cisplatin level, Mice were sacrificed 1 day after dosing, in total five doses. 
The tumor tissues were collected for further analysis. To compare the TME remodeling after single 
and multiple doses (4 doses), the collected tumor tissues 2 days after single and multiple treatments 
were subjected for western-blot analysis, immunofluorescence staining, Masson trichrome staining 
for Wnt16 and other extracellular matrix components. To analysis the TME remodeling of NPs 
penetration, DiI labeled NPs were IV injected 1 day before sacrificing (refer to flow cytometry 
analysis for details). To evaluate the combinatory efficacy on the large tumor, treatments were 
initiated 14 days post inoculating, when tumor volume reached ~700 mm3 in size. Mice were then 
randomized into 4 groups (n = 5) subjected to the following treatments: PBS, siWnt NPs, cisplatin 
NPs and siWnt NPs/cisplatin NPs respectively. IV injections were performed every day (siRNA 0.6 
mg/kg and cisplatin 1.0 mg/kg) with total 4 treatments. Tumor volume and body weight were 
continuously monitored for another week post last injection to determine combination effect on tumor 
regression and resistance.   
3.3.13 Flow Cytometry Analysis 
To study the cell population that took up NPs in tumors, mice were administrated with DiI 
labeled cisplatin NPs at a dose of 0.1 mg/kg DiI and were sacrificed 8h post IV injection. Fresh tumor 
tissues were dissociated with 1 mg/mL collagenase Type IV (Invitrogen), 1 mg/mL hyaluronidase 
(Sigma) and 200 µg/mL DNAase I (Invitrogen) in DMEM/ 2% FBS for 40 min to generate a single 
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cell suspension (1×106 cells/mL). The UMUC3 cells were pre-transfected with red fluorescence 
protein (RFP), fibroblasts were pre-transfected with green fluorescence protein (GFP). RFP and GFP 
were used to define tumors and fibroblasts, respectively. Leukocytes portion were stained with APC 
conjugated CD45 antibody at a 1:100 dilution. The cells were then subjected to flow cytometry 
analysis after washing. The ratio of DiI NPs distributed in different cell populations was then 
calculated. To analysis the TAFs ratio-changes after treatments, tumor tissues were collected after 
single dose and multiple doses treatment of cisplatin NPs, siWnt NPs, or combination of the two. 
siCont NPs were injected into the cisplatin NPs treated group as a control of siWnt NPs. Tumor 
tissues were dissociated and the ratio of GFP labeled fibroblasts in the dissociated cells was analyzed 
by flow cytometry on a BD FACSAria instrument (Beckon Dickinson). DiI-labeled cationic 
liposomes (DOTAP/Chol: 1:1) were used as a tool to monitor the effect of TME remodeling on NPs 
perfusion. DiI labeled liposomes were prepared by mixing 2% DiI into the lipid membrane and 
followed by sequential extrusion. To quantify the accumulation ratio of DiI labeled cationic 
liposomes in tumors subjected to different treatments (including single or multiple doses), 1 day after 
liposomes injection, mice were sacrificed and single cells were subjected to flow cytometry for DiI 
positive cells calculation. All the experiments were conducted in triplicate. The flow data were 
analyzed using FlowJo 7.6.1 (FLOWJO, Ashland, OR) 
3.3.14 In vivo Imaging of NPs Distribution and TME Remodeling 
For the imaging of NPs distribution, DiI labeled cisplatin NPs were prepared by mixing 2% 
DiI with DOTAP, cholesterol and cisplatin nanocores to formulate the final NPs. Mice were 
administrated with DiI labeled NPs at a dose of 0.1 mg/kg DiI and were sacrificed 8h post IV 
injection. To localize and visualize of NPs penetration, tumor was frozen and sectioned. Frozen tumor 
sections were fixed with cold methanol for 15 min and 1% triton for 5 min, double stained with CD31 
and αSMA primary antibodies at 4ºC overnight followed by incubation with FITC-labeled secondary 
antibody for 1h at room temperature. The sections were also directly stained with DAPI and covered 
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with a coverslip. The sections were observed using a Nikon light microscope (Nikon Corp., Tokyo). 
Five randomly selected microscopic fields were quantitatively analyzed by using Image J software.  
For imaging the remodeling of TME, tumor tissues were collected after single or multiple doses of 
treatment, and processed for paraffin sections. Paraffin block sections of desmoplastic UMUC3/3T3 
with different treatments were then deparaffinized, antigen recovered, blocked and probed with ECM 
markers (including αSMA, fibronectin) and Wnt16 for immune-fluorescence staining and immuno-
histochemical staining. Collagen content was visualized using Masson trichrome staining. Apoptotic 
cells were analyzed by TUNEL assay. All staining protocols are detailed in the supplemental methods.  
3.3.15 Enzyme-Linked Immunosorbent Assay (ELISA) of Wnt16 in the CM 
Activated NIH3T3 were pretreated with siWnt NPs or siCont NPs followed by cisplatin 
(NPs), washed and recovered overnight. Wnt16 concentration in the CM was measured by ELISA 
with the mouse Wnt16 ELISA KIT (BioSource) according to the manufacturer’s protocol, using 
recombinant mouse Wnt16 protein as a standard.  
3.3.16 Western-Blot Analysis 
Please refer to Section 2.3.15 
3.3.17 Lentiviral Luciferase Reporter Assays 
The activation of Wnt pathway in the neighboring naïve fibroblast by damaged fibroblast was 
evaluated using TCF/LEF reporter assay. To produce stable Wnt-reporter cell lines, NIH3T3 cells 
were transduced with the Cignal Lenti TCF/LEF Reporter (luc) kit for 48h. Following transduction, 
the cells were cultured under puromycin selection to generate a homogenous population of transduced 
cells. Acitivated NIH3T3 and Wnt-reporter cell lines were seeded on to the upper chamber and lower 
chamber of the non-direct contact co-culture system respectively. The upper chamber received 
different treatments as previously mentioned. Four hour post co-culture, bottom cells were collected 
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and luciferase assays were performed using a Luciferase Assay Kit (Promega, Inc.) according to the 
manufacturer's instruction. 
3.3.18 Immunohistochemical Staining of Wnt16 
Immunohistochemical staining (IHC) was performed using a standard strepavidin-biotin-
peroxidase complex method as previously reported. In brief, one day post the small tumor inhibition 
study on the desmoplastic UMUC3/3T3 model, tumor tissues were collected and processed for 
paraffin sections. Paraffin block sections of UMUC3/3T3 tumors with different treatments were then 
deparaffinized, antigen recovered, blocked and probed with Wnt16 primary antibody (1:100 dilution) 
at 4 C overnight, and then detected using a rabbit specific HRP/DAB dectection IHC kit as 
recommended by the manufacturer (Abcam, Cambridge, MA). Cell nuclei were counter-stained with 
hematoxylin. Percentage of Wnt16 coverage were quantified by Image J of five representative 
microscopic fields.   
3.3.19 TUNEL Assay 
Paraffin-embedded tumor sections was deparaffinized and rehydrated. The slides were then 
stained using a TUNEL assay kit (Pierce) according to the manufacturer’s instruction.  
3.3.20 Mason Trichrome Staining  
Paraffin-embedded tumor sections was deparaffinized and rehydrated. The slides were then 
stained using a Masson Trichrome Kit (St. Louis, MO) according to the manufacturer's instruction. 
3.3.21 Immunofluorescence Staining  
Paraffin embedded tissues were prepared by the UNC Tissue Procurement Core and the slices 
were deparaffinized, antigen recovered, permeablized and fixed if necessary, and blocked with 1% 
BSA at room temperature for 1h. Cell markers were detected with antibodies conjugated with 
fluoreophores as indicated. Images were taken using fluorescence microscopy. For the purpose of 
double staining, primary antibodies with different species origins were applied and different 
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secondary antibodies with non-overlap flureophores were adopted. For the immunofluorescence 
staining of in vitro cell samples, cell were fixed with 2% PFA for 15 min, washed, permeablized, and 
processed to staing with the same protocol as the in vivo tumor samples. Confocal images were taken 
accordingly (Laser Sacning. Zeiss 510 Meta). 
3.3.22 Serum Biochemical Value Analysis and Hematology Assay 
Mice that were IV injected with PBS, siCont NPs, siWnt NPs, cisplatin NPs and cisplatin NPs 
plus siWnt NPs every other day for a total 5 doses were subjected to a toxicity assay. One day post 
treatments, blood was collected from mice of different treatments and centrifuged at 4000 rpm for 5 
min to obtain the serum. Creatinine, blood urea nitrogen (BUN) serum aspartate aminotransferase 
(AST) and alanine aminotransferase (ALT) were assayed as indicators of renal and liver function. As 
to the hematology assay, whole blood was collected and white blood cells (WBC), red blood cells 
(RBC), platelets (PLT), hemoglobin (HGB) and hematocrits (HCT) were counted for the detection of 
myelosuppression. Organs including heart, liver, spleen, lung and kidney were collected and fixed for 
H&E staining by UNC histology facility to evaluate the organ-specific toxicity.    
3.4 Results  
3.4.1 Elevated Expression of Wnt16 in the Cisplatin NPs Treated Desmoplastic UMUC3/3T3 
Tumor Fostered Drug Resistance  
Cisplatin NPs was prepared according to the previously published protocol with minor 
adjustments [177, 194]. Anisamide targeted cisplatin NPs (cisplatin NPs, if no specific indication) 
were spherical and had a small particle size (~ 30 nm measured by TEM, ~35 nm measured by 
ZetaSizer) with homogeneous distribution and a high drug loading (Figure 3.2A). As shown in 
Figure 3.2B, cisplatin NPs (1mg/kg) significantly inhibited the growth of the desmoplastic 
UMUC3/3T3 model compared with free cisplatin.  However, relapse and resistance occurred in the 
cisplatin NPs treated group after repeated injections. To determine the underlying mechanism of 
acquired-resistance to cisplatin NPs treatment, tissues were collected after multiple PBS or cisplatin 
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NPs exposures and analyzed for Wnt16 expression. Elevated levels of Wnt16 were found in the 
cisplatin NPs treated desmoplastic UMUC3/3T3 tumors over tumors treated with either PBS or free 
cisplatin (Figure 3.2C).  To examine the role of Wnt16 in basal type bladder cancer resistance, we 
tested the ability of recombinant Wnt16 protein to induce cisplatin resistance in vitro (Figure 3.2D). 
The IC50 of cisplatin to basal type UMUC3 cells continually increased from 12.4 to 30 µM as the 
concentration of Wnt16 was increased from 0 to 12 µg/mL. To evaluate whether the effective 
concentration of Wnt16 that induced cisplatin resistance in vitro was physiologically relevant, we 
quantified the concentration of Wnt16 upregulated by cisplatin NPs in vivo. Wnt16 concentrations in 
cisplatin NPs treated tumors (up to 6.5 µg/ml) was within the concentrations of Wnt16 sufficient to 
induce cisplatin resistance (Figure 3.2 and Figure 3.3). Thus, results confirm that elevated Wnt16 (as 
a major DRP molecule) can attenuate tumor cells’ sensitivity to cisplatin treatment. Furthermore, 
recent studies correlate the basal subtype of bladder cancer with increased stromal content and a poor 
prognosis due to resistance [225, 226].  Basal-like bladder tumors also demonstrated increased levels 
of Wnt16 (Figure 3.2E), indicating the role of Wnt16 in facilitating drug resistance in clinical 
samples. Increased Wnt16 expression after treatment has therefore been associated with elevated 
tumor drug resistance. Evidence points to the validity of using Wnt16 as a molecular target for 
translational and investigatory purposes to determine the efficacy of systems designed mediate 
treatment induced drug resistance.  
3.4.2 Off-target Distribution of Cisplatin NPs to TAFs Facilitated the TAF-specific 
Upregulation of Wnt16 
We next sought to determine the cellular origin of Wnt16 production within tumors. Wnt16 
expression has been detected on uterine stroma and was overexpressed by damaged stromal cells 
surrounding prostate tumors [70, 227]. To examine whether stromal cells were responsible for Wnt16 
upregulation in the desmoplastic UMUC3/3T3 model, major cellular components of the desmoplastic 
UMUC3/3T3 model (UMUC3 cells and the mouse fibroblast NIH3T3) were treated in vitro with 
cisplatin. In order to mimic in vivo TAFs, NIH3T3 was pre-conditioned with TGF-β to obtain a TAF-
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like phenotype. Results showed elevated amounts of Wnt16 in both the cell lysate and conditioned 
medium from TGF-β activated NIH3T3 cells after exposure to either free cisplatin or cisplatin NPs 
treatment (Figure 3.4A). In contrast, Wnt16 expression was not induced in UMUC3 cells or other 
epithelial cancer cell lines (Figure 3.4 and Figure 3.5). To further confirm the origin of the 
upregulated Wnt16 level in vivo, a UMUC3 tumor model was developed without the addition of 
NIH3T3. This model contained a lowered amount of TAFS [74]. Cisplatin NPs therefore failed to 
induce Wnt16 in the UMUC3 model, which further confirms the TAF-origin of Wnt16 and eliminated 
potential confounding sources such as macrophages and endothelial cells (Figure 3.4C). A patient 
derived xenograft model of human basal type bladder cancer (Figure 3.4 and Figure 3.7) was also 
investigated for clinical relevance and exhibited upregulation Wnt16 after repeated cisplatin NPs 
treatment. Wnt16 upregulation is therefore not an artifact of NIH3T3, but also exists in primary 
fibroblasts. Consistent with previous reports, these studies confirm the TAF-origin of cisplatin 
induced Wnt16. 
Off target distribution of therapeutic agents to TAFs can foster the secretion of DRP 
molecules, in particular Wnt16, and facilitate the off-target resistance [70]; therefore the cell types 
responsible for uptake of cisplatin NPs in the desmoplastic UMUC3/3T3 model were further 
investigated. A single cell suspension was prepared with tumor samples (150~200 mm3) from tumor 
bearing mice treated intravenously with DiI-labeled cisplatin NPs. Stable transgene expression of 
GFP, RFP and fluorophore conjugated antibody against mouse CD45 defined fibroblasts, cancer cells 
and leukocyte populations. Data indicated that fibroblasts were responsible for ~36% uptake of non-
targeted cisplatin NPs, while tumor cells and leukocytes took up ~52% and ~8% respectively (Figure 
3.6A). When particle surfaces modified with the active targeting ligand for Sigma R, AA, increased 
the percentage of fibroblast NPs uptake from ~20% to ~30% (Figure 3.6B). Western-blot analysis 
confirmed Sigma R expression on TAFs and explained the positive internalization of targeted 
cisplatin NPs (data not shown). These observations indicate that fibroblasts are responsible for 
majority off target internalization of targeted and non-targeted cisplatin NPs. The distribution of 
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targeted DiI NPs was visualized through immunofluorescence staining of different intratumoral cell 
types (Figure 3.6C). It was found that TAFs located in close proximity to blood vessels were 
responsible for uptake of NPs (Figure 3.6C), indicating that fibroblast distribution of therapeutic NPs 
is inevitable due to the spatial distribution and the proximity of fibroblasts to blood vessels. To assess 
the off-target distribution induced damage responses, which could facilitate the subsequent secretion 
of Wnt16, we examined the cisplatin-induced apoptosis in tissues from tumor bearing mice treated 
with cisplatin NPs or PBS (data not shown). Apoptosis assay shown that approximately half of 
apoptotic cells were TAFs, which correlates with the aforementioned off-target internalization ratio of 
cisplatin NPs by fibroblasts and confirmed the damage responses. Therefore, TAFs are a significant 
off target deposition site for cisplatin NPs. Deposition of cisplatin NPs in TAFs are followed by DNA 
damage and the paracrine secretion of Wnt16, which contributes to the development of drug 
resistance.  
3.4.3 Wnt16 Knockdown Inhibits Growth and Invasion of Neighboring Bladder Cancer Cells 
Due to the prominent role of Wnt16 in mediating tumor cell resistance, combined delivery of 
cisplatin NPs with siRNA targeting Wnt16 in fibroblasts was suspected to enhance anti-tumor 
efficacy. Liposome-hyaluronic acid-protamine nanoparticles (LPH NPs) were previously optimized 
for systemic delivery of siRNA to tumor sites. LPH NPs was formed by combining siRNA against 
Wnt16 with hyaluronic acid and condensed with cationic protamine to form negatively charged 
polyplexes. Polyplexes were then coated with cationic lipids via electrostatic interaction with PEG to 
prolong systemic circulation. The final LPH-NPs was about 50 nm in diameter with surface charge of 
25 mV, as determined by Zetasizer (Figure 3.8) [217]. To improve fibroblast internalization and 
ensure fibroblast specific knockdown of Wnt16, AA was conjugated onto LPH for enhanced 
internalization. Furthermore, mouse specific siRNA was used to increase selectivity to mouse 
fibroblasts. With these precautions in place, LPH NPs loaded with mouse anti-Wnt16 siRNA (siWnt 
NPs) were able to decrease cisplatin induced Wnt16 protein levels in activated NIH3T3, without 
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affecting UMUC3 tumor cells (Figure 3.8B). To determine whether the level of secreted Wnt16 
would be affected by siRNA, concentration of Wnt16 in the CM from fibroblasts exposed to different 
treatments was quantified by an ELISA Assay. Fibroblasts were pretreated with LPH NPs, followed 
by cisplatin (NPs) for 3h, washed and incubated with full media overnight to obtain the CM. Results 
indicated that both free cisplatin and cisplatin NPs induced paracrine secretion of Wnt16. NPs 
induced limited secretion compared to free cisplatin due to the insufficient drug release within the 3 h 
incubation. Though control siRNA and lipids that composed the NPs didn’t affect Wnt16 secretion; 
siWnt NPs abolished expression of Wnt16 (Figure 3.8C). These findings further confirm the efficient 
knockdown of Wnt16 using LPH. Knockdown of Wnt16 was then revealed by the inhibition of the 
secreted Wnt16-mediated paracrine effect. The aforementioned CMs were added to cisplatin (10 µM) 
treated UMUC3 cells to evaluate the paracrine effect. As expected, CM from cisplatin treated 
fibroblasts showed higher activity in protecting UMUC3 cells from cisplatin induced apoptosis 
compared with conditioned media from cells without cisplatin treatment. Activity was abolished if 
fibroblasts were treated with siWnt NPs (Figure 3.8D). These experiments also indicated that Wnt16 
secreted from cisplatin damaged fibroblasts is both necessary and sufficient to induce resistance in a 
paracrine manner in neighboring cancer cells.  
Next, possible mechanisms of Wnt16 induced tumor cell resistance were investigated. A non-
contact co-culture system of NIH3T3 in the upper chamber and UMUC3 in the lower chamber was 
established using a transwell configuration (Figure 3.9A) [218]. Previous studies indicated that 
Wnt16 mainly activates the canonical Wnt/β-catenin pathway [70, 228]. In an attempt to confirm that 
the Wnt/β-catenin signaling pathway in UMUC3 cells was activated by the Wnt16 secreted from 
cisplatin NPs treated fibroblasts, immunofluorescence was used to visualize β-catenin localization in 
UMUC3 cells in the lower chamber at different time points after co-culture [219]. As shown in 
Figure 3.9B, β-catenin was primarily located in the membrane during the initial 2 h of co-culture. 
However, cisplatin NPs treated NIH3T3 cells promoted increased β-catenin and nuclear localization 
in UMUC3 cells, particularly 4h after co-culture, suggesting activation of Wnt pathway. As expected, 
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siWnt NPs treatment of fibroblasts suppressed nuclear translocation of β-catenin in UMUC3 cells.  In 
addition, downstream targets of β-catenin including c-Myc and Cyclin-D1, were up-regulated in 
tumor cells co-cultured with cisplatin or treated fibroblasts (Figure 3.9C) [229, 230]. Such 
observations was absent when co-culturing UMUC3 with fibroblasts treated with siWnt NPs alone or 
in combination with cisplatin. Control siRNA NPs (siCont NPs) and human specific siWnt NPs were 
controls and no biological functions were found.   
The paracrine function of Wnt16 on tumor cells was further investigated. Cell apoptosis was 
measured by the cleavage of major apoptotic protein (PARP). Results paralleled aforementioned 
findings, which indicated the role of Wnt16 on attenuating cisplatin-induced apoptosis (Figure 3.8C). 
The Wnt signaling pathway is known to enhance cell motility and invasiveness via epithelial-
mesenchymal transition (EMT) [70, 219]. EMT is a known mechanism for cisplatin induced 
resistance in pancreatic cancer [231]. Loss of E-cadherin and gain of N-cadherin are the main 
characteristics of EMT [70]. Consistent with this notion, UMUC3 cells in the lower chamber 
exhibited decreased expression of E-cadherin and increased expression of N-cadherin when co-
cultured with cisplatin treated NIH3T3 in the upper chamber (Figure 3.9C). This EMT phenotype 
was abolished when UMUC3 cells exposed to siWnt NPs treated fibroblasts.  EMT also indicates 
tumor cell mobility. A scrape assay was performed to evaluate cell mobility using the non-contact co-
culture system. Twenty hours after co-culture, cisplatin treated NIH3T3 enhanced mobility of 
neighboring UMUC3 cells in the lower chamber. This finding was reversed with Wnt16 
downregulation in fibroblasts (Figure 3.9D). Experiments identify Wnt16 as a mediator of tumor cell 
resistance and metastasis; therefore, knockdown of Wnt16 in fibroblasts using siRNA sensitizes 
neighboring tumor cells to cisplatin treatment and improves patient prognosis.  
3.4.4 Wnt16 Knockdown Blocks the Biological Function and Increases Cisplatin Sensitivity of 
Neighboring Stroma Cells 
TAFs that were not directly treated with cisplatin NPs (hereafter referred to as naïve TAFs) 
were also affected by paracrine Wnt16 secreted from cisplatin treated fibroblasts. To determine if 
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Wnt signaling was activated in the neighboring naïve TAFs, we generated an activated NIH3T3 cell 
strain with stable expression of Wnt reporter using a Cignal Lenti T cell factor/lymphoid enhancer-
binding factor (TCF/LEF) Reporter Kit and seeded these cells on the lower chamber of the non-
contact co-culture system (Figure 3.10B). Results indicated that cisplatin treated TAFs in the upper 
chamber of the system could activate the canonical Wnt signaling in naïve fibroblasts in the lower 
chamber. Enhanced luciferase intensity was observed 4 h after co-culture, which was temporally 
consistent with the direct stimulation of fibroblasts in the lower chamber a by Wnt16 recombinant 
protein. Only siWnt NPs suppressed the expression of Wnt16 and completely blocked the activation 
of β-catenin signaling. Fibronectin secreted from functional TAFs has been shown to increase 
extracellular matrix (ECM) rigidity and promote tumor malignancy [55].  Fibronectin levels can serve 
as an important indicator to evaluate the relationship of Wnt16 knockdown on ECM remodeling as 
fibronectin expression is closely regulated by the canonical β-catenin mediated Wnt pathway [232].  
Results indicated elevated fibronectin levels in cisplatin treated naïve fibroblasts relative to the 
untreated fibroblasts (Figure 3.10C). Such effects were abolished in the presence of siWnt NPs. This 
observation was further confirmed by immunofluorescence staining of fibronectin in the lower 
chamber (Figure 3.10D). Finally, an MTT assay was carried out to show that a deficiency of Wnt16 
did not influence the cell viability of the activated fibroblasts (Figure 3.10E). This finding further 
confirmed Wnt16 protein does not play a pro-proliferative or pro-apoptotic role in regulating 
fibroblasts growth, but rather protects the cells from cisplatin induced cell death. In keeping with this 
notion, the combination of activated fibroblasts with siWnt, and cisplatin facilitated cell death, while 
siCont NPs did not (Figure 3.10F).  Overall, the data concluded that paracrine secretion of Wnt16 
activated the canonical Wnt pathway in neighboring fibroblasts, inducing the secretion of fibronectin, 
facilitating collagen crosslinking and fostering their resistance to future cisplatin assault.  
Endothelial cells are another group of stroma cells that neighbor the cisplatin NPs treated 
fibroblasts. The paracrine functions of Wnt16 on endothelial cells were further investigated using a 
non-contact co-culture tube formation assay (Figure 3.10G).  A recent study indicated that a plasmid 
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encoding the Wnt16 gene accelerated tube formation in cultured primary mouse cavernous 
endothelial cells, suggesting a role in cavernous angiogenesis [233-235]. Therefore, it was further 
hypothesized that knockdown of Wnt16 could also inhibit angiogenesis. Data in this study indicated 
that Wnt16 secreted from both NIH3T3 fibroblasts (in the upper chamber of the co-culture system) 
and recombinant Wnt16 protein induced tube formation of endothelial HUVECs (Figure 3.10H), 
confirming the hypothesis and suggesting anti-angiogeneic properties caused by siWnt NPs would 
likely foster tumor inhibition.     
3.4.5 Dynamic Monitoring of the Tumor Microenvironment Remodeling by Cisplatin NPs 
and siWnt NPs       
The consequences of the paracrine effects of Wnt16 on neighboring stroma cells was 
examined. Based on a previous study of TAFs role in TME and endothelial cells’ role in angiogenesis 
[236, 237], paracrine effects of Wnt16 was hypothesized to regulate TME remodeling and blood 
vessel angiogenesis in neighboring TAFs. To investigate this dynamic remodeling process, single 
dose and multiple doses of solo or combo treatments were carried out in the desmoplastic 
UMUC3/3T3 model. Parameters including TME markers, NPs distributions and cisplatin 
accumulation were characterized to elucidate the remodeling process. Consistent with a previous 
study, a single dose of cisplatin NPs was efficient in remodeling the TME [74]. Representative 
immunostaining images (Figure 3.11A) indicated that cisplatin significantly modulated TME 
modification through reducing the expression of α SMA, a marker of TAF-activation, and fibronectin, 
which facilitates the deposition and crosslinking of collagen and elastin in cancerous tissues.[55, 238] 
Consistently, both collagen content and collagen crosslinking were reduced in cisplatin NPs treated 
groups (Figure 3.11A and B). The changes in expression levels of major ECM proteins were further 
confirmed by western blot analysis (Figure 3.11C).  
A desmoplastic UMUC3/3T3 consisting of GFP expressing NIH3T3 cells and UMUC3 cells 
was generated to determine the basis for TME remodeling after a single dose of cisplatin NPs. 
Survival of GFP+ fibroblasts decreased significantly in the cisplatin NPs treated group compared to 
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other treatment groups (Figure 3.11D), suggesting that the depletion of TAFs was a driving force for 
the disruption of ECM. Meanwhile, DRP molecules such as Wnt16 did not reach sufficient 
concentrations to induce drug resistance. It was hypothesized that decreasing collagen content would 
improve the intratumoral distribution of NPs based on previous studies of the tumor interstitial matrix 
[52, 105]. To test the hypothesis, intratumoral accumulation of DiI-labeled liposomes (70 nm in 
diameter) was quantified via flow cytometry. Consistent with the hypothesis, improved NPs 
accumulation was observed in tumors treated with cisplatin NPs compared to the control (siCont NPs) 
(Figure 3.11E). Improved NPs penetration indicated a better therapeutic effect.  
While a single dose of cisplatin NPs induced antitumor efficacy, efficacy was temporary as 
the resistant phenotype gradually reappeared in both tumor cells and neighboring TAFs. To examine 
acquired resistance in TAFs, desmoplastic UMUC3/3T3 models were dosed with multiple rounds of 
cisplatin NPs or siWnt NPs. After 4 doses, the Wnt16 expression level was significantly elevated in 
the cisplatin NPs group (Figure 3.11F), driving the balance between efficacy and resistance towards 
the end of TAFs resistance. Results were consistent with upregulation of ECM markers, including 
αSMA, FAPα, fibronectin and collagen (Figure 3.11F-H). The resistance of TAFs to cisplatin NPs 
after multiple doses was assessed by quantitative analysis of the GFP+ fibroblast percentage in 
residual tumors. In contrast to decreasing GFP+ cell ratios found in the single dose cisplatin NPs 
group (Figure 3.11D), the survival ratio of GFP+ fibroblasts increased by ~2-fold after repeated 
cisplatin NPs doses (Figure 3.11I).   
  In order to overcome resistance induced by dynamic cisplatin NPs treatment, a combinatory 
nano-therapy or solo nanoformulations designed to kill more than 80% TAFs were utilized to 
improve TAF-depletion efficiency [72, 74]. With these platforms, prolonged tumor inhibition was 
observed, but resistance relapsed in residual fibroblasts. Furthermore, fibrotic internalization of high 
dose chemotherapy risks inducing systemic toxicity. As most DRP molecules are upregulated in 
treatment-induced cells, specific knockdown of DRP molecules to baseline would be beneficial to 
improve chemotherapy outcomes. In addition, since DPR molecules, such as Wnt16, lack pro-
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apoptotic properties, the combination of DPR inhibitors over chemotherapy would be a safer and less 
toxic route. In the current study, siWnt NPs in combination with cisplatin NPs fosters the efficacy of 
solo cisplatin NPs treatment after a single dose and reversed the cisplatin NPs induced resistance after 
multiple doses (Figure 3.11A-C, F-H). Efficacy was measured in terms of depletion of TAFs and 
ECM markers. Furthermore, siWnt NPs alone could decrease the expression of TME markers, rather 
than deplete fibroblasts. This confirms the previous hypothesis that solo siWnt NPs induced tumor 
inhibition through TME remodeling but did not induce killing effects. 
Wnt 16 is also thought to regulate blood vessel remodeling. Results indicated that, multiple 
cisplatin NPs treatments increased the density of CD31 (an indicator of blood vessels), which 
correlates with the observation in the previous tube formation study (Figure 3.12A). Downregulation 
of Wnt16 through siWnt NPs induced decreased angiogenesis and vascular remodeling in the 
desmoplastic UMUC3/3T3 model (Figure 3.12A). Since angiogenesis accelerates tumor progression, 
it is highly likely that the anti-angiogeneic properties caused by siWnt NPs foster tumor inhibition 
[219]. However, inhibition of angiogenesis weakens the enhanced permeability and retention (EPR) 
effect and is likely to compromise NPs-mediated drug delivery efficiency [8]. Yet, results indicated 
that multiple doses of cisplatin NPs/siWnt NPs, promote the penetration of both DiI labeled 
liposomes (Figure 3.11E and J) and cisplatin NPs (Figure 3.12B) compared to cisplatin NPs alone. 
The discrepancy between weakened EPR and enhanced NPs penetration was most likely due to the 
argument that siWnt NPs treatment may prune immature vessels and remodel the vasculature to more 
closely resemble the structure of normal vessels. Consistent with previous research, this so-called 
“tumor vessel normalization” benefits the delivery of small molecule chemo drugs to tumors, and also 
the accumulation of soft NPs such as liposomes (less than 100 nm) and small, solid NPs such as 
cisplatin NPs [8]. In addition, the decreased collagen crosslinking and remodeled TME could also 
decrease the overall interstitial fluid pressure and contribute to the enhanced NPs distribution and 
penetration.  
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3.4.6 Intravenous Administration of siWnt NPs with Cisplatin NPs Effectively Inhibited 
Desmoplastic UMUC3/3T3 Tumor Growth at Early or Late Stage 
Based on the aforementioned effects of Wnt16 knockdown on neighboring tumors and the 
overall TME, the therapeutic efficacy of systemically delivered siWnt NPs with cisplatin NPs in the 
desmoplastic UMUC3/3T3 model was conducted as a proof of concept study. Real-time expression of 
Wnt16 under cisplatin NPs treatment were carefully monitored by western blot (Figure 3.13B). 
Results indicated a gradual upregulation of Wnt16 in response to cisplatin treatment. Therefore, 
simultaneous administration of siWnt NPs with cisplatin NPs was selected as the treatment course 
rather than sequential dosing or two-staged dosing methods to achieve continuous inhibition of 
Wnt16 expression (Figure 3.13B). Dose levels and dosing schedules of siWnt16 were adjusted via 
tiered optimizing procedures (Error! Reference source not found.). When tumor sizes reached 150-
200 mm3, treatment was administered every other day (Figure 3.13A). The combination of cisplatin 
NPs (1mg/kg) and siWnt NPs (0.6 mg/kg) exhibited the greatest antitumor efficacy, resulting in 
progression-free survival for up to 7 days after the last treatment.  By comparison, tumors in mice 
treated with cisplatin NPs without siWnt NPs aggressively relapsed up to approximately 10x their 
original size 7 days after the last dosing  (Error! Reference source not found. and Figure 3.13A). 
siCont had no influence on tumor growth, ruling out potential from the delivery vehicle. Western blot 
analysis confirmed stable knockdown of Wnt16 expression in siWnt NPs and combo treated groups 
over the course of treatment (Figure 3.13B). Immunohistochemistry (IHC) images revealed a 4 to 5-
fold silencing of Wnt16 expression in the combo group over cisplatin NPs treated groups one day 
after the last dosing (Figure 3.13C), which was consistent with the western results (Figure 3.13D). In 
addition, siWnt NPs could also sensitize an desmoplastic UMUC3/3T3 model towards cisplatin NPs 
treatment and lead to extensive apoptosis accounting for better therapeutic outcomes in the combo 
treatment (Figure 3.13E).    
Late stage solid tumors are notorious for well-structured tumor stroma, composed of intricate 
blood vessels in the basement membrane secreted by local TAFs. Recent studies indicated off-target 
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distribution of NPs in fibroblasts of the late stage tumor is greatly intensified compared to small 
tumors (data not shown). Therefore, the combinatory therapeutic outcome of siWnt NPs with cisplatin 
NPs in late stage tumors was further investigated. 700 mm3 tumors received daily injections to ensure 
a better therapeutic outcome. As shown in Error! Reference source not found., cisplatin NPs and 
siWnt NPs showed a mild tumor inhibition effects when administered separately. However, 
combinatory therapy presented potent efficacy, even in large tumors. Results indicated the 
combination could effectively knockdown Wnt16, shrink the tumor and delay tumor growth (Figure 
3.14). Only negligible decreases in body weight and no abnormal blood parameters were observed in 
all groups (Table 3.1, Figure 3.15 and Figure 3.16).  Altogether, these results verified our hypothesis 
that the cisplatin NPs combined with siWnt NPs indeed exhibited superior antitumor efficacy in both 
small and large aggressive desmoplastic UMUC3/3T3 tumors, and considered as a promising 
therapeutic regimen for future clinical evaluations. 
3.5 Discussion and Conclusion 
Our study discussed the off-target distribution of NPs into non-tumor stroma cells and 
underlined the controversial consequence of TAF dispositions of therapeutic NPs. Internalization of 
cisplatin into TAFs resulted in their immediate killing, blocking the secretion of stroma factors, and 
violating the communication between fibroblasts and tumor cells, subsequently inhibited tumor 
growth. However, chronic exposure of TAFs to cisplatin activated the DRP and promoted the 
secretion of DRP molecules, leading to tumor cell resistance and metastasis, stroma reconstruction 
and angiogenesis (Figure 3.17). To address the problem, we proposed the combination of DRP 
inhibitors as a proof of concept to enhance the anti-tumor outcome of chemotherapy in the stroma-
rich cancer models. From coherent studies, we determined Wnt16 as one of the major DRP molecules 
that regulated the treatment-induced cisplatin resistance, and developed LPH NPs as a carrier that 
efficient deliver siRNA against Wnt16 to TAFs to foster the cisplatin NPs efficacy. Most importantly, 
we found a dramatically enhanced antitumor effect for the combination therapy even in the late stage 
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stroma-rich bladder cancer with prolonged survival and few side effects. Moreover, detailed 
mechanistic studies revealed multiple benefits of downregulating Wnt16, mainly through regulating 
paracrine interaction with different neighboring cell populations, including sensitizing neighboring 
tumor cells towards cisplatin, remodeling neighboring fibroblasts and TME, and inhibiting 
neighboring vessel angiogenesis. Therefore, our study suggest that exploring the major secreted DRP 
molecules in tumor-stroma crosstalk and co-delivering two regiments that could kill the fibroblasts as 
well as inhibit the secretion of these major factors would be of significant clinical potential. The 
results of this study will serve as a gateway for future development of NPs to explore the complicated 
tumor microenvironment.   
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Table 3.1 Effect of different treatments on serum ALT, AST, BUN and creatinine levels 
 
Treatment 
BUN 
mg/dL 
Creatinine 
mg/dL 
AST  
U/L 
ALT  
U/L 
PBS 22 ± 2 0.1 149 ± 33 41 ± 12 
siCont NPs 22 ± 2 0.2 176 ± 25 30 ± 4 
Cisplatin NPs 22 ± 5 0.2 168 ± 28 33 ± 5 
siWnt NPs 20 ± 3 0.1 193 ± 35 56 ± 5 
siWnt NP/cisplatin NPs 21 ± 1 0.2 245 ± 22 54 ± 4 
Normal Range 12 - 33 0.2 - 0.9 54 – 298 17 - 132 
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Figure 3.1 Illustration of the Non-contact Co-culture Model for mechanistic study 
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Figure 3.2 Cisplatin NPs induced UMUC3/3T3 tumor resistance through elevated expression of 
Wnt16.  
A. Graphical presentation and TEM images of the cisplatin NPs. Particle size, zeta potential and drug 
loading were characterized and presented. B. Tumor growth inhibition of cisplatin NPs or free 
cisplatin (of 1.0 mg/kg cisplatin) in the demosplatic UMUC3/3T3 tumor model. The arrowhead 
indicates dosing time. C. Western blot analysis of Wnt16 protein level in the resistant tumors. 
Intensity of the protein bands was quantified using Image J (n = 3, * P < 0.05). Wnt16/GAPDH value 
in PBS group was set as 1. D. Dose response curves of UMUC3 cells treated with different levels of 
recombinant Wnt16 protein (n = 4, * P < 0.05, ** P < 0.01, compared with the untreated group). E. 
Expression level of Wnt16 in different subtypes of bladder cancers in patients. Data were collected 
and analyzed from The Cancer Genome Atlas (TCGA) database (* P < 0.05, compared to the basal 
type).   
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Figure 3.3 Quantification of in vivo Wnt16 protein level.  
A. Standard curve was established by western blot using recombinant Wnt16 protein from 0.1 ng to 
15 ng. Quantification of protein band was calculated by image J and shown in C.  Certain amount of 
tissue samples were collected from PBS treated tumor and cisplatin NPs treated tumor, tumor lysate 
was collected and the protein content in the tumor was measured by western and calculated based on 
the standard curve. The concentration of Wnt16 in the tumor was calculated based on the sample 
volume and Wnt16 content and shown in Figure D. In the PBS treated tumor, Wnt16 concentration 
was ~0.5 μg/mL, indicating a baseline level of Wnt16 existed in the untreated tumor. In the cisplatin 
NPs treated tumor, protein level was increased up to ~6.5 μg/mL, which was consistent with the 
concentration of Wnt16 in vitro that induced bladder cancer resistance.   
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Figure 3.4 TAF-origin of cisplatin induced Wnt16.  
A. In vitro western blot analysis of Wnt16 level in cisplatin treated UMUC3, activated fibroblast 
NIH3T3 cells and its conditioned medium. B. Scheme of cisplatin NPs (1 mg/kg) treatment regimen 
on the UMUC3 xenograft and PDX tumors, which is same with the UMUC3/3T3 tumors. C. Western 
blot analysis of Wnt16 protein level in the UMUC3 xenograft and PDX tumors. Two representative 
samples of each group were presented. Intensity of the protein bands was quantified using Image J (n 
= 3, * P < 0.05), compared to GAPDH as a loading control. Wnt16/GAPDH value in PBS group was 
set as 1. 
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Figure 3.5 Wnt16 level in different tumor cell lines treated with cisplatin 
Results shown that Wnt16 were not elevated in response to cisplatin treatment on all the listed cancer 
cell lines. 
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Figure 3.6 Cisplatin NPs were delivered off-target to TAFs in the UMUC3/GFP-3T3 tumors 
after intravenous injection.  
A and B. Flow cytometry analysis of the cell populations that took up cisplatin NP in the 
UMUC3/GFP-3T3 tumors. Compositions of the DiI positive cells were shown in (A). Ratios of 
fibroblasts (of total fibroblasts) that took up NP were shown in (B) (n = 3, * P < 0.05). C. 
Fluorescence imaging of intratumoral cisplatin NP distribution. TAF (αSMA: green), blood vessels 
(CD31: magenta), DiI-labeled NP (red) and nucleus (DAPI: blue) were shown. Arrowhead and the 
asterisk insert indicate the off-target distribution of NPs in TAFs. 
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Figure 3.7 Pathology and treatment of PDX model 
A. Masson trichrome staining of the collagen. B. Fluorescence staining of αSMA revealed the stroma-
rich pathology of the PDX model. C. PDX tumor growth inhibition curve. 
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Figure 3.8  In vitro gene transfection of siWnt NPs.  
A. Graphical and TEM images of the LPH NPs. Particle size, zeta potential were characterized and 
presented. B. Western blot analysis of the Wnt16 expression in NIH3T3 cells as an indicator of in 
vitro transfection of the siRNA encapsulated LPH NPs. C. Knockdown of Wnt16 excretion was 
assayed by ELISA in the conditioned media from different treatments. DOTAP/Chol liposomes were 
set as a material control for cisplatin NP (n = 3). D. MTT assay of UMUC3 treated with the 
aforementioned CM along with cisplatin (n = 4). (For all listed analysis, * P < 0.05, ** P < 0.01). 
Note that, since both the free and NP form of cisplatin shown comparable effect in (C), either was 
applied to all the studies, only representative results were shown. 
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Figure 3.9  Mechanistic study of Wnt16 on neighboring tumor cells.  
A. Scheme of a non-contact co-culture system (upper: NIH3T3, lower: UMUC3). This system was 
used in the scratch assay, β–catenin translocation assay and western blot. B. Confocal images of β-
catenin nucleus translocation in the lower UMUC3 (Scale bars 20 μm). C. Western blot analysis of 
Wnt pathway down-stream proteins (c-myc and cyclin D1), EMT markers (E-cadherin (E-cad) and N-
cadherin (N-cad)) and apoptotic marker (cleaved PARP) in the lower UMUC3 chamber after co-
culture. D. Scratch assay in the lower UMUC3 20 h after co-culture. * Moving distance compared to 
0h, n = 3. Scale bar is 100 μm. 
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Figure 3.10 In vitro mechanistic study of Wnt16 on neighboring stromal cells.  
A. Scheme of a non-contact co-culture system (upper and lower: NIH3T3). B. Assay of canonical 
Wnt pathway signaling through activation of luciferase labeled fibroblasts was performed in the lower 
chamber after co-culture. Relative luciferase units (RLU) were quantified (n = 4), Wnt16 protein, 1 
µg/mL. C. Western blot analysis of fibronectin in the lower chamber when upper chamber was 
pretreated with cisplatin. D. Confocal images of immunofluorescence (IF) staining of fibronectin in 
the lower chambers (fibronectin: green, cell nucleus: blue), scale bar represents 20 μm. E. Cell 
proliferation of activated NIH3T3 transfected with siWnt NPs or siCont NPs at different 
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concentrations (n = 4).  F. Viability of activated NIH3T3 across a range of cisplatin concentrations 
with transfection of anti-Wnt16 or control siRNA (concentration of siRNA was 180 nM) (n = 4, * P < 
0.05) (G) Scheme of a non-contact co-culture system (upper: NIH3T3 and lower: HUVEC). H. Tube 
formation was monitored in HUVEC cells as indicators for angiogenesis 4h after co-culture. HUVEC 
cells were stained by calcium AM (green). I. The number of formed tubes was calculated. Five 
randomly selected microscopic fields were quantitatively analyzed by Image J. Scale bar represents 
100 μm. (n = 5, * P < 0.05, ** P < 0.01, *** P < 0.001). 
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Figure 3.11 Dynamic tumor microenvironment remodeling by cisplatin NPs and siWnt NPs.  
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Single (A-E) and 4-dose treatment (F-J) of siCont NPs (1), siCont NPs/cisplatin NPs (2), siWnt NPs 
(3) and siWnt NPs/cisplatin NPs (4) were intravenously administered to mice separately with cisplatin 
1.0 mg/kg and siRNA 0.6 mg/kg. Tissue samples were collected 2 days after injection. (A) and (F). IF 
staining of fibronectin, αSMA. The nuclei were stained with DAPI (blue), fibronectin and αSMA 
were stained red. Collagen was stained using Masson trichrome. The blue color represents collagen 
content, while the cytoplasm was stained red. Scale bar is 100 μm. (B) and (G) Quantitative analysis 
of fibronectin, αSMA and collagen content using Image J from 5 randomly selected microscopic 
fields.  (C) and (H) Western blot analysis of TAF markers: FAP α, αSMA, fibronectin and Wnt16 
protein levels in the tumors after treatment. (D) and (I) GFP-3T3 was used to form the UMUC3/3T3 
model. The ratio of GFP positive TAFs was quantified by flow cytometry after treatment (n = 8). (E) 
and (J) DiI-labeled liposomes (~70 nm) were IV injected one day before sacrificing the mice. 
Fluorescent liposome accumulations and penetrations in the UMUC3/3T3 tumors were quantified by 
flow cytometry (n = 3). For all statistical analysis, * P < 0.05; ** P < 0.01; *** P < 0.001, the 
statistical analysis was calculated by comparison with the untreated group if not specifically 
mentioned. 
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Figure 3.12  Blood vessel remodeling by cisplatin NPs and siWnt NPs after multiple doses.  
A. Influence of Wnt16 on blood vessel was evaluated in vivo by IF staining endothelial cells with 
CD31 (red) after multiple treatments.  B. Distribution of DiI labeled cisplatin NPs 8h after IV 
injection in different treatments of the UMUC3/3T3 model. Five images of each group from the two 
experiments were quantified and the result is shown on right. For all the statistical analysis, the 
difference was calculated by comparison with the untreated group if not specifically mentioned. In all 
quantifications, * P < 0.05, ** P < 0.01, *** P < 0.001. 
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Figure 3.13 IV injection of siWnt NPs with cisplatin NPs inhibited UMUC3/3T3 tumor growth.  
A. Intravenous injection of siWnt NPs with cisplatin NPs inhibited the growth of the desmoplastic 
bladder xenografts (UMUC3/3T3) when the tumor was small (volume ~150 mm3, n = 5-7). B. 
Expression of Wnt16 in the cisplatin NPs and the combo group over the course of treatment by 
western blot analysis. Tumor tissues were collected 1 day after each dosing intervals. C. IHC staining 
of Wnt16 on tumor tissues at the end point of tumor inhibition study. Wnt16 was stained brown and 
the cell nuclei were stained blue. The scale bar represents 100 μm. The Wnt16 content of 5 randomly 
selected microscopic fields was quantified using Image J. The quantification bar chart is shown on the 
right. D. Western blot analysis of Wnt16 levels in tumors 1 day after treatment. Three samples were 
taken randomly from three mice in each treatment group. The intensity of the Wnt16 western band 
was analyzed by Image J and calculated based on content of GAPDH. Wnt16/GAPDH value in PBS 
group was set as 1. Quantification is shown on right. E. Effect of NPs on the UMUC3/3T3 model 
apoptosis using TUNEL assay. The scale bar represents 100 μm. Five images were quantified and the 
data is shown on right.  In all quantifications, * P < 0.05; ** P < 0.01; *** P < 0.001. 
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Figure 3.14 IV injection of siWnt NPs (0.6 mg/kg) with cisplatin NPs (1 mg/kg) led to tumor 
regression when the tumor is big (volume ~700 mm3).  
Arrow heads indicate the dosing schedule of siWnt NPs (blue) and cisplatin NPs (black)  (n = 4, *** 
P < 0.001). 
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Figure 3.15 HE staining of major organs from 5 injections of PBS, siCont NPs, cisplatin NPs, 
siWnt NPs and siWnt NPs/cisplatin NPs.  
No toxicity was found to the major organs after different therapy. 
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Figure 3.16 Hematological test of whole blood collected from healthy nude mice treated with 5 
doses of different treatments as indicated. 
No significant difference between PBS group and the treatment group. WBC, white blood cell; HCT, 
hematocrit; PLT, platelet; HGB, hemoglobin; RBC, red blood cell (n = 4). 
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Figure 3.17 Diagram of the proposed mechanism 
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 CHAPTER 4: IN SITU GENERATION OF TUMOR-SUPPRESSIVE FIBROBLASTS BY 
HARNESSING OFF-TARGET DISPOSITIONS OF NANOPARTICLES IN TUMOR 
ASSOCIATED FIBROBLASTS5 
4.1  Summary   
The off-target distribution of nanoparticles (NPs) to fibroblasts illustrates a delivery barrier; 
compromising treatment of desmoplastic tumors. However, fibroblasts’ uptake of NPs can be utilized 
to modify fibroblasts into synthesizing secretable cytotoxic proteins. To achieve this, plasmids 
encoding secretable TNF-related apoptosis-inducing-ligand (sTRAIL) were loaded in lipid-coated 
protamine DNA complexes (LPD) and delivered to fibroblasts in desmoplastic bladder xenografts. 
After 3 doses, ~70% of sTRAIL producing cells were fibroblasts. The secreted TRAIL induced 
apoptosis within neighboring tumor nests. Additionally, residual fibroblasts reverted to a quiescent 
state due to insufficient activation, further compromising tumor growth and remodeling the 
microenvironment to favor second-wave nano-therapy. This strategy was also applied to treat an 
orthotopic pancreatic cancer xenograft, where the desmoplastic reaction remains overhanging issue 
limiting delivery of therapeutic NPs. Promisingly, sTRAIL LPD efficiently delayed pancreatic tumor 
growth. Collectively, the targeting and in situ modification of fibroblasts provides a new paradigm for 
treating desmoplastic malignancies. 
   
                                                   
5This chapter previously appeared as a manuscript soon to be submitted 
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4.2 Introduction  
The enhanced permeation and retention (EPR) effect describes the increased intra-tumoral 
accumulation and cellular uptake of therapeutic nanoparticles (NPs) in oncology, which demonstrates 
promising in vitro and preclinical responses [239]. Unfortunately, the early promises of several 
therapeutic NPs have failed to translate clinically [240]. One of the major mechanisms proposed for 
this failure regards heterogeneous drug uptake and off-target response in stromal cells within the 
tumor [241]. Specifically, tumor associated macrophages (TAMs) are a major off-target depletion site 
for NPs [240, 242]. Additionally, in desmoplastic condition, the tumor associated fibroblasts (TAFs), 
as the major stroma cells wrapping around blood vessels, constitute another barrier for NPs 
extravasation [169, 239]. The case is most prominent in pancreatic ductal adenocarcinoma (PDAC), 
where activated alpha smooth muscle (αSMA) positive pancreatic stellate cells compose 15 to 40% of 
total tumor mass [115, 243, 244].  
Off-target distribution of therapeutic NPs can result in adverse effects. In a previous study, 
we found a nano-formulation of cisplatin delivered to TAFs led to the secretion of survival factors, 
such as Wnt16 to support the proliferation of neighboring tumor cells [169]. In another study, 
disposition of DC101, a VEGFR2-blocking antibody, in pericytes or myofibroblast-like cells was 
found to be a major resistance mechanism in VEGF inhibitor therapy [245].   
To circumvent stroma-induced resistance, depleting stroma cells has been proposed to 
improve tumor cells’ capture of therapeutic agents [110, 246]. However, stromal depletion strategies 
run the risk of eliminating stromal components needed for tissue homeostasis, paradoxically 
facilitating tumor metastasis [117]. Stromal components can produce small proteins (e.g. cytokines) 
secreted in situ, which can bypass stromal cells barriers and bind avidly to targeted cells causing 
overexpression of their receptors. For example, proinflammatory cytokines (e.g. TNF-α, IL-6) 
secreted from infiltrated macrophages inhibit the growth of tumor cells [247]. Owing to the ability for 
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cytokines to modulate tumor growth, the idea of engineering an in-situ stromal depot capable of 
secreting cytotoxic proteins emerged in the current study. 
The best way to generate this theoretical stromal depot is gene therapy, as gene therapy 
allows proteins to be produced locally at higher rates and quantities than through systemic delivery of 
recombinant proteins [248]. While the off-target delivery of therapeutic NPs to stromal components 
traditionally compromise the efficacy of tumor specific treatments, this phenomena can be exploited 
to specifically deliver genes to stroma cells, to provide the basis for in-situ synthesis and secretion. 
Since macrophages and fibroblasts are the major off-target sites of NPs in stroma-vessel type (this 
term is used to define the common structure of desmoplastic tumors that blood vessels are embedded 
in stroma area) desmoplastic tumors, they are excellent candidates for the in-situ programming. 
However, expression of plasmids in macrophages is limited by the macrophages natural enzymes for 
degradation [249]. In addition, the regeneration of macrophage or other circulating monocytes limits 
the persistency of gene expression [239]. Therefore, TAFs may be a more suitable protein producing 
reservoir as a locally recruited cell population. 
The TNF-related apoptosis-inducing ligand (TRAIL) efficiently induces apoptosis in a wide 
range of tumor cells while sparing normal cells, making it an ideal candidate for cancer therapy [250]. 
Full-length TRAIL is a transmembrane protein lacking a leader sequence for extracellular secretion. It 
can then only be proteolytically cleaved to bind to the death domain-containing receptors  on the cell 
surface, leading to caspase-dependent apoptosis [248]. Therefore, effects of TRAIL are limited to 
cells near the plasmid transfected cells, compromising the therapeutic efficacy [251]. Thereby, a 
secretable form of TRAIL (sTRAIL) was engineered. sTRAIL consists of an extracellular domain of 
TRAIL fused with an the extracellular domain of Flt3L at the NH2 terminal. Flt3L is a ligand for flt3 
tyrosine kinase receptor, whose extracellular domain aids in the secretion of various proteins from 
cells [252]. It was then necessary to utilize the off-target distribution of NPs to target sTRAIL 
containing NPs toward fibroblasts, seeking to make them tumor inhibitive. The overarching goal was 
to use in-situ gene expression of sTRAIL in fibroblasts to reprogram fibroblasts to secrete cytotoxic 
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cytokines and induce the apoptosis of neighboring tumor cells in desmoplastic tumors. The utilization 
of TRAIL-resistant low proliferating fibroblasts as a gene producing reservoir has two important 
advantages: (a) allow a comparatively long gene expression compared to sensitive tumor cells and (b) 
maintain the stroma cell components for tissue homeostasis.         
To confirm the proof of concept, a stroma-vessel desmoplasia model was established by co-
inoculating UMUC3 bladder cancer cells with NIH3T3 fibroblasts. The fibroblast content was 
adjusted to ~25% corresponding to the average level in desmoplastic tumors. Lipid coated protamine 
DNA complexes (LPD) was developed and utilized for encapsulating sTRAIL plasmids. The 
fibroblasts’ expression of sTRAIL and the apoptosis of neighboring tumor cells were assessed. The 
concept was further evaluated on a clinical relevant orthotopic desmoplastic PDAC model BXPC3. 
As expected, the expression of sTRAIL was primarily in fibroblasts. The in situ expression of 
sTRAIL by fibroblasts induced potent tumor inhibition. However, residual TAFs unexpectedly 
reverted to quiescence, presumably due to death of neighboring tumor cells. This led to the 
remodeling of tumor microenvironment (TME) and provides a new paradigm for second-wave 
nanoparticle therapy.  
4.3 Materials and Methods 
4.3.1 Materials 
1,2-dioleoyl-3-trimethylammonium-propane chloride salt (DOTAP) was purchased from 
Avanti Polar Lipids, Inc. (Alabaster, AL). 1,2-distearoryl-sn-glycero-3-phosphoethanolamine-N-
[methoxy (polyethyleneglycol-2000) ammonium salt (DSPE-PEG2000) was obtained from NOF 
America Corporation. The hydrophobic dye, 1,1’-Dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine 
perchlorate (DiI) was purchased from Thermo Fisher Scientific, Inc. (Carlsbad, CA).  Cholesterol and 
protamine were purchased from Sigma-Aldrich (St Louis, MO) Cisplatin was purchased from Acros 
Organics (Fair Lawn, NJ). DSPE-PEG-AA was synthesized based on the previous established 
protocols [173].  An expression vector containing the human TRAIL open reading frame was 
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purchased from InvivoGen (San Diego, CA). Primers for PCR, qPCR were purchased from Integrated 
DNA Technologies (Coralville, IA), Invitrogen (Grand Island, NY), and Bio-rad (Hercules, CA). All 
the other chemicals were purchased from Sigma-Aldrich unless otherwise mentioned. 
4.3.2 Cell lines, Animals and Antibodies 
The mouse embryonic fibroblast cell lines NIH3T3 and the human lung fibroblasts MRC-5 
were purchased from UNC Tissue Culture Facility. The human bladder transitional cell line UMUC3 
was provided by Dr. William Kim (University of North Carolina at Chapel Hill, NC). The human 
pancreatic cancer BXPC3-Luc2 was purchased from PerkinElmer (Waltham, MA). UMUC3 and 
NIH3T3 were maintained in Dulbecco’s Modified Eagle’s Media (Invitrogen, CA), supplemented 
with 10% feta bovine serum (FBS) (Sigma, MO) or 10% bovine calf serum (Sigma, MO), 1% 
penicillin and streptomycin (100 µg/mL) (Invitrogen, CA). BXPC3-Luc2 were cultured in RPMI-
1640 medium (Invitrogen, CA), supplemented with 20% FBS, while MRC-5 were cultured in αMEM 
(Invitrogen, CA) supplemented with 10% FBS. Female nude mice of 6-8 weeks-old were obtained 
from and raised by the University of North Carolina animal facility. All animal handling procedures 
were approved by the University of North Carolina at Chapel Hill’s Institutional Animal Care and 
Use Committee. Primary and secondary antibodies used for western blot (WB), flow cytometry (flow 
cyt), immunofluorescence staining (IF) and immunohistochemistry (IHC) staining are listed in 
APPENDIX I . 
4.3.3 Preparation and Characterization of LPD 
LPD were prepared through a stepwise self-assembly process based on a well-established 
protocol [217]. Briefly, DOTAP and cholesterol (1:1, mol/mol) were dissolved in chloroform and 
solvent was removed by rotary evaporator. The lipid film was then hydrated with distilled water to 
make the final concentration of 10 mmol/L cholesterol and DOTAP. Then, the liposome was 
sequentially extruded through  200 nm, and 100 nm polycarbonate membranes (Millipore, MA) to 
form 70–100 nm unilamellar liposomes. The LPD polyplexes core were formulated by mixing 140 μL 
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of 36 μg protamine in 5% glucose with equal volume of 50 μg plasmid in 5% glucose. The mixture 
was incubated at room temperature for 10 minutes and then 60 μl cholesterol/ DOTAP liposomes (10 
mmol/L each) were added. Post insertion of 15% DSPE-PEG and DSPE-PEG-AA were further 
performed at 60 °C for 15 minutes. The size and surface charge of the NPs were determined by 
Malvern ZetaSizer Nano series (Westborough, MA). TEM images were acquired where NPs were 
negatively stained using a JEOL 100 CX II TEM (JEOL, Japan).  
4.3.4 sTRAIL and TRAIL Construction 
The p-sTRAIL containing genes encoding a Flt3L leader sequence, isoleucine zipper, the 
extracellular domain of TRAIL, followed by an internal ribosome entry site and GFP under a CMV 
promoter were previously constructed and provided by Dr. Shawn Hingtgen (University of North 
Carolina at Chapel Hill, NC). To establish the p-TRAIL construct, the sTRAIL sequence was cleaved 
from the p-sTRAIL vector via digesting with XhoI/BamHI (New England Biolabs, CA). Then the full 
length TRAIL cDNA was amplified by PCR using a sense primer containing the XhoI site (5’-
CAGCCTCGAGCGACCATGGCTATGATGGAGGTC-3’) and an antisense primer containing the 
BamHI site (5’-CAGCGGATCCTTAGCCAACTAAAAAGGCCCCG-3’). The amplified DNA was 
digested with XhoI/BamHI, and inserted into the XhoI/BamHI site of the pre-removed p-sTRAIL 
construct.  The insertion of the full length TRAIL was confirmed by double digestion and PCR.  The 
p-sTRAIL sequence was verified using Applied Biosystems 3730xl Genetic Analyzers. 
4.3.5 In vitro Transfection of LPD-encapsulating sTRAIL and TRAIL 
Activated NIH3T3 cells (incubating with 10 ng/mL TGF-β overnight) were grown until 80% 
confluent in 6-well plates. Then LPD loaded with sTRAIL and TRAIL (1µg of the plasmids) were 
added to each well in the presence of Opti-MEM. The medium was refreshed 4h post-transfection and 
incubated overnight. The expression of TRAIL and sTRAIL was measured at mRNA level by qPCR 
analysis with GAPDH as a loading control. Lipofectamine®-2000 (Invitrogen, CA) was used as a 
positive control for the transfection study following the manufacturer’s protocol.  
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4.3.6 GFP and RFP Lentivirus Transduction in NIH3T3 Fibroblasts.  
Protocols are similar to that discussed in the previous chapter (Section 2.3.6).    
4.3.7 Non-contact Co-culture Model for Mechanistic Study 
A non-contact co-culture system was established according to a previous protocol with little 
adjustment [218]. In brief, activated NIH3T3 cells were seeded into a transwell filter (polycarbonate 
membrane insert, 0.45-µm pore, Corning Inc.). Before co-culture, transwell insert were transfected 
with sTRAIL, TRAIL, GFP and PBS using Lipofectamine®-2000 for 4 h. Immediately after the insert 
cells were washed thoroughly with PBS, the co-culture started by putting the insert into the lower 
chambers pre-seeded with UMUC cells. After a determined time of co-culture, the bottom cells were 
used in the following experiments. Cell number counts. Twenty-four hours after co-culture, UMUC3 
cells were stained with calcein AM (Invitrogen, CA) and visualized using a fluorescence microscope. 
The number of cells was quantified using Image J from 5 randomly selected microscopic fields. 
Annexin V/Propidium Iodide apoptosis assay. Twenty-four hours after co-culture, tumor cells were 
collected and stained with Annexin V and propidium following the manufacturer’s protocol (BD 
Pharmingen™, CA). Early apoptosis and late apoptosis were quantified using flow cytometry on a 
BD FACSAria instrument (Beckon Dickinson, CA).  
4.3.8 In vitro Analysis of Cell Proliferation 
UMUC3 and activated NIH3T3 cells were cultured with sTRAIL LPD, TRAIL LPD, and 
GFP LPD, respectively, at different concentrations for 4h, and then washed and cultured overnight. 
Cell viability was assayed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to 
address cytotoxicity of TRAIL in fibroblasts and tumor cells.   
4.3.9 Collection of Conditioned Medium 
Conditioned medium (CM) was collected as described elsewhere [207, 218]. Activated 
NIH3T3 cells were treated with GFP LPD, sTRAIL LPD and TRAIL LPD respectively with Opti-
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MEM medium for 4 h. After treatments, the cells were rinsed thrice with PBS and left overnight in 
DMEM medium with 5% BCS. The culture medium was then collected and centrifuged at 900 rpm 
for 5 min, and then supernatant was filtered through a 0.45-µm filter and collected as CM for further 
study. Cytotoxicity in tumor cells. The CM from different treatments groups were used to culture 
UMUC3 cells pre-seeded in 96-well plates. Twenty-four and 36 h after incubation, cell viabilities of 
UMUC3 were quantified using an MTT assay respectively. Enzyme-linked Immunosorbent Assay 
(ELISA) of sTRAIL in the CM. To measure the concentration of TRAIL, CM collected from 3T3 
cells and MRC-5 cells pretreated with different amounts of sTRAIL or TRAIL LPD were subjected to 
an ELISA for human TRAIL (R&D Systems, MN) following the manufacturer’s instructions. 
Recombinant human TRAIL protein was used as a standard.  
4.3.10 Tumor Growth Inhibition 
The stroma-vessel UMUC3/NIH3T3 model was established as previously reported with little 
modification [74, 195]. In brief, UMUC3 cells (5×106 and NIH3T3 cells (2.5×106) were 
subcutaneously co-inoculated into the right flank of mice with Matrigel (BD biosciences, CA) at a 
ratio of 1:1 (V/V). Treatments were initiated on the 11th day when tumor sizes reached ~500 mm3. 
Mice were then randomized into 4 groups (n~7 per group) as follows: Untreated group (PBS), GFP 
LPD, TRAIL LPD and sTRAIL LPD. IV injections were performed Q.O.D for a total of 4 doses of 50 
µg plasmid/mice. Tumor volume (1/2*length*length*width) was measured every day with a digital 
caliper (Thermo Fisher Scientific, PA) and body weight was also recorded. The desmoplastic 
BXPC3-Luc2 model was established by orthotopic injection of 1X106 cells into the tail of pancreas. 
Injections of sTRAIL, TRAIL, GFP LPD were started 15 days after inoculation and dosed every 2 
days, in total of 4 times. Tumor growth was monitored using IVIS® kinetics Optical System (Perkin 
Elmer, CA) twice a week. The increases of tumor volumes were calculated as the radiance of the 
intensities.   
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4.3.11 Flow Cytometry Analysis 
To study the cell population that took up NPs within tumors, mice were administrated with 
DiI-labeled LPD at a dose of 0.1 mg/kg DiI and were sacrificed 10, 24, 48 and 72h post IV injection. 
Fresh tumor tissues were dissociated with 1 mg/mL collagenase Type IV (Invitrogen), 1 mg/mL 
hyaluronidase (Sigma, MO) and 200 µg/mL DNAase I (Invitrogen, CA) in DMEM/ 2% FBS for 40 
min to generate a single cell suspension (1×106 cells/mL). The fibroblasts were pre-transfected with 
green fluorescence protein (GFP). Leukocytes portion were stained with APC conjugated CD45 
antibody at a 1:100 dilution. The cells were then subjected to flow cytometry analysis after washing. 
The ratios of DiI-labeled NPs distributed in different cell populations were then calculated. To 
analysis the expression of IRES GFP in fibroblasts and other cells within the bulk tumor, tumor 
tissues were collected after single dose or multiple doses treatments. To study the distribution in 
UMUC3/3T3, fibroblasts were pre-transfected with RFP; in BXPC3 tumors, TAFs were labeled with 
αSMA primary antibody, followed by Alex Fluor® 647 conjugated secondary antibody. Tumor 
tissues were dissociated and the ratio of GFP expressed fibroblasts in the dissociated cells was 
analyzed by flow cytometry on a BD FACSAria instrument (Beckon Dickinson, CA).  To quantify 
the expression of TRAIL and TAFs markers in RFP-fibroblasts of the UMUC3/3T3 model, the 
dissociated cells were sorted using MoFlo XDP (Beckman Coulter, CA), and the collected fibroblasts 
and other cells counterpart were processed through RNA extract, DNA reversion and qPCR analysis. 
4.3.12 Quantitative Real-time PCR (qPCR) Assay 
Total RNA was extracted from the cell lysates, tumor tissues, or cells sorted from MoFlo 
XDP (Beckman Coulter, CA) using RNeasy Kit (Qiagen, CA). The cDNA was reverse-transcribed 
with the First-Strand Synthesis System for qPCR (Invitrogen, NY). Then ~100ng cDNA was 
amplified using the Taqman Universal Probes Supermix system (Bio-rad, CA) or iQTM SYBR® 
Green Supermix system (Bio-rad, CA). All the human or mouse specific primers for qPCR reactions 
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are listed in APPENDIX II. GAPDH was used as the endogenous control. Reactions were conducted 
with the 7500 Real-Time PCR System and the data were analyzed using the 7500 software.  
4.3.13 Western-blot Analysis 
Please refer to Section 2.3.15. 
4.3.14 Fluorescence Images of GFP in the RFP-positive Fibroblasts 
At determined time points after treatment, tumors were excised and fixed in 4% 
paraformaldehyde for 2 h, and then submersed and frozen in O.C.T. After cryosectioning, the 5µm 
frozen cryosections were washed with PBS twice, and mounted with Prolong® Gold antifade reagent 
with DAPI (Invitrogen, CA). GFP and RFP were visualized in the cryosections using Eclipse Ti-U 
inverted microscope (Nikon Corp., Japan) at 10X magnification and analyzed on Image J.  
4.3.15 Immunofluorescence Staining 
Paraffin-embedded tissues were prepared by the UNC Animal Histopathology Core. The 
slices were deparaffinized, and the antigen was recovered, permeablized, and fixed, if necessary, and 
blocked with 1% BSA at room temperature for 1h. Cell markers were detected with primary 
antibodies followed by secondary antibodies conjugated with fluorophores as indicated. Images were 
taken using Eclipse Ti-U inverted microscope (Nikon Corp, Japan) or confocal microscopy (Laser 
Sacning. Zeiss 510 Meta, Japan). 
4.3.16 Immunohistochemical Staining of pSMAD2 and Blood Vessels 
Immunohistochemical stainings of pSMAD2, αSMA and CD31 from adjacent sections of 
paraffin-embedded tumor samples were prepared by UNC Translational Pathology Laboratory. 
Images were taken by an Aperio ScanScope CS Digital Slide Scanner.  
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4.3.17 Masson’s trichrome Staining 
Paraffin-embedded tumor sections were deparaffinized and rehydrated. The slides were then 
stained using a Masson’s Trichrome Kit (Sigma, MO) following the manufacturer's instructions. 
4.3.18 TUNEL and αSMA Immunofluorescence Co-staining 
Paraffin-embedded tumor sections were deparaffinized and rehydrated. GFP fluorescence 
from GFP-plasmid or GFP transfected cells was quenched during the embedding and fixing process. 
αSMA staining was performed following the immunofluorescence staining protocol. The slides were 
then stained using a TUNEL assay kit (Promega, MI) according to the manufacturer’s instructions. 
Five to ten representative images from each treatment were processed using Eclipse Ti-U inverted 
microscope (Nikon Corp., Japan) and analyzed on Image J. 
4.3.19 Serum Biochemical Value Analysis and Hematology Assay 
Mice that were IV-injected with PBS, TRAIL LPD, sTRAIL LPD, and GFP LPD Q.O.D for a 
total of 4 doses were subjected to a toxicity assay. For 1-day post treatments, blood samples were 
collected from mice of different treatment groups and centrifuged at 4000 rpm for 5 min to obtain the 
serum. Serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatinine and 
blood urea nitrogen (BUN) were assayed as indicators of liver and renal functions. As to the 
hematology assay, whole blood was collected, and then platelets (PLT), hemoglobin (HGB), 
hematocrits (HCT), white blood cells (WBC) and red blood cells (RBC) were counted as to detect 
myelosuppression. Organs including heart, liver, spleen, lung, and kidney were collected and fixed 
for H&E staining by the UNC Animal Histopathology Core to evaluate the organ-specific toxicity.    
4.3.20 Statistical analysis 
Statistical analysis was undertaken using Prism 5.0c Software. A two-tailed t-test or a one-way 
analysis of variance (ANOVA) was performed when comparing two groups or more than two groups, 
respectively. In one-way ANOVA analysis, only statistical analysis between important comparison 
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groups was presented. Statistical significance was defined by a value of p < 0.05. Data were shown as 
mean ± SD.  
4.4 Results  
4.4.1 Identification of Fibroblasts as the Major Off-target Cell Population for LPD Uptake 
within a Stroma-vessel Tumor Model 
The LPD preferentially deliver macromolecules, including siRNA, mRNA and plasmid DNA 
to the malignant cells for anticancer therapy in vivo. To prepare LPD, anionic plasmid was condensed 
with cationic protamine to form a slightly anionic complex core. The core was coated with the 
preformed cationic liposomes (DOTAP, cholesterol and DSPE-PEG). Anisamide (AA) was further 
conjugated onto the surface of NPs as a ligand for cells overexpressing the sigma receptor (Sigma R) 
(including tumor cells and TAFs). The final NPs were ~ 70 nm in diameter, with a surface charge of 
~25 mV, as measured by a Zetasizer (Table 4.1). TEM images confirm the size of LPD and indicate 
its spherical shape and homogenous distribution (Figure 4.1). 0.5 % DiI was incorporated into the 
lipid membrane of LPD (DiI-labeled LPD) as an in vivo tracker for evaluatng the time-lapse bio-
distribution of the NPs. 
A stroma-vessel type desmoplastic tumor model was generated from simultaneous 
subcutaneous inoculation UMUC3 bladder cancer cells along with NIH3T3 fibroblasts (UMUC3/3T3) 
(Figure 4.2A). DiI-labeled LPD reached UMUC3/3T3 tumors within 10 h of intravenous injection, 
and plateaued over 48 h (Supplementary Fig. S1C). Consistant with other NPs of similar size, the 
liver and spleen were the major organs of uptake for fluorescent NPs. Flow cytometry was performed 
to determine LPD accumulation in various cell populations within the bulk tumor mass. NIH3T3 was 
pre-transfected with GFP and inoculated together with UMUC3 (UMUC3/GFP-3T3). Stably 
expressed GFP and fluorophore conjugated antibody against mouse CD45 defined fibroblasts and 
leukocytes populations, respectively. Results show that ~27% of the cells within the bulk tumor are 
fibroblasts (GFP positive) while ~16% are CD45+ leukocytes. The majority of remaining cells, as 
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shown in a previous study, are tumor cells (Figure 4.2B) [169]. The time-lapse association of DiI-
labeled LPD within different cell populations in-situ was then determined by flow cytometry. More 
than ~60% of fibroblasts took up LPD at 10 h post intravenous injection, accounting for ~65% of the 
total NP-associated cells (Figure 4.2 and Figure 4.3). Despite gradual clearance or degradation of 
the fluorescent NPs, ~20% of fibroblasts still remain DiI positive 72 h after NPs injection. On the 
contrary, only ~20% CD45+ leucocytes took up DiI LPD initially. Furthermore, while tumor cells 
comprise 40% of cells within the total tumor mass, less than 10% of tumor cells took up NPs over the 
time of the observation. These analyses ultimately indicate that fibroblasts are the major off-target 
cell populations responsible for LPD uptake in the stroma-vessel type tumor models.   
4.4.2 In vitro Transfection of Fibroblasts with sTRAIL in LPD Induces Apoptosis of 
Neighboring Tumor Cells 
A bioactive secretable form of TRAIL was constructed by Hingtgen et al, through fusing 
coding sequences for the extracellular domain of Flt3L (a.a1-81) and an isoleucine zipper (ITZ) to 
promote trimerization, with the aa.114-281 of TRAIL [253, 254]. p-TRAIL encoding the human full-
length TRAIL cDNA, and p-GFP encoding GFP, were constructed as controls, respectively (Figure 
4.4). To simultaneously monitor the cellular origin of the gene expression, intracellular protein GFP 
was co-expressed with sTRAIL or TRAIL by fusing the internal ribosomal entry site (IRES) sequence 
and genes encoding GFP with the aforementioned sequences. The prepared plasmid constructs were 
then encapsulated into LPD through the aforementioned self-assembly process. Particles size and zeta 
potential remained constant in regardless of types of plasmids encapsulated (Table 4.1). The gene 
expression efficiency of LPD encapsulating TRAIL or sTRAIL plasmid was assessed in-vitro with 
NIH3T3. NIH3T3 was pre-conditioned with TGF-β to obtain a TAF-like phenotypes. Twenty-four 
hours after transfection, mRNA levels of the extracellular domain of TRAIL (exTRAIL, same for 
both TRAIL and sTRAIL) were determined using the Real-Time Quantitative Reverse Transcriptase-
Polymerase Chain Reaction (qPCR). Data suggests the expression efficiency of sTRAIL LPD and 
TRAIL LPD are similar in activated fibroblasts. Moreover, the LPD delivered plasmids showed 
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slightly lower, but comparable transfection efficiency compared with those delivered with the 
commercial transfection agent lipofectamine®-2000 (Figure 4.5).  
TRAIL activates the Caspase 3/8 dependent apoptosis pathway and thereby amplifies the 
apoptotic response in epithelial-derived cells [35]. Indeed, we found that the viability of UMUC3 
transfected with TRAIL or sTRAIL, but not GFP, was drastically decreased (Figure 4.4B). No 
significant difference was observed between cells treated with TRAIL or sTRAIL, most likely due to 
the sufficient transfection of cells with the plasmids. Therefore, secretion was not a limiting step in-
vitro for cytotoxicity [36]. Consistently, normal fibroblasts (e.g. murine NIH3T3, or human MRC-5) 
were resistant to the TRAIL, likely from the overexpression of decoy receptors or an alternate 
downstream pathway [251]. Secretion is a major requirement for overcoming the stroma barriers and 
benefiting antitumor therapy in desmoplastic tumors. To this end, the secretion of sTRAIL was 
evaluated. Equal amounts of sTRAIL, TRAIL, GFP were transfected into the activated NIH3T3 using 
LPD. Supernatant was collected 48 h post transfection and assayed using ELISA for the secreted 
TRAIL protein. Consistent with previous studies, abundant sTRAIL was detected in media while the 
concentration of full-length TRAIL was ~50 times lower in media of NIH3T3; suggesting that the 
leader sequence is essential for sTRAIL released (Figure 4.4C) [28]. Next, sTRAIL released into the 
culture media was assayed for biologically activity (data not shown). The growth media for UMUC3 
was replaced with culture supernatants from NIH3T3 cells transfected with sTRAIL, TRAIL or GFP 
as a control. UMUC3 with modified culture supernatant was then incubated for another 24 h or 36 h. 
The culture supernatant containing sTRAIL, but not TRAIL, exerted a significant cytotoxic effects on 
UMUC3. The neighboring effect between fibroblasts and tumor cells were further confirmed by non-
direct contact co-culture (Figure 4.4D). In brief, UMUC3 (bottom layer) was co-cultured with 
activated fibroblasts (upper layer) preloaded with different plasmids. The total cell number was 
significantly lower in the sTRAIL co-culture group. Further, ~13.2% early apoptosis and ~6.7% late 
apoptosis was observed in the sTRAIL co-culture group as compared to other treatment groups 
(Figure 4.4D). All together, these data verify the prerequisites for in-situ gene modification of 
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fibroblasts: (a) fibroblasts are resistant to both sTRAIL and TRAIL, while tumor cell are sensitive to 
them; (b) sTRAIL can be efficiently released within the supernatant allowing (c) the neighboring 
effect to occur instantly. 
4.4.3 Secreted TRAIL Induces Superior Antitumor Efficacy in the Stroma-vessel 
Desmoplastic Bladder Cancer Model 
The efficacy of systemically delivering sTRAIL was then evaluated on the UMUC3/3T3 
tumor model. Treatment began when tumor sizes reached 500 mm3, allowing the stroma-vessel 
structure to be well-formed. Equal amounts of plasmids in LPD NPs were intravenously injected into 
mice Q.O.D for a total of four injections. As shown in Figure 4.6A, the mean tumor growth in mice 
treated with sTRAIL LPD was significantly inhibited compared to the GFP-LPD treated group. It is 
reasonable to assume that GFP-LPD exhibited a slight antitumor effect, likely from the non-specific 
induction of inflammatory cytokines from the cargos and DNA backbones [255]. To demonstrate the 
neighboring effect induced from sTRAIL, the full-length TRAIL LPD, representing a form of TRAIL 
which could not be highly secreted, was administrated as a control. As expected, full length TRAIL 
showed minimal antitumor efficacy compared to sTRAIL. qPCR analysis of the mRNA expression 
using primers positioned simultaneously at the extracellular domain (exTRAIL) for both TRAIL and 
sTRAIL  suggest comparable expression of sTRAIL and TRAIL in tumors treated with four doses  
LPD treatment (Figure 4.6C). This, in conjunction with the in vitro transfection data (Figure 4.5), 
indicates a similar transfection efficiency between these two plasmids and dismisses the possibility 
that a difference in expression levels between sTRAIL and TRAIL affect the antitumor effect. 
Notably, both TRAIL and sTRAIL LPD induced >7 times greater expression of exTRAIL compared 
to the PBS treated group with a baseline level of endogenous TRAIL. Additionally, the expression of 
mRNA persisted at least four days after the endpoint dose, suggesting relatively long gene expression 
profiles. qPCR assay using primers specific for sTRAIL confirms the expression of sTRAIL plasmid. 
With a lower baseline level compared to exTRAIL mRNA, the relative sTRAIL production was ~200 
times higher relative to the control. Results indicate the potency of gene transfection and suggest a 
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promising therapeutic outcome (Figure 4.6D). There was no significant decrease in body weight 
observed in any of the four treatment groups (Figure 4.6B), indicating that none of the plasmids 
caused toxicity. The results verified the hypothesis that sTRAIL secreted in situ indeed exhibited 
superior antitumor efficacy in a stroma-vessel desmoplastic tumor model.  
4.4.4 The sTRAIL LPD were Delivered to and Expressed in Fibroblasts in situ   
To elucidate whether the superior efficacy of sTRAIL resulted from in situ engineering of 
fibroblasts, the loco-regional expression of sTRAIL was assessed in the cell populations within the 
tumor mass. Since the intracellular protein GFP was fused with sTRAIL through an IRES sequence, 
the cells that expressed GFP represented cells that secrete sTRAIL. Moreover, to visualize the 
fibroblasts, RFP-3T3 was inoculated with UMUC3 using a similar method described above. Notably, 
the xenograft developed from UMUC3 cell lines alone had minimal to no endogenous fibroblasts. 
Therefore, the RFP-fibroblasts constitute the majority of fibroblast populations in the UMUC3/3T3 
model. As shown in Figure 4.7A-D, clear indications of fibroblast components (RFP) were present, 
sparing the GFP auto-fluorescence in the untreated group. Mice that were treated with a single dose of 
sTRAIL LPD exhibited a moderate GFP expression, exclusively localized within the RFP-fibroblasts. 
The expression of GFP was enhanced following the second injection of NPs, but still overlapped with 
RFP-fibroblasts. The strongest GFP expression was elicited after four doses of NPs. The expression 
of GFP was quantitatively confirmed using flow cytometric analysis (Figure 4.7E). Consistent with 
the fluorescent images, overall expression of GFP increased in a dose dependant manner, but the 
majority of expression was limited to RFP-fibroblasts. This data confirmed that fibroblasts are the 
major reservoir for in-situ generation of LPD delivered proteins. This was most likely due to off-
target distribution of NPs and relatively high and stable expression of genes in fibroblasts compared 
to other off-target cell populations, mainly leucocytes (macrophages). Notably, the expression of GFP 
in other cells were observed two days after endpoint dose (Figure 4.7D and E), suggesting that a 
portion of NPs have overcome the fibroblast elicited barriers and entered into the tumor nest. 
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However, the expression of GFP in this group of cells decreased dramatically four days after the 
endpoint injection while the expression in fibroblasts remained constant. There are two hypothesized 
mechanisms related with the observations: (a) the tumor cells (within the other cell populations) may 
internalize the NPs but undergo apoptosis immediately or (b) the infiltrating leukocytes take up the 
NPs, but cells circulate afterwards. Either cell population demonstrated transient expression of the 
genes compared with local TRAIL resistant fibroblasts, confirming fibroblasts as the most suitable 
candidate for an engineered reservoir. The expression level of sTRAIL mRNA was further assayed in 
the RFP-fibroblasts sorted from tumors with three doses sTRAIL or GFP LPD treatments (Figure 
4.7F). As expected, only the fibroblasts treated with sTRAIL LPD elicited the synthesis of sTRAIL 
mRNA, ~60 times higher than other cells in the same tumor or in GFP LPD treated cells within other 
tumors. Again, this confirms fibroblasts as the major and most suitable in-situ engineering reservoir 
for sTRAIL protein.   
4.4.5 Neighboring Effect Unveiled the Apoptotic Effect of TRAIL in the Stroma-vessel 
Desmoplastic Bladder Cancers 
In support of our hypothesis that the in-situ engineering of fibroblasts with sTRAIL bypassed 
the stroma barriers and induced the efficient death of neighboring tumor cells. The distribution of 
apoptotic cells was then examined using terminal deoxynecluotidyl transferase dUTP nick end 
labeling (TUNEL) assay.  TAFs were simultaneously visualized by staining with α-SMA. Figure 
4.8A show that the apoptotic area grows in area around α-SMA positive TAFs as the doses increases. 
Tumor sections from several areas in different tumors after each dose (in total 3 doses) were then 
analyzed to quantify the average distances between apoptotic cells and the nearest α-SMA positive 
TAFs. Only 3 doses were recorded since most of the sTRAIL were synthesized by fibroblasts within 
the 3 doses. After single injection, nearly all apoptotic cells were within just 50 µm of the nearest α-
SMA positive TAF. The distribution radius of apoptotic cells increases with dose and over time 
(Figure 4.8B).  The data therefore substantiates the claim that a neighboring effect of fibroblasts is 
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indeed present in fibroblasts in situ, facilitated by diffusion, and amplified with escalated dosing 
schedules. The apoptotic assay was also performed in other treatment groups two days after the 
endpoint treatments (Figure 4.8C). As expected, minimal apoptosis was observed in the PBS and 
GFP LPD group, whereas a small amount of TUNEL-positive nuclei were observed in groups treated 
with TRAIL LPD. We hypothesized that the proteolytically cleaved extracellular domain of the full-
length TRAIL induced apoptosis of neighboring tumor cells, or a paucity of NPs diffused through 
TAFs layer, inducing the synthesis of TRAIL and apoptosis in neighboring tumor cells, thus 
explaining the limited apoptotic cells observed in the TRAIL LPD NPs in vicinity of TAFs.  In 
comparison, an extensive amount of apoptotic cells was observed in the sTRAIL LPD group. In 
addition, the residual fibroblasts (especially TAFs) were clustered, sparing the tumor nest structure. 
Potent, well-dispersed apoptosis along with this disordered and clustered fibroblast structure 
suggested a tumor microenvironment less structurally and functionally capable of growth and 
progression. Therefore, the superior antitumor activity of sTRAIL LPD compared to other treatment 
groups was verified.  
4.4.6 Apoptosis of Neighboring Tumor Cells Induced by sTRAIL LPD Causes 
Reprogramming of Residual Fibroblasts, Facilitating the Delivery of Second-wave 
Therapeutic NPs  
The function of residual fibroblasts was then examined. The level of collagen, a major 
extracellular matrix (ECM) protein, was assessed after multiple sTRAIL treatments in mice bearing 
UMUC3/RFP-3T3 [69]. Unexpectedly, the collagen content decreased ~3-fold compared to other 
treatment groups (Figure 4.9). Reductions were also observed on other proteins unique to fibroblast 
activation which are of functional significance in the TME, including fibronectin and hepatocyte 
growth factor (HGF) (Figure 4.10A) [117, 169, 201]. In addition, the activation marker of fibroblasts 
within the bulk tumor mass, including αSMA and fibroblasts activation protein alpha (FAPα) 
decreased by ~ 90% and ~84% (compared to total RFP-fibroblasts), respectively (Figure 4.10B) [117, 
169, 256]. These data suggest that residual TAFs are shifting from an activated toward a quiescent 
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state. However, the proteins described above are not exclusively secreted by fibroblasts. For example, 
expressions of FAPα and fibronectin have been found in tumor cells [257, 258]. To further confirm 
the state shift of fibroblasts within the TME, we sorted the RFP fibroblasts from the dissociated cells 
collected from the tumor mass after 3 doses of sTRAIL LPD. Indeed, we found the mRNA level of 
collagen and ACTA2 (α SMA) in sTRAIL treated fibroblasts decreased 2 to 5 fold compared to 
untreated fibroblasts (Figure 4.10C). Meanwhile tumors treated with full length TRAIL or GFP-LPD 
failed to affect desmoplasia, which eliminates any possibility of TRAIL directly inducing fibroblast 
reprogramming (Figure 4.9 and Figure 4.10). Since it is commonly accepted that the majority of 
TAFs are transdifferentiated from resident fibroblasts in response to TGF-β [259], the downstream 
portions of TGF-β signaling, including pSMAD2 and plasminogen activator inhibitor type 1 (PAI-1) 
was examined [256, 259, 260]. Indeed, data revealed a decreased level of pSmad2 nuclei staining and 
an inhibition of the transcriptional activation of PAI-1 in fibroblasts of sTRAIL treated tumors 
(Figure 4.10C and Figure 4.11). Again this supports the reprograming of TAFs.  
It is conceivable that reprogrammed TAFs re-establish a physiological and metabolic 
environment adverse to tumor growth. The restoration of normal stroma also released the interstitial 
fluid pressure (IFP) and opened up the compressed intratumoral vasculature (Figure 4.12). Therefore, 
it was questioned whether the remodeled TME would be more sensitive to second-wave nanocarriers: 
which describes an additional course of chemotherapy following microenvironment modulation. A 
lipid coated cisplatin nanoparticle (LPC NPs, ~30 nm) was previously developed in our lab and used 
for the tumor accumulation study herein. Detailed characterizations of the NPs were described by 
Guo et al [177]. A single dose of cisplatin NP (1.9 mg/kg of cisplatin) was intravenously injected into 
mice bearing UMUC3/3T3 xenografts. Twenty-four hours post injection, tumor tissues were collected 
and the level of platinum was quantified using inductively coupled plasma mass spectrometry (ICP-
MS). As shown in Figure 4.13B, pre-treatment of the tumors with sTRAIL LPD leads to a ~2 -fold 
increase of cisplatin retention. To demonstrate the possible therapeutic benefits of the two-wave 
therapBy, mice were first pretreated with 3 doses of sTRAIL LPD as shown in Figure 4.13.  Results 
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herein suggest that the two-wave therapy significantly inhibits and delays the tumor growth more than 
single modality therapy. In conclusion, the data suggest residual fibroblasts and TME after sTRAIL 
treatment are remodeled, benefiting not only the sTRAIL-mediated antitumor efficacy, but also the 
delivery of a second-wave chemotherapy.   
4.4.7 In situ Engineering of Pancreatic Stellate Cells with sTRAIL LPD Shows Promising 
Antitumor Efficacy in an Orthotopic Desmoplastic Pancreatic Cancer BXPC3  
To evaluate if the above-mentioned findings could be recapitulated in more clinically relevant 
desmoplastic tumors, the anti-tumor efficacy of sTRAIL LPD was assessed on mice bearing human 
pancreatic adenocarcinoma BXPC3. This study, along with others, has shown that BXPC3 are 
stroma-vessel type desmoplastic tumors characterized with nests of tumor cells surrounded by vessel-
embedded fibrotic tissues (Figure 4.14) [52, 68, 92]. The cultured BXPC3 had greater sensitivity to 
TRAIL compared to other pancreatic cancer cell lines [261]. To visualize tumor growth in vivo, 
BXPC-3 cells were stably transfected with luciferase vector (BXPC3-Luc2). BXPC3-Luc2 was 
orthotopically injected into the tail of the pancreas. Dosing schedule of sTRAIL LPD is presented in 
Figure 4.15A.  Consistent with the aforementioned UMUC3/3T3 study, PBS, GFP LPD and TRAIL 
LPD were set as controls. Bioluminescence images were obtained twice a week. Tumor volume 
correlated from the number of photons emitted from the tumor were assessed (Figure 4.15B) and 
quantified (Figure 4.15C).  Results demonstrate that sTRAIL LPD, but not other treatment groups 
effectively inhibit tumor growth. To verify that the hypothesis regarding in-situ engineering of 
fibroblasts occurred in BXPC3 model, the expression of GFP (the IRES-GFP from sTRAIL and 
TRAIL LPD or GFP from GFP LPD) in fibroblasts and other cells was examined. Indeed, more than 
~25% of fibroblasts expressed GFP, accounting for 40% of the total GFP expressing cells within 
tumor mass (Figure 4.15D). In addition, only 8% within the CD45+ leucocytes population expressed 
GFP (Figure 4.16). This, again, supports the claim that fibroblasts are the primary engineered in-situ 
population for sTRAIL secretion. To verify fibroblasts induced neighboring effect and the remodeling 
of TME, the post-treatment apoptosis and collagen level was shown in Error! Reference source not 
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found.A and B. Consistently, an increased amount of TUNEL positive cells was localized in vicinity 
of fibroblasts and the overall level of collagen decreased.  Once again, the results above clearly 
demonstrate that in-situ engineering of fibroblasts benefits anti-cancer therapy in stroma-vessel 
desmoplastic tumors.   
4.4.8 Toxicity Evaluation for the Different Treatments and Blood Chemistry Analysis  
The results of the toxicological evaluation demonstrates little to no noticeable morphological 
changes in major distribution organs of LPD, e.g. liver and spleen for all of the treatment groups 
(Figure 4.18A). The serum biochemical value analysis demonstrated that the sTRAIL treatment 
group had no liver (aspartate aminotransferase and alanine aminotransferase) or kidney (creatinine 
and blood urea nitrogen) toxicity caused by tumor progression (Table 4.2). Hematology performed on 
the blood samples shows no significant reduction of cell in sTRAIL treated mice compared to the 
control groups, suggesting the treatment did not cause anemia (Figure 4.18B).  
4.5 Discussion and Conclusion 
Despite recent advances in nano-therapeutics, efficacy against desmoplastic tumors including 
pancreatic cancer and advanced urothelial carcinoma, has not changed in decades [117]. In part, the 
dense stromal barrier captures NPs, preventing them from reaching the tumor [74, 239]. Given the 
large amount of NPs delivered to fibroblasts, it makes sense to utilize this natural feat and target 
cancer treatment through fibroblasts. Inspired by fibroblast’s ability to secrete tumor supportive 
cytokines to neighboring tumor cells [262, 263], modification of fibroblasts to secrete tumor 
suppressive cytokines through gene delivery with NPs was proposed in the current manuscript. The in 
situ engineering of fibroblasts harnesses the location of fibroblasts between blood vessels and tumor 
cells, bypassing major cellular barriers for NPs delivery; subsequently converting fibroblasts from a 
tumor supporting role to a tumor depletion center.   
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The choice of a secretable tumor suppressive factor should not be understated. TRAIL is a 
highly selective, tumor apoptosis-inducing cytokine. The resistance of mesenchymal stroma cells, 
especially fibroblasts to TRAIL was a conceivable mechanism for the clinical failure of TRAIL [251]. 
However, this feature demonstrates fibroblasts as a durable synthesis reservoir for TRAIL, with 
prolonged expression compared to other TRAIL-sensitive cells. In reality, TRAIL-secreting human 
mesenchymal stem cells have demonstrated prolonged delivery of TRAIL in glioma therapy [264]. In 
order to achieve the original hypothesis, TRAIL was fused with a leader sequence into a bioactive 
secretable form (sTRAIL). Despite the comparable cytotoxicity observed in vitro with both sTRAIL 
and TRAIL plasmid, only sTRAIL encapsulated in LPD induced superior antitumor efficacy in 
desmoplastic tumors. Consistent with the in situ fibroblast engineering hypothesis, we found the 
majority of sTRAIL was expressed within fibroblasts within 3 doses of sTRAIL LPD. The 
penetration of sTRAIL protein is another concern for the in situ engineering of fibroblasts. Compared 
to most monoclonal antibodies, the trimerized sTRAIL with a smaller molecular weight offered rapid 
diffusion. The current work illustrated that apoptotic tumor cells induced by sTRAIL LPD can be 
observed 500 µm away from the nearest fibroblast (Figure 4.8B). Compared to the average diameter 
(400 µm) of tumor nests in the UMUC3/3T3 model, the depth of penetration was undoubtedly 
sufficient to induce potent efficacy.   
The apoptosis of tumor cells destroyed the nest structure within tumors; keeping fibroblasts 
as the major population of remaining cells. A quiescent characteristic marked by a reduction in ECM 
protein synthesis and decreased TAFs marker expression in the residual fibroblasts was found only 
after sTRAIL treatment. Down regulation of pSMAD2 in fibroblasts suggested this process may be 
mediated by TGF-β [259, 265]. Though further mechanistic studies should be conducted, the original 
hypothesis stated the apoptosis of neighboring tumor cells reciprocally contribute to reprogramming 
of TAFs due to insufficient TGF-β signaling activation. Support for this can be found in that pSMAD 
was also downregulated in apoptotic tumor cells, which was mediated through autocrine signaling of 
TGF-β. Additionally, the phenotype of fibroblasts in TRAIL treatment group remained constant, 
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demonstrating TRAIL had minimal direct effect on fibroblasts. Reverting of TAFs has a dual benefit. 
Firstly, the cellular and structural changes of the stroma resulted from “normalized” fibroblasts are 
reported to exert tumor-suppressive forces and signals, potentially inhibiting tumor growth [117, 266]. 
The second benefit is the reduction of the fibrotic content, which decompresses the intratumoral 
vasculature, creating a window for a second-wave nanotherapy [6, 117]. Such expectations were 
presented both in theory and in the current study. Treatment with sTRAIL LPD significantly 
enhanced the delivery, retention and efficacy of additional cisplatin NPs.  
Moreover, the potency of sTRAIL LPD monotherapy, observed on a hypovascular orthotopic 
pancreatic carcinoma (BXPC3) further, verified the feasibility of this in situ engineering approach. 
The result is promising as only a small population of therapeutic NPs have shown efficacy against 
desmoplastic pancreatic cancer.  
Collectively, a novel regimen for the treatment of desmoplastic tumors was developed by 
taking advantage of the NPs’ natural intratumoral off-target distribution (Figure 4.19). Three 
advantages highlight the sophistication of this approach: (1) the traditionally problematic binding site 
barrier was used to induce potent apoptosis within the tumor nest with only a single conventional 
gene therapy agent. (2) The fibroblasts in situ were not only engineered to secrete a cytotoxic protein, 
but mechanistically reprogrammed to be tumor suppressive in a feedback fashion. (3) Lastly, 
reprogramming of fibroblasts paved the way for coupling signal-dependent stromal reprogramming 
with tumor-directed cytotoxic NPs and perhaps immunologic drugs, offering a new paradigm in the 
treatment of desmoplastic tumors. Furthermore, fibroblasts could be engineered to produce various 
cytokines, orchestrating the overall suppressive tumor microenvironment to achieve a more sustained 
antitumor response.  
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Table 4.1 Characterization of LPD NPs 
Sample Size (nm) PDI Zeta Potential (mV) 
Luciferase LPD 74.6±3.1 0.23±0.02 25.1±3.2 
GFP LPD 78.6±2.5 0.25±0.04 24.9±4.8 
TRAIL LPD 76.8±1.2 0.22±0.01 25.7±5.6 
sTRAIL LPD 76.9±2.3 0.28±0.03 27.3±3.8 
 
 
Table 4.2 Blood chemistry after treatments 
Samples AST U/L ALT U/L BUN mg/dL Creatinine 
PBS 239±45 43.5±7.5 16.7±2.5 0.1 
GFP LPD 239±32 40.5±4.5 22.0±4.2 0.1 
TRAIL LPD 206±25 50.0±8.4 16.8±3.2 0.1 
sTRAIL LPD 214±32 51.3±10.4 16.2±4.6 0.1 
Range 54~298 17-132 12-33 0.1~0.9 
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Figure 4.1 Characterization of LPD.  
A. Scheme of the structure of LPD. B. Representative TEM image of LPD. C. Fluorescent imaging of 
the biodistribution of DiI-labeled LPD at determined time points. 
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Figure 4.2 Cell populations that take up LPD in the stroma-vessel type tumors.   
A. The schematic architecture of stroma-vessel tumors.  The immunofluorescence (IF) staining (on 
the right) shows the histology of a stroma-vessel tumor model: UMUC3/3T3. Examination reveals 
nests of tumor cells, with areas rich in fibrotic components (filled by αSMA positive TAFs, shown 
in red) between them. CD31 positive blood vessels (shown in cyan) are embedded in the 
interstitium near the fibroblasts, almost no vessels are observed inside the nests of tumor cells.  B. 
Flow cytometry gating of the cell populations in the UMUC3/GFP-3T3 tumors. ~16% of 
dissociated cells are CD45+ leucocytes, while ~27% are GFP fibroblasts (NIH3T3 was pre-
transfected with the GFP gene). Other cells are mainly tumor cells. C. Flow cytometry histograms 
of the percentage of cells that took up DiI-labeled LPD in each cell population in the 
UMUC3/GFP-3T3 tumor models. Mice bearing UMUC3/GFP-3T3 tumors were intravenously 
injected with DiI-labeled LPD. At determined time points, tumors were dissociated and analyzed 
by flow cytometry. D. Quantitation of the percentage of DiI positive cells in each population (based 
on the flow data), n = 4.   
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Figure 4.3 Calculation of DiI positive cells in each cell population by flow cytometry (n = 4).  
Only mean values are presented at each time points. 
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Figure 4.4 Secretable TRAIL produced by fibroblasts induces apoptosis of neighboring 
UMUC3 tumor cells.                              
A. schematic representation of plasmid encoding green fluorescence protein (GFP) fused with 
sTRAIL or TRAIL (as a less secretable control). B. Cell proliferation of cancer cells, UMUC3 and 
fibroblasts, NIH3T3 transfected with TRAIL, sTRAIL, GFP at different concentrations (MTT assay, 
n = 4). UMUC3 cells are sensitive to both TRAIL and sTRAIL treatment, while NIH3T3 are 
resistant. C. The releasing of sTRAIL protein into the supernatant were determined using ELISA 
(against TRAIL). Both NIH3T3 and MRC-5 (lung fibroblasts) transfected with sTRAIL secreted 
TRAIL protein. However, minimal soluble TRAIL was detected in both cell line when transfecting 
with TRAIL (n = 3, ** P < 0.01, compared to sTRAIL LPD treatment). D. The neighboring effect of 
the sTRAIL protein was determined by a non-contact co-culture study. After co-cultured for 24 h, the 
total number of UMUC3 cells in the bottom were counted. Cells were visualized by Calcein AM 
staining (shown in green). Apoptosis of bottom UMUC3 cells were assessed using annexin V/PI 
staining and flow cytometry (n = 3). 
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Figure 4.5 In vitro transfection efficiency of LPD.  
sTRAIL or TRAIL plasmid was encapsulated into LPDs respectively. Transfection efficiency was 
determined by qPCR analysis of the mRNA level of TRAIL 24 h after transfection. Lipofectamine-
2000 was used as a positive control, and GFP NP was set as a negative control. LPD induced 
comparable expression of protein compared to lipofectamine-2000. The expression efficiency for 
TRAIL is similar to that of sTRAIL (n=3). 
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Figure 4.6 Intravenous administration of sTRAIL LPD inhibited stroma-vessel UMUC3/3T3 
tumor growth.                        
A, B tumor inhibition curve and body weight changes, respectively, of mice bearing stroma rich 
bladder cancer (UMUC3/3T3). Mice were treated with PBS, GFP LPD, TRAIL LPD or sTRAIL LPD 
at a plasmid concentration of 50 µg/mice, for 4 times (n = 6~8, * P < 0.05, ** P < 0.01, *** P < 
0.001, in the legend, compared to PBS group; in the data, compared to each time point of the TRAIL 
LPD group). C, D. qPCR quantitation of relative mRNA levels of  TRAIL or sTRAIL in the treated 
tumors. The primers for the extracellular domain of TRAIL (C) or primers specifically for sTRAIL 
were used for the detection (n = 6, ** P < 0.01, n.s, no significant difference, compared to PBS 
group).   
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Figure 4.7 Expression of TRAIL (or fusion GFP) in the fibroblasts in situ.                                                                                      
A-D, IF staining of green fluorescence protein (GFP) (shown green), RFP-fibroblasts (shown red) and 
cell nuclei (DAPI, shown blue) at indicated time points after treatment on cryo-tumor tissues 
collected. Results showed that the majority of expression of GFP fusion protein co-localized with the 
RFP-labeled fibroblasts. E. Flow cytometry analysis of GFP’s association with RFP-fibroblasts at 
indicated time points in the dissociated cells from the collected tumor tissues (n = 4). The association 
of GFP in fibroblasts increased dose-dependently. F. One day after 3 doses of sTRAIL LPD, the RFP-
labeled fibroblasts were sorted by flow cytometry. sTRAIL mRNA level in the RPF-labeled 
fibroblasts and other unlabeled cells were analyzed and compared with the untreated group (n = 4, ** 
P < 0.01). The inserted chart indicates gating of the RFP fibroblasts. 
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Figure 4.8 Fibroblasts (in situ) that secreted TRAIL induced the apoptosis of neighboring 
tumor cells.  
A. IF staining of αSMA and TUNEL from tumor tissues (paraffin-embedded sections) after dose 
escalation of sTRAIL LPD NPs. Dashed lines indicate edge of the tumor nests. B. Quantification 
of relative apoptotic cells’ distance from the nearest αSMA positive fibroblasts after different 
doses of sTRAIL LPD NPs. Numbers on top indicate the furthest distance of apoptotic cells to 
αSMA after different treatments.  C. Paraffin-embedded tissues sections from UMUC3/3T3 
tumors 2 days after final treatments were stained for αSMA (red, myofibroblasts) and TUNEL 
(green, apoptosis). 
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Figure 4.9 sTRAIL LPD decreases the collagen content 
A. Masson’s trichrome staining of the collagen after endpoint treatments. B. Quantification of the 
trichrome staining (n = 5, ** P < 0.01, compared to PBS group). 
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Figure 4.10 sTRAIL LPD induces the reprogramming of residual fibroblasts and remodeling of 
TME.  
A. Western blot analysis of the TME markers mainly secreted by TAFs, and TAF markers. Intensities 
of each ECM protein were calculated by comparing to the RFP-transfected fibroblasts and shown on 
right. Protein/RFP ratios in the PBS group were set as 1 (n = 3, * P < 0.05, ** P < 0.01, compared to 
the PBS group). B. mRNA levels of TAF markers in the sorted RFP-fibroblasts after sTRAIL 
treatment (n = 5, * P < 0.05, *** P < 0.01, compared to the PBS group).  
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Figure 4.11 TGF-β pathway was downregulated after sTRAIL LPD treatment 
Immunohistochemistry (IHC) staining of αSMA and pSMAD2 in the adjacent sections of PBS and 
sTRAIL LPD groups. Red dotted circles indicate tumor nests; yellow dotted circles indicate 
fibroblasts.  
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Figure 4.12 sTRAIL LPD induces normalization of blood vessel 
IHC staining of blood vessel (CD31, shown as brown) after different treatments. sTRAIL LPD 
induces decompression of blood vessels. Red arrows indicate the decompressed vessels. 
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Figure 4.13 Remodeling of TME facilitates the delivery and antitumor effect of a second-wave 
nanoformulated cisplatin.  
A. Dosing schedule of the second-wave chemotherapy. B. ICP-MS analysis of cisplatin accumulation 
1 day after a single dose of cisplatin NP (LPC NP) in mice pre-treated with sTRAIL LPD or without 
pre-treatment (n = 5, *** P < 0.001). C. Tumor inhibition curve of LPC NP after treating the tumors 
with sTRAIL LPD. Cisplatin (1.9 mg/kg) was dosed (n = 5, * P < 0.05).   
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Figure 4.14 Histology of orthotopic BXPC3-Luc2 xenograft.  
(A) and (B) immunofluorescence staining of fibroblasts and blood vessels. Examination revealed a 
stroma-vessel architecture, where nests of tumor cells (representative tumor nests are highlighted with 
yellow dotted circles) are surrounded by αSMA-positive fibroblasts (shown in red). Most of the 
CD31-positive blood vessels (only in A, shown in cyan) were embedded between αSMA-positive 
fibroblasts. (C) Masson’s trichrome staining was used to visualize the collagen structure (shown in 
blue) in the BXPC3-Luc2 tumors. Tumor nests were also observed. 
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Figure 4.15 Intravenous administration of sTRAIL LPD inhibited the orthotopic desmoplastic 
BXPC3 tumor growth.  
A. dosing schedule of sTRAIL treatment on BXPC3. B. IVIS images of BXPC3 tumor after different 
treatments (n = 5). C. Tumor inhibition curve o BXPC3 (n = 6-10, *P < 0.05 compared to PBS 
group). D. Flow cytometry analysis of GFP’s association with αSMA positive fibroblasts 2 days after 
the third injection of the LPD (n = 4, * P < 0.05, ** P < 0.01).  
 
 
Figure 4.16 Expression of GFP within different cell populations of BXPC3-Luc2 tumors after 3 
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doses of NPs.  
(A) Single-cell suspensions of the bulk tumor mass were stained with αSMA and CD45 and gated 
into various cell populations, quantified here as fractions of the total number of cells analyzed. (B) 
Flow cytometry analysis of the cell population that expresses GFP (the protein co-synthesized with 
TRAIL or sTRAIL) in the tumors. The total GFP-positive cells were considered as 100%. The % of 
each cell population that expressed GFP are shown. (C) The fraction of GFP-positive CD45
 
positve 
cells in the entire CD45
 
positive cell population was calculated.   
 
 
  
Figure 4.17 Tumor environment changes after treatments in BXPC3 model. 
A. Immunofluorescent staining of αSMA and TUNEL from BXPC3-Luc2 tumor tissues after 
different treatments. B. Masson’s trichrome staining for collagen from BXPC3-Luc2 tumors after 
different treatments.  C. The quantification of collagen levels (n = 4~5, * P < 0.05). 
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Figure 4.18 Cytotoxicity of LPD.  
A. H&E staining of the major organs indicates minimal toxicity after sTRAIL LPD and TRAIL LPD 
treatment. B. Whole blood count assay indicates no obvious cell counts changed after therapy.   
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Figure 4.19 Diagram of proposed mechanism 
A. Plasmid encoding secretable TRAIL protein is condensed with protamine, and further 
encapsulated into PEGylated liposomes coating with AA targeting motif (LPD). Diagram of the p-
sTRAIL LPD is shown. B. LPD is systemically delivered to tumor region, and then extravasated 
from blood vessel due to the EPR effect. In most desmoplastic tumors, a thick layer of fibroblasts 
wraps around the blood vessel. Tumor associated fibroblasts (TAFs) are the major cells taken up the 
targeted LPD. C. sTRAIL protein issynthesized by TAFs and diffuses to the neighboring tumor 
cells. Apoptotic tumor cells, reciprocally failed to activate local fibroblasts, reverting the TAFs to 
normal fibroblasts (NFs). NFs can suppress tumor growth on one end, remodel the TME and 
increase the penetration of a second wave chemotherapeutic NPs on the other. Collectively, this 
multi-wave therapy can induce potent growth inhibition of the desmoplastic tumors. 
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 CHAPTER 5: SYNERGISTIC DEPLETION OF TUMOR ASSOCIATED 
FIBROBLASTS VIA COMBINED GEMCITABINE AND CISPLATIN 
NANOPARTICLES IMPROVES DESMOPLASTIC BLADDER CANCER 
TREATMENT6 
5.1 Summary 
Previous chapters discussed the potential of either priming the damaged TAFs or reverting 
TAFs to quiescent state for improved NP penetration and anti-cancer efficacy. Another direct and 
efficient strategy to improve therapeutic outcome of NPs is to deplete TAFs. Our previous study have 
shown that single dose of cisplatin NPs could partially remove TAFs, but resistant occurred, 
conversely increasing desmoplasia after multiple times of treatment. This is partly due to the 
insufficient removal of TAFs. To prolong the stroma depleting effect, a more potent depletion agent 
should be used. Combination therapy can result in synergistic effect that superior than the 
monotherapy of each regimen. Therefore, we proposed the use of a nano-formulation of gemcitabine 
in combination with the previously used cisplatin NPs. As expected, this combination not only 
induced potent killing of tumor cells, but was detrimental to TAFs compared to cisplatin NPs 
monotherapy. Using the desmoplastic bladder cancer xenograft (UMUC3/3T3), we show that 85% of 
TAFs were depleted and 87% of the remaining TAFs were apoptotic 4 day after a single injection of 
combo NPs. The effect continued after 4 doses of combo NPs, where the recruitment of αSMA-
positive fibroblast was decreased by more than 87%. Combo NPs nearly halted tumor growth with 
little evidence of general toxicity.  
                                                   
6This chapter previously appeared as a research article in Journal of Controlled Release. The original 
citation is as follows: Jing Zhang, Lei Miao, Shutao Guo, Yuan Zhang, Lu Zhang, Andrew Satterlee, 
William Y. Kim and Leaf Huang, synergistic anti-tumor effects of combined gemcitabine and 
cisplatin nanoparticles in a stroma-rich bladder carcinoma model, Journal of Controlled Release, 2014, 
182 (28):90-96. Lei Miao was listed as a co-first author. 
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And the combo NP treated tumors became 2.75-fold more permeable than those treated with 
monotherapy. We concluded that the stroma depletion through combination therapy would be a 
promising strategy for the treatment of desmoplastic tumors.  
5.2 Introduction 
Bladder cancer, the fourth most common cancer diagnosed in men and the eighth in women, 
remains a concern due to its prevalence and tendency to progress and recur [1-3]. Advances in drug 
delivery are needed and nanomedicine in particular holds promise as a means to improve 
bioavailability and systemic circulation [4,5]. These therapies exploit the enhanced permeability and 
retention (EPR) effect in tumors, thereby increasing the chemotherapeutic dose to tumor tissue, at the 
same time sparing normal tissue from exposure [6].   
Cancer has long been believed to be cell-autonomous and to date most research has focused 
directly on the malignant cells themselves. Several recent studies, however, suggests that 
carcinogenesis is also determined by a favorable tumor microenvironment (TME) [7]. Fibroblasts are 
the principal cellular component of the TME. Fibroblasts that have been recruited, activated and 
accumulated in vicinity to tumor cells are referred to as tumor-associated fibroblasts (TAFs) or 
myofibroblasts. TAFs can even be the most abundant type of cell within the desmoplastic tumors, 
notably pancreatic and breast carcinoma [8,9]. They contribute to tumor growth and invasiveness by 
remodeling the extracellular matrix (ECM), secreting various soluble factors (growth factors and 
cytokines), and suppressing immune responses. Though direct depleting of stroma cells have brought 
up a lot of paradoxical concerns, such as promoting resistance and diminishing immune surveillance; 
this strategy is still considered as a potential approach to improve NPs’ perfusion and enhance the 
anti-cancer effect if potent and suitable depleting agents are chosen [10].    
Myofibroblasts tend to be present in invasive bladder tumors [13]. To identify and verify the 
potency of the TAF-targeted stroma depleting agent for treatment of bladder cancer, we used the 
desmoplatic bladder cancer model (UMUC3/3T3) previously developed in our study. In this specific 
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model, fibroblasts were subcutaneously co-injected along with cancerous cells and Matrigel, a 
permissive extracellular matrix preparation. This desmoplastic tumor model recapitulates the stroma 
structure of the original invasive urothelial carcinoma found in patients.    
Data in previous chapter suggest that chemo-drug cisplatin is a stroma-depleting candidate. 
The AA-targeted cisplatin NPs developed in our lab can target to fibroblasts that wrap around tumor 
vessels, with an upregulated expression of receptor for AA, namely the Sigma R. However, 
insufficient apoptosis of fibroblasts paradoxically induce the resistance of neighboring cells through 
damage-induced secretion of Wnt16, subsequently promoting tumor expansion. Thereby, we 
hypothesize that combination strategy that potentiates the stroma-depleting function of cisplatin NPs 
would enhance the overall anti-tumor performance. Gemcitabine has been utilized in combination 
cisplatin in the treatment of bladder cancer. A novel NPs developed in our lab that encapsulate 
gemcitabine monophosphate (GMP, the bioactive form of gemcitabine) have shown promising 
anticancer effect for the treatment of non-small-cell lung cancer [16]. In both cases of GMP NPs and 
cisplatin NPs, high drug entrapment efficiency was achieved with NPs diameters of approximately 45 
nm and 40 nm for GMP NPs and Cisplatin NPs, respectively. So, we proposed that combination of 
GMP NPs and cisplatin NPs should be a potent stroma depleting agent.  
Our current work aimed to use the desmoplastic bladder cancer xenograft (UMUC3/3T3) 
developed in our lab to evaluate GMP NPs and Cisplatin NPs combination therapy (Combo NPs) in 
terms of TAF-targeting and depletion capability. Similar to combination strategies towards cancer 
cells, combination of cisplatin NP and GMP NP induced superior apoptosis of TAFs compared to 
monotherapy of each. We also investigated the time-lapse changing of collagen deposition and tumor 
permeability after combination therapy. Since cisplatin NP and GMP NP combination also exhibited 
strong synergy towards tumor cells, the anti-tumor activities plus stroma depleting efficacy were also 
evaluated.    
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5.3 Material and Methods 
5.3.1 Materials 
Gemcitabine monophosphate disodium salt (GMP, purity≥97%) was provided by Qualiber, 
Inc. (Chapel Hill, NC). Cisplatin (cis-diamminedichloroplatinum (II)) was purchased from Sigma-
Aldrich (Dorset, UK). GMP NPs (including 3H-labeled GMP NPs) and Cisplatin NPs were prepared 
as described previously [16,17]. Size distribution and zeta potential were measured on a Malvern 
ZetaSizer Nano series (Westborough, MA). 
The human bladder transitional cell line UMUC3 was from the American Type Culture 
Collection (ATCC), and the mouse embryonic fibroblast cell line NIH3T3 (UNC Tissue Culture 
Facility) were cultured in Dulbecco’s modified Eagle’s Media (DMEM) (Invitrogen, Carlsbad, CA) 
supplemented with penicillin (100 U/mL) and streptomycin (100 µg/mL) (Invitrogen), and 10% fetal 
bovine serum (Sigma, St. Louis, MO)/10% Bovine calf serum (Hyclone, Logan, Utah), respectively. 
Cells were cultivated in a humidified incubator at 37 ºC and 5% CO2 and harvested with 0.05% 
trypsin-EDTA before subculture.  
Female nude mice 6-8 weeks of age were used in all studies. All work performed on animals 
was approved by the Institutional Animal Care and Use Committee at University of North Carolina at 
Chapel Hill. 
5.3.2 Preparation of GMP NP and Cisplatin NP 
The GMP cores were formulated using 180 µL of 60 mM GMP mixed with 12.5 mM 
Na2HPO4 (pH=9.0) (final concentration) to reach a total volume of 600 µL. This solution was then 
added into 20 mL of oil phase containing cyclohexane/Igepal CO-520 solution (71/29). Then 400 µL 
of 20 mM dioleoylphosphatydic acid (DOPA) in chloroform was added and stired for 10 min. Six-
hundred µL 2.5 M CaCl2 was added to a separate 20 mL oil phase The two separate micro-emulsions 
were then mixed. After stirring for 5 min, another 400µL of 20mM DOPA was added into the 
emulsion. The emulsion was allowed to continually stir for another 20 min before 40mL of absolute 
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ethanol was added. The ethanol emulsion mixture was centrifuged at 10,000 g for 15 min to pellet the 
cores and the supernatant was then discarded. The GMP core was washed twice with absolute ethanol 
and dried under N2. The GMP core pellets were suspended in chloroform. 330µL GMP core in 
chloroform was mixed with 38.7 µL of 25 mg/ml cholesterol, 28 µL of 25 mg/ml 1,2-Dioleoyl-3-
trimethylammonium-propane chloride salt (DOTAP), 76.8 µL of 25 mg/ml 1,2-distearoryl-sn-
glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol-2000) ammonium salt (DSPE-
PEG2000) and 19.2 µL of 25 mg/ml DSPE-PEG-AA (DSPE-PEG-AA). The lipid mixture was 
evaporated to remove chloroform. The film on the vial wall was dissolved in 30 μL tetrahydrofuran 
followed by 50 μL absolute ethanol, and then suspended in 160 μL distilled water. After brief 
sonication, the solution was dialyzed in distilled water to obtain GMP NP. The Cisplatin cores were 
prepared avoiding of light. Briefly, 200 mM cis-[Pt(NH3)2(H2O)2] (NO3)2 and 800 mM KCl in water 
were separately dispersed in a solution composed of cyclohexane/Igepal CO-520 (71:29, v/v) and 
cyclohexane/Triton-X100/hexanol (75:15:10, v/v/v) (3:1) to form a well-dispersed, water-in-oil 
reverse microemulsion. One hundred microliters of DOPA (20 mM) was added to the Cisplatin 
precursor phase and the mixture was stirred. Then, the two emulsions were mixed for another 30 min 
while the reaction proceeded. After that, ethanol was added to the microemulsion and the particles 
were collected by centrifugation at 12,000 g. After being extensively washed with ethanol 2-3 times, 
the pellets were redispersed in chloroform. Finally, 1.0 mL of Cisplatin core, 50 μL of 20 mM 
DOTAP, 50 μL of 20 mM cholesterol and 50 μL of 10 mM DSPE-PEG2000 or DSPE-PEG-AA were 
combined. After evaporating the chloroform, the residual lipids were dispersed in 1.0 mL of distilled 
H2O. After brief sonication, the solution was dialyzed in distilled water to obtain Cisplatin NP. 
5.3.3 Characterization of NPs 
Nano-sized GMP and Cisplatin cores were viewed under a JEOL 100CX II TEM (Tokyo, 
Japan). Particle size distribution and zeta potentials of the nanoparticles were determined by dynamic 
light scattering and electrophoretic light scattering, respectively, both using a Malvern ZetaSizer 
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Nano series (Westborough, MA). GMP entrapment efficiency was measured by a UV 
spectrophotometer (Beckman Coulter Inc., DU 800 spectrophotometer) and the EE % of Cisplatin 
was determined by ICP-MS (NexIONTM 300, Perkin Elmer Inc), respectively.  
For drug loading study, 3H-labeled GMP NPs were prepared as described previously and 1% 
(molar ratio) of N-4-nitrobenzo-2-oxa-1,3-diazole phosphatidylethanolamine (NBD-PE) was 
incorporated to the outer leaflet. The final GMP NPs and Cisplatin NPs were centrifuged at 13,200 
rpm for 3 times, and each time was 15 minutes. Then, the supernatant was removed and the final 
pallet was resuspended and lyophilized for 48 hours. Dried NPs were weighted and the 3H 
radioactivity and Cisplatin measurement were determined using the liquid scintillation analyzer (the 
instrument has been described in the materials section) to calculate the amount of GMP and ICP-MS 
(NexIONTM 300, Perkin Elmer Inc) to calculate the amount of Cisplatin. The drug loading for GMP 
NP and Cisplatin NP were determined by the weight of GMP (Cisplatin)/ the weight of purified NPs, 
respectively. 
5.3.4 Desmoplastic  Subcutaneous Xenograft Bladder Tumor Model 
To establish the xenograft model, UMUC3 (5×106) and NIH3T3 cells (2×106) in 100 µL of 
PBS were subcutaneously co-injected with Matrigel (BD Biosciences, CA) at a ratio of 1:1 (v/v) into 
the right flank of mice. For the standard subcutaneous bladder tumor model, only UMUC3 cells 
(5×106) were injected. Tumor volume was measured every three days starting on day seven after 
inoculation. The formula: V=(L×W2)/2 was applied to calculate tumor volume, where V is the tumor 
volume, L the larger perpendicular diameter and W the smaller perpendicular diameter. Tumor 
growth normalized to the original volume calculated on the first day of measurement. Tumor sections 
collected on day eight for the two animal models and also those of clinical patients (kindly supplied 
from Dr. William Kim, Lineberger Comprehensive Cancer Center, UNC) were stained with 
hematoxylin and eosin (H&E), immunofluorescent staining for αSMA (FITC labeled) and CD31 
(Alexa Fluor 647 labeled). For immunofluorescence, slides were deparaffinized with xylene and a 
 172 
 
graded alcohol series. After antigen retrieval, sections were blocked with 10% goat serum and then 
incubated with polycolonal rabbit anti-αSMA antibody (Abcam, Cambridge, MA, USA) and anti-
CD31 (BD Biosciences, CA, USA) at 1:100 dilution overnight at 4 ºC. Immunocomplexes were 
visualized with the corresponding FITC-labeled and Alexa Fluor 647 secondary antibody at a 1:1000 
and 1: 100 dilution respectively for 1 h at room temperature in the dark. Slides were rinsed with PBS 
and cover slipped with Vectashield containing DAPI (Vector laboratories, Burlingame, CA). Digital 
images were acquired by an Eclipse Ti-U inverted microscope (Nikon Corp., Tokyo, Japan) ×20 
magnification and quantitatively analyzed on Image J (National Institutes of Health). 
5.3.5  In vitro Cell Viability of Free GMP and Cisplatin on UMUC3 Cells and Analysis of 
Synergistic Effects of Free Drug Combinations. 
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay was conducted to 
evaluate in vitro viability of free GMP, Cisplatin and their combinations. Briefly, cells were seeded in 
96-well plates at a density of 3,000 cells per well 24 h prior to drug treatment. Subsequently, cells 
were treated with free drugs and drug combination with various molar ratio at series of dilutions in 
full medium. Following 48 h treatment, 20 μL MTT (5 mg/mL) reagent was added for an additional 4 
h incubation at 37 °C. The medium was discarded, the formed formazan salt was dissolved in 150 μL 
of DMSO and absorbance was read at 570 nm using a multidetection microplate readers (Plate 
CHAMELEON™ V-Hidex). Cell survival rates were calculated as normalized to control untreated 
wells. Each concentration was tested in four wells and data presented in means±standard error means 
(SD). The mean drug concentration required for 50% growth inhibition (IC50) was determined using 
CompuSyn software (Version 1.0, Combo-Syn Inc., U.S.) using the median effect equation: 
Fa=[1+(IC50/D)m]−1, where Fa is the fraction of affected cells, D is drug concentration and m is the 
Hill slope. 
Combination Index (CI) Analysis of free drug combination based on the Chou and Talalay 
method [18] was performed using CompuSyn software. Briefly, for each level of Fa the CI values for 
GMP and Cisplatin combinations were calculated according to the following equation: 
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CI=(D)1/(Dx)1+(D)2/(Dx)2, where (D)1 and (D)2 are the concentrations of each drug in the 
combination resulting in Fa×100% growth inhibition, and (Dx)1 and (Dx)2 are the concentrations of 
the drugs alone resulting in Fa×100% growth inhibition. CI values for drug combinations were 
plotted as a function of Fa. CI values less than 1 or more than 1 demonstrate synergism or antagonism 
of drug combinations, respectively. 
5.3.6 Pharmacokinetic Study 
Pharmacokinetic studies were performed on xenograft tumor-bearing nude mice innoculated 
subcutaneously with a mixture of UMUC3 and NIH3T3 cells. Animals were randomly divided into 
two groups (n=4) and intravenously injected with free GMP containing a tiny fraction of 3H-Labeled 
free cytidine monophosphate, and Cisplatin (Combo Free) and Combo NP at a dose of 16 mg/kg and 
1.6 mg/kg respectively. At 5 min, 20 min, 40 min, 1h, 2h, 4h, 8h and 24h post injection, 
approximately 45 mg whole blood was collected from the tail vein (For free Cisplatin and Cisplatin 
NP groups, only data of first 8 hours were recorded since data collected from the last two time points 
were under detection<0.2 ng/mL).. Pharmacokinetic data was expressed as a percentage of injected 
dose for each drug. For measurement of GMP, 10 to 20 mg of blood was immediately mixed with 
10× NCS® II Tissue Solubilizer (Amersham Biosciences, Inc) and digested at 60°C overnight. Three 
hundred μL of hydrogen peroxide (30% in water, Fisher) was added to the samples and vortexed to 
bleach the blood color, and then the sample was mixed with 4 mL scintillation cocktail (Fisher Inc). 
The 3H radioactivity in the blood samples was counted using a liquid scintillation analyzer (TRI-
CARB 2900 TR, Packard Bioscience Co.). For the measurement of cisplatin, approximately 30 mg of 
blood was digested with 400 μL 60% nitric acid (Acros Organic) at 70°C overnight and measured by 
Inductively Coupled Plasma-Mass Spectroscopy (ICP-MS, NexIONTM 300, Perkin Elmer Inc). 
5.3.7 Platinum Adduct Staining 
Tumor-bearing mice were randomized into four groups (n=5) as follows: Control group, 
Cisplatin NP (Cisplatin: 1.6 mg/kg), Combo NP #1 (Cisplatin: 1.6 mg/kg, GMP: 12 mg/kg) and 
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Combo NP #2 (Cisplatin: 1.6 mg/kg, GMP: 16 mg/kg). Single i.v. injection was performed for each 
treatment. Twenty-four hours later, tumor was fixed in 10% formalin and paraffin-embedded 
sectioned for platinum adduct staining. The sections were incubated with anti-platinum modified 
DNA antibody [CP9/19] (1:250 dilution) from Abcam Inc. overnight at 4 ºC. FITC-labeled goat anti-
rat IgG antibody (1:200, Santa Cruz biotechnology, Inc.) was used for 1 h at room temperature in 
dark place. The sections were also stained by DAPI and observed by an Eclipse Ti-U inverted 
microscope (Nikon Corp., Tokyo, Japan) at ×20 magnification and analyzed on Image J (National 
Institutes of Health). 
5.3.8 Tumor Accumulation of GMP and Cisplatin in Established Animal Model 
To measure tumor accumulation of Combo Free and Combo NPs, animals were randomly 
divided into two groups (n = 6) and intravenously injected with free GMP containing a tiny fraction 
of 3H-Labeled free cytidine monophosphate, which is believed to have the similar pharmacokinetic 
profile as GMP [16] and Cisplatin (Combo Free) and Combo NPs at a dose of 16 mg/kg and 1.6 
mg/kg respectively. Three mice of each group were sacrificed at each predestinate time point, and 
approximately 45 mg of blood was withdrawn using the tail bleeding method. Tumor uptake of GMP 
and Cisplatin were expressed as the percentage of the injected dose per gram tumor. For measurement 
of GMP, 10 to 20 mg of blood was immediately mixed with 10× NCS® II Tissue Solubilizer 
(Amersham Biosciences, Inc) and digested at 60°C overnight. Three hundred μL of hydrogen 
peroxide (30% in water, Fisher) was added to the samples and vortexed to bleach the blood color, and 
then the sample was mixed with 4 mL scintillation cocktail (Fisher Inc). The 3H radioactivity in the 
blood samples was counted using a liquid scintillation analyzer (TRI-CARB 2900 TR, Packard 
Bioscience Co.). For the measurement of Cisplatin, approximately 30 mg of blood was digested with 
400 μL 60% nitric acid (Acros Organic) at 70°C overnight and measured by Inductively Coupled 
Plasma-Mass Spectroscopy (ICP-MS, NexIONTM 300, Perkin Elmer Inc). 
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5.3.9 Anti-tumor Efficacy in desmoplastic Xenograft Bladder Tumor Model 
On day seven after implantation, mice were randomized into seven groups (n=5) as follows: 
Saline (Control group), free GMP (GMP Free), free Cisplatin (Cisplatin Free), combination of free 
GMP and Cisplatin (Combo Free), GMP NPs, Cisplatin NPs and combination of GMP NPs and 
Cisplatin NPs (Combo NPs). IV injections were performed every three days for a total of 3 injections 
with the GMP dose at 16 mg/kg and Cisplatin at 1.6 mg/kg. Tumor volume was measured every three 
days using the aforementioned method. Body weight was also recorded. Mice were sacrificed two 
days after the last injection by CO2 asphyxiation and tumors were excised. A portion of the tumor was 
fixed in 10% formalin and paraffin-embedded sectioned for H&E staining, TUNEL assay, and αSMA 
immunofluorescence by an operator blinded to the treatment groups.  
5.3.10 In vivo Toxicity Analysis 
After three daily injections, blood was collected from the venous plexus of the eye and 
centrifuged at 4,000 rpm for 5 min. Serum alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), blood urea nitrogen (BUN) and creatinine levels were assayed as indicators 
of hepatic and renal function. Organs (heart, liver, spleen, lung, kidney) were fixed and sectioned for 
H&E staining. 
5.3.11 Tissue Analysis 
Tumor sections were stained for TUNEL assays as recommended by the manufacturer 
(Promega, Madison, WI). DAPI mounting medium was dropped on the sections for nuclear staining. 
Apoptosis was also determined by H&E staining. Tumors were also prepared for αSMA 
immunofluorescence (FITC label). Images were acquired by an Eclipse Ti-U inverted microscope 
(Nikon Corp., Tokyo, Japan) at ×20 magnification and analyzed on Image J (National Institutes of 
Health). 
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5.3.12 TAF-Targeting Efficacy in the Desmoplastic Bladder Tumor Model 
Mice with 200 mm3 tumors were treated with a single dose of Combo NPs (GMP 16 mg/kg, 
Cisplatin 1.6 mg/kg) (n=24). Every 24 hours, mice were sacrificed. Tumors were excised and 
sectioned for αSMA (Alaxa Fluor 647)/TUNEL immunofluorescence double staining and Masson’s 
trichrome (Sigma, USA). 
5.3.13 Analysis of Tumor Permeability 
Drug permeability in the tumor was evaluated by Evans Blue assay [19]. Tumor-bearing mice 
were randomized into three groups (n=3) as follows: Control group, Combo Free and Combo NPs. 
Single i.v. injection was performed for each treatment with the GMP dose at 16 mg/kg and Cisplatin 
at 1.6 mg/kg. Twenty-four hours later, 100 mg/kg of Evans Blue (10 mg/ml in 0.9% NaCl) was 
intravenously injected. After 30 min, mice were sacrificed and blood and tumor tissue were 
homogenized in a 0.1% sodium sulfate/acetone mixture (7:3 v/v) at a ratio of 1:9. Samples were 
maintained at ambient temperature in the dark overnight and then centrifuged at 1,000 g for 5 min. 
Supernatants were used to determine absorbance at 620 nm. The amount of Evans Blue in tumor 
tissue was expressed as μg/g tissue. 
5.3.14 Statistical Analysis 
Results were expressed as a mean ± standard deviation. Student’s t-test and one-way analysis 
of variance (ANOVA) test were used to evaluate statistical significance. A P value of P < 0.05 was 
considered to indicate statistical significance. 
5.4 Results and Discussion 
5.4.1 Characterization of GMP NPs and Cisplatin NPs 
The dioleoylphosphatydic acid (DOPA) was employed as a pre-coating reagent for the nano-
sized CaP cores. The lipid coating prevents the core from aggregation during the centrifugal 
separation step and makes it soluble in chloroform. The DOPA layer coating CaP core served as the 
 177 
 
inner leaflet lipid and a variety of lipids for the outer leaflet could simply be added into the CaP core 
solution in chloroform. The choice of the asymmetric outer lipids plays an important role in the 
pharmacokinetics and tissue distribution of the final nanoparticles [20]. Asymmetric lipid bilayer-
modified nanoparticles for GMP and Cisplatin were prepared as previously reported [16,17]. Particles 
with a core-shell shape were 44.5±0.2 nm and 40.6±0.2 nm for GMP NPs and Cisplatin NPs, 
respectively. Particles exhibited high entrapment efficiency at around 49.5% and 44%, and zeta 
potential of 11.5±0.6 mV and 5.6 ±0.3 mV for GMP NPs and Cisplatin NPs, respectively. The drug 
loading was 23±2 wt % and 82±5 wt % for GMP NPs and Cisplatin NPs, respectively (data not 
shown). 
5.4.2 Histopathology for the Desmoplastic Bladder Cancer Model (UMUC3/3T3) 
Xenografts with UMUC3 and/or NIH3T3 cells and patient tumor sections were stained with 
H&E and αSMA (FITC labeled). Results suggest that the UMUC3/3T3 was enriched with stroma 
structure (H&E) and αSMA positive cells (17.5±3.2%), compared to the subcutaneous bladder model 
with injection of UMUC3 cells alone (1.8±0.6%, UMUC3). This UMUC3/3T3 model recapitulates 
the human bladder tumor structure (14.8±2.1%, Patient) (Figure 5.1A). Alpha-SMA-positive 
fibroblasts located near CD31-positive blood vessel endothelial cells, suggesting a stroma-vessel 
architecture of this model, which was consistent with previous studies (Figure 5.1B). Moreover, the 
desmoplastic UMUC3/3T3 xenografts grew more aggressively compared to UMUC3 only xenograft 
(Figure 5.1C). Whereas, no tumor growth was observed when NIH3T3 cells alone were inoculated 
(data not shown). Therefore, such desmoplastic tumor closely mimics the structure of human bladder 
cancer isolates, enabling us to better understand the synergistic effect of Combo NP on tumor 
inhibition and TAF-targeting effect. 
5.4.3 Combo NPs depletes TAFs in the tumor, modifies collagen deposition 
Taking advantage of the desmoplastic UMUC3/3T3 model, the interaction of TAFs with the 
combined drugs was then investigated. The ratio of αSMA positive cells were firstly evaluated after 
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multiple injections. As shown in Figure 5.2, Combo Free, GMP NPs and Cisplatin NPs exhibited 
partial efficacy in reducing fibroblasts, but the Combo NPs showed the fewest αSMA positive cells 
compared to all the treatment groups (P < 0.05). To examine the mechanism of the potent TAF 
depleting effect of Combo NPs, we conducted a single injection of Combo NPs and detected the 
apoptotic fibroblasts every 24 h after injection. Figure 5.3A-C presents the double staining for 
TUNEL and αSMA and the quantitative results. Firstly, 4.9% cells were induced to undergo apoptosis 
one day after Combo NPs injection, among which 56.6% apoptotic cells were αSMA-positive. It 
suggests that the fibroblasts are more likely to be killed compared to tumor cells. From day one to day 
two, the apoptotic fibroblasts in total apoptotic cells increased dramatically and more than 60% 
fibroblasts were apoptotic. The apoptotic cells in fibroblasts even reached 87.2% on day four, which 
was 45% higher than that in tumor cells. The results indicate that the apoptosis of fibroblasts not only 
began before that of carcinoma cells but also substantially resulted in fibroblasts depletion. By the last 
two days, the apoptotic fibroblast (%) in total fibroblast was significantly decreased to nearly 1%. 
Secondly, the collagen on Day four became 14.9% of the original collagen on day 0, which is also 
different from that of Day three. It shows that the killing effect of Combo NPs on TAFs in the first 
three days resulted in the decreased deposition of collagen on Day four, which also started to 
increased since day five (Figure 5.3D). Two hypothesizing reasons explained the efficient depleting 
of fibroblasts. One is that the stroma-vessel structure of desmoplastic bladder cancer determines the 
distribution pattern of systemic delivered NPs. TAFs that distributed along the vessels would be the 
first target for combo NPs. The other is that myofibroblasts were likely to be more sensitive to 
Combo NPs than that of bladder carcinoma cells.   
5.4.4 Synergistic effect induced by tumor accumulation of GMP NPs and Cisplatin NPs 
To examine the aforementioned hypothesis, in vitro toxicity analysis of combined GMP and 
Cisplatin free drugs and nanoparticles was performed after 48 h treatment of UMUC3 cells (Figure 
5.4A and B) or NIH3T3 cells (data not shown). The combination index (CI) was calculated using a 
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series of molar ratios and amounts of GMP and Cisplatin. CI values were analyzed according to Chou 
and Talalay [18] using CompuSyn software (ComboSyn, Inc., Paramus, NJ, USA). From the CI vs Fa 
plot (Figure 5.4C), Synergy, as indicated by a CI < 1, occurred over a broad range of drug ratios. The 
CI fell between 0.1 and 0.3 occurred when GMP and Cisplatin were present at molar ratios ranging 
from 10: 1 to 1: 1. When the cytotoxicity study of GMP NPs and Cisplatin NPs was investigated, the 
combination of GMP NPs and Cisplain NPs at ratio of (10:1) was indicated to exhibit better 
performance over single nanoparticles alone over a range of concentration with the lowest IC50. 
Synergy was also observed in Figure 5.4D when molar ratio of GMP NPs to Cisplatin NPs at 10:1 
with CI < 1. Further evaluation on NIH3T3 using the same ratio NPs combination suggest that 
NIH3T3 has similar and comparable sensitives (data not shown). Gemcitabine has been reported to 
affect the expression of key proteins involved in nucleotide excision repair (NER) and mismatch 
repair (MMR), thereby inhibiting repair of DNA damage caused by Cisplatin (Figure 5.7) [21]. 
Synergy between gemcitabine and Cisplatin might be related to the reduced DNA repair of intra-
strand and possibly inter-strand cross-links of Cisplatin [22]. The comparably potent synergistic effect 
in fibroblasts is one important mechanism for the observed potent stromal depletion effect.  
Next, we investigated the synergistic effect of Combo NPs and Combo Free in vivo. The 
resulting pharmacokinetics (Figure 5.5) suggests that Combo NPs provides advantages over Combo 
Free. About 40% to 45% of the GMP NPs were retained in the blood circulation after 2 h after bolus 
administration, while the free GMP was rapidly cleared within 20 min. AUC and half life of Cisplatin 
NPs 1.4 to 1.7 times higher than that of Cisplatin free drug, which had more than 80% been cleared at 
the first 20 min. Incorporation of GMP and Cisplatin in lipid bilayer coated nanoparticles modified 
with hydrophilic polyethylene glycol increased the drug retention in the circulation, reduced the drug 
clearance, consistent well with our previous pharmacokinetic studies [16]. However, there are 
significant discrepancy in the PK profile of GMP NPs and Cisplatin NPs. One explanation for the 
difference is that GMP NPs with highly positive charges (11.5 mV) are more likely to bind with 
serum proteins, leading to longer circulation in the system but lower tissue distribution; however, 
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Cisplatin NPs with relatively neutral charges (5.6 mV) worked in the opposite way. Moreover, 
Cisplatin NPs produced a slightly higher accumulation than GMP NPs in tumor after a single 
injection (Figure 5.4E). Both nanoparticles showed significantly higher tumor accumulation (more 
than 10% of injected dose per gram remained in the tumor 10 h post injection) than the free drugs 
(less than 2% of injected dose per gram left 10 h post injection). The possible reason is the 
phenomenon known as enhanced permeability and retention (EPR). The vasculature of tumors is 
comprised of poorly aligned and defective endothelial cells lacking innervation [23,24]. Nanoparticle 
formulations can increase tumor accumulation through the EPR effect and with a specific targeting 
ligand can enhance tumor cell uptake through a receptor mediated pathway. 
The ratio of GMP to Cisplatin (mol: mol) in tumor after Combo NPs injection, which is in the 
synergistic range of nanoparticles (Figure 5.4B) was 8.35:1, and 6.75:1 at 5 h and 10 h after injection 
(Figure 5.4E); therefore, a synergistic effect took place. The GMP to Cisplatin molar ratio for the 
Combo Free injection was much higher than for Combo NPs, and out of the synergistic range (Figure 
5.4C). Since synergistic effect of Combo NP was observed both on tumor cells and fibroblasts (in 
vitro), we further hypothesize that this Combo NP can result in potent anti-tumor effects by 
simultaneously inhibiting the growth of both the tumor cells and fibroblasts [25,26]. 
5.4.5 Anti-tumor effect of combined therapy 
As expected, we report the potent anti-tumor efficacy of the Combo NPs in our stroma-rich 
bladder tumor model at a dose of 16 mg/kg for GMP and 1.6 mg/kg for Cisplatin. We first determined 
whether Combo NPs can exhibit synergistic anti-tumor effects without significant adverse effects 
(Figure 5.6).  
When treatment began on day seven after inoculation, free Cisplatin (1.6 mg/kg) 
monotherapy showed little anti-tumor effect, with Cisplatin NPs being more effective than free drug 
(P < 0.05). Tumor growth was delayed significantly in mice treated with free GMP and GMP NPs 
compared to the control group after multiple doses. In comparison, Combo NPs treated tumors had 
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significantly smaller volume than the other six groups at the end of the experiment, showing growth 
of only 0.3-fold more than the day one tumor volume. No weight loss was observed in any treatment 
group, indicating that the treatment was well tolerated (data not shown). The enhanced tumor growth 
inhibition exhibited by nanoparticles should be attributed to the endocytosis mediated by the Sigma R 
and EPR effect [27], which is also indicated by the tumor accumulation study aforementioned. 
Nanoparticle formulation with specific targeting ligand can increase tumor accumulation through 
EPR effect and enhanced tumor cell uptake through receptor-mediated pathway. Furthermore, in vivo 
maintenance of drug ratios shown to be synergistic in vitro was proved to provide increased efficacy 
in preclinical tumor model [28]. Therefore, the synergistic effect proved by the tumor accumulation 
study, enable the Combo NPs to show the most outstanding effect on tumor growth inhibition in 
comparison with GMP NPs and Cisplatin NPs alone. 
Stroma-rich tumor-bearing mice were sacrificed two days after the final injection and the 
tumors were sectioned for TUNEL assay. In the TUNEL assay(refer to [74]), the Combo NPs 
exhibited the most effective killing effects and induced a 16.1-fold higher amount of apoptotic cells 
compared with control group . This was more potent than the Combo Free treatment group, which 
showed 55.5% less apoptosis than that of the Combo NPs. There was no significant difference among 
Combo Free, GMP NPs and Cisplatin NPs groups (P > 0.05). Free Cisplatin treatment had limited 
ability to induce apoptosis in tumor cells. The results indicate the combination of GMP NPs and 
Cisplatin NPs augment the intrinsic cytotoxicity. This finding is consistent with data in Figure 3 that 
the Combo NPs exerts synergistic anti-tumor effects. 
5.4.6 Tumor vessel permeability 
Passive targeting of liposomal formulations is mediated mainly by the enhanced vascular 
permeability of tumor vessels. To evaluate vascular permeability after Combo Free and Combo NPs 
treatment, tumor bearing mice were intravenously injected with Evans Blue, which binds to serum 
albumin and then tend to accumulate in tissues with leaky vasculature [19]. Vascular permeability 
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was found to be nearly 21.3 and 2.7 times higher in the Combo NPs group than in the Control and 
Combo Free groups, respectively (Figure 5.8). Besides the increasing transport through vasculature, 
the enhanced intratumoral uptake of Evans Blue might also be contributed to tumor priming effect by 
substantial apoptosis caused by pretreatment with single injection of Combo NPs (Figure 5.8), which 
could reduce tumor cell density, expend the interstitial space and then promote the penetration into 
three-dimensional tumor histocultures [31,32]. Further investigation is desired for the mechanism of 
greater tumor uptake of Evans Blue. 
The more pronounced accumulation from Combo NPs could be attributed to the synergistic 
effect of GMP NPs and Cisplatin NPs on the tumor blood vessels: (1) Combo NPs could significantly 
reduce the expression of vascular endothelial growth factor (VEGF) (Figure 5.9), which is an 
important mediator of tumor angiogenesis, and enhance the extent of tumor vasculature abnormalities, 
which impairs the tumor growth [33-35]. This finding is consistent with previous result that Combo 
NPs exerts higher tumor inhibition (Fig. 3); (2) Because of their sensitivity or proximity to tumor 
blood vessels, the TAFs will be first killed by nanoparticles distributed in the stoma and the collagen 
in stroma will be depleted. This depleting effect could possibly be helpful for better distribution of 
antitumor compounds in the tumor area which would hardly have access to the tumor cells otherwise 
[36], and enhance the total drug tumor accumulation and transport to carcinoma cells. 
5.5 Conclusions 
In this study, anti-tumor effects of Combo NPs were investigated in a stroma-rich xenograft 
bladder cancer model. GMP and Cisplatin accumulated in treated tumor tissue at a molar ratio and 
concentration expected to have synergistic anti-tumor effects. Combo NPs’ ability to inhibit tumor 
growth was enhanced relative to Combo Free with no obvious toxicity. The effectiveness of Combo 
NPs could be attributed to its effect on both carcinoma cells and TAFs. The anti-tumor activity of 
Combo NPs may result from the combined effects of TAFs depletion with alterations in collagen 
deposition, increased uptake of chemotherapeutic drugs by the tumor and apoptosis of carcinoma 
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cells. Since the standard first line chemotherapy for muscle invasive bladder cancer is now 
gemcitabine plus Cisplatin [37,38], the result of our study suggest that Combo NPs could be tested 
clinically to replace free drug combination. 
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Figure 5.1 Histopathology of bladder cancer 
Representative H&E and αSMA staining of tumors formed by injection of UMUC3 cells (20×) 
without or with NIH3T3 cells and from patient sections. B. Stroma-vessel architecture of 
UMUC3/3T3 was visualized by immunofluorescence co-staining of αSMA positive TAFs (shown as 
green) and CD31 positive blood vessels (shown as red) C. Tumor growth curve of UMUC3 
xenografts and UMUC3/3T3 xenografts. Measurements were initiated when the tumor volume 
reached ~200 mm3. Tumor growth increment was presented by normalizing to the original volume on 
the 1st day of measurement (Vt/V0) (n = 5). 
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Figure 5.2 Effects of different treatments on the inhibition of fibroblast growth  
Fibroblasts were shown as αSMA positive cells (green). Quantitative results were analyzed by 
Image J and shown as white insert.  
 
 
 
  
PBS GMP Free Cisplatin Free Combo Free 
GMP NP Cisplatin NP Combo NP 
18.2±3.8 % 12.5±2.1 % 15.5±5.6 % 12.2±2.2 % 
8.5±1.6 7.9±2.1 % 2.2±0.8 % 
Green: αSMA (TAF); Blue: DAPI (nuclei) 
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Figure 5.3 Stroma depletion after single dose of combo NPs. 
A. Immunofluorescence double staining for αSMA-positive fibroblasts (red), TUNEL (green) and 
apoptotic fibroblasts (yellow). B. Quantitative results for TUNEL-positive cells and αSMA-positive 
fibroblasts. C. Quantitative results for apoptotic fibroblasts expressed as the percentage of total 
apoptotic cells and fibroblasts. D. Quantitative results for collagen expressed by the area (%). E. 
Masson’s trichrome stain for collagen (blue) in tumor-bearing mice treated with a single injection of 
the Combo NP. Tumors were excised on Day 0 and every 24 h for 7 days for analysis and expressed 
as 0 (Day 0) to 7 (Day 7) in the image. * P <0.05. 
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Figure 5.4 In vitro sensitivities of UMUC3 and NIH3T3 to GMP and cisplatin 
Cytotoxicity study of free drug combination (A) and drug nanoparticles combination (B) at variable 
molar ratios; the corresponding CI vs Fa plot for free drug combination (C); the corresponding CI vs 
Fa plot for drug nanoparticles combination (D), and tumor accumulation of GMP NP and GMP Free 
(Red bars) and Cisplatin NP and Cisplatin Free (Blue bars) at 5 h and 10 h after administration (n = 3) 
(E). 
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Figure 5.5 Pharmacokinetics profiles of GMP (free or NPs) and cisplatin (free or NPs). 
Pharmacokinetic parameters were calculated and listed in the tables. (n = 4) 
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Figure 5.6 Tumor growth inhibition effects of different formulations on desmoplastic bladder 
cancer model (UMUC3/3T3) 
GMP Free, Cisplatin Free, Combo Free, GMP NPs, Cisplatin NPs and Combo NPs were administered 
intravenously every third day for total three injections. Data are mean ± S.D. Statistics are as follows: 
* P < 0.05 vs. Control; #P < 0.05 vs. Combo NP; there is no significant difference among groups 
marked with “#”, n = 5. 
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Figure 5.7 DNA-Platinum adduct formation after combo NPs treatment 
The detection of DNA-Platinum adduct (green) (20×) of Control group (A),Cisplatin NP (Cisplatin: 
1.6 mg/kg) (B), Combo NP #1 (Cisplatin: 1.6 mg/kg, GMP: 12 mg/kg) (C) and Combo NP #2 
(Cisplatin: 1.6 mg/kg, GMP: 16 mg/kg) (D); E. Quantitative results expressed as the percentage of 
DNA-Platinum adduct of each group. *: P < 0.05. 
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Figure 5.8 Evaluation of the tumor vessel leakiness 
Evans Blue staining of mice to determine tumor vessel leakiness. Mice were injected with 100 
mg/kg of Evans blue. After 30 min, the mice were sacrificed, and samples from the tumors were 
removed. The concentration of Evans Blue was then determined spectrophotometrically. Results 
are shown as the mean weight of Evans Blue per gram tissue. * P < 0.05 vs. Control; # P < 0.05 vs. 
Combo NP (n = 3). 
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Figure 5.9 Effects of the combination of GMP NPs and Cisplatin NPs on VEGF expression in 
UMUC3/3T3 bearing mice 
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 CHAPTER 6: NANOPARTICLES WITH PRECISE RATIOMETRIC CO-LOADING 
AND CO-DELIVERY OF GEMCITABINE AND CISPLATIN FOR TREATMENT OF 
DESMOPLASTIC BLADDER CANCER7 
6.1 Summary 
Previous chapter shows that combination of gemcitabine monophosphate (GMP) NPs and 
cisplatin NPs is an efficient stroma depletion strategy and also a potent management of malignancy. 
Synergistic therapeutic outcome is only achieved when cells are exposed to the two regimens at an 
optimal ratio. However, due to diverse physicochemical properties of gemcitabine and cisplatin, no 
free drug cocktails or nanomaterials are capable of co-loading and co-delivering these two drugs at an 
optimal ratio. Herein, we develop a novel nano-platform with precise ratiometric co-loading and co-
delivery of gemcitabine and cisplatin for synergistic anti-tumor effects. Based on previous work, we 
utilize a solvent displacement method to ratiometrically load dioleoyl phosphatidic acid (DOPA)-
gemcitabine monophosphate (GMP) and DOPA coated cisplatin-precipitate nanocores into the same 
PLGA NPs. These cores are designed to have similar hydrophobic surface properties. GMP and 
cisplatin are engineered into PLGA NPs at an optimal synergistic ratio (5:1, mol:mol) with over 70% 
encapsulation efficiency and were ratiometrically taken up by tumor cells in vitro and in vivo. 
                                                   
7This chapter previously appeared as a research article in Advanced Functional Materials. The 
original citation is as follows: Lei Miao, Shutao Guo, Jing Zhang, William Y. Kim and Leaf Huang, 
Nanoparticles with precise ratiometric co-loading and co-delivery of gemcitabine monophosphate and 
cisplatin for treatment of bladder cancer, Advanced Functional Materials, 2014, 24 (42):6601-6611. 
Shutao Guo was listed as a co-first author 
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These PLGA NPs exhibit synergistic anti-cancer effects in the desmoplastic bladder cancer 
model (UMUC3/3T3). A single injection of dual drugs in PLGA NPs can significantly inhibit tumor 
growth. This nanomaterial-system solves problems related to ratiometric co-loading and co-delivery 
of different hydrophilic moieties and provides possibilities for co-loading hydrophilic drugs with 
hydrophobic drugs for combination therapy. 
6.2 Introduction 
Combination therapy is particularly effective in the treatment of HIV/AIDs and cancer. It 
provides a general means to maximize therapeutic efficacy, overcome treatment resistance, and 
diminish adverse effects [267, 268]. Optimized doses and molar ratios of combined drugs are critical 
to promote synergistic rather than antagonistic effects [269-271]. However, differential 
pharmacokinetics and distribution of individual drugs within the conventionally administered 
“cocktail” lead to deviation from the optimized ratio during systemic delivery. This fact makes 
predicting improved in vivo therapeutic outcomes from in vitro synergistic effects a real clinical 
challenge [272]. Nanomaterial-based delivery is one approach to unifying dual-drug pharmacokinetics 
[271]. However, it is rather difficult to load drugs with drastically different physical chemistry into 
the designed nano-carriers, which is why only a few nanoparticulate formulations [273-276] were 
able to reach the goal. Although attempts have been made, precise loading and ratiometric delivery of 
drugs with diverse solubility, steric configuration and other physicochemical properties still remains a 
challenge.[277, 278] Moreover, combining individual therapeutic blocks together without interference 
their own functionalities adds to the complexity of compact nanostructures for combination drug 
delivery [279, 280]. 
Cisplatin is considered the gold standard in several first-line combination therapies.[281] A 
nano-particulate approach used to enhance the ratio-dependent synergistic cisplatin-related 
combination therapy is rarely reported due to the difficulties in loading cisplatin along with other 
types of drugs into a single NPs and the possible chemical interference with other groups of drugs 
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such as nucleic acids [196, 282]. Limited solubility of inorganic cisplatin in both water and oil 
significantly hinders the development of NPs with high drug loading and encapsulation efficacy [177]. 
Gemcitabine monophosphate (GMP), an organic hydrophilic drug, was chosen for combination 
therapy with cisplatin. It is well known that Gemcitabine is widely used as a first line therapy in 
combination with cisplatin for the treatment of bladder cancer. However, Gemcitabine relies on 
nucleoside transporters [283] to enter into cells where it is subsequently phosphorylated by 
deoxycytidine kinase to form active intermediates for DNA synthesis interference. GMP is one of the 
active intermediates of Gemcitabine [284]. Since the addition of the first phosphate group in GMP 
formation is the rate-limiting step, we anticipate GMP to be an efficient therapeutic drug candidate 
with great commercial value that can exhibit a synergistic effect in combination with cisplatin [285, 
286]. Due to the significant difference in physicochemical properties, co-encapsulation of cisplatin 
and GMP is difficult. Therefore, NPs that can ratiometrically co-encapsulate and co-deliver native 
cisplatin and GMP while not compromising the drug activity, are highly desired.  
In the previous chapter, we have prepared dioleoyl phosphatidic acid (DOPA) coated calcium 
phosphate cores with the capability of loading GMP (GMP core) [287]; as well as DOPA coated 
cisplatin cores (CP core), where cisplatin serves as both nanocarrier and anti-cancer drug [177, 288]. 
The surface and size similarities between these two categories of cores provide us a methodology to 
unify these two drugs with drastically disparate solubility and polarity into a standardized 
hydrophobic physicochemical property. Unifying physicochemical characteristics of dual drugs is the 
prerequisite for ratio-controlled loading and delivery.   
Based on this rationale, we report a novel strategy to achieve both precise ratiometric loading 
and delivery of cisplatin with GMP. Cisplatin and GMP were originally formulated into DOPA 
coated CP cores and DOPA coated GMP cores. As shown in Figure 6.1A, PLGA NPs are used to 
incorporate these two separate hydrophobic cores through the solvent displacement method. 
Ratiometric loading of GMP and cisplatin were first examined. With the confirmation of ratiometric 
loading property of PLGA NPs, we further proposed that this dual-drug containing NPs could be 
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ratiometrically delivered to the site of malignancy at the optimal ratio (Figure 6.1B). This hypothesis 
was tested in vitro via release kinetics study and cellular uptake study, and in vivo via tumor 
accumulation analysis. We then hypothesized that co-delivery of both drugs at an optimized ratio 
would result in synergistic anticancer efficacy. A stroma-rich human bladder cancer xenograft model 
was used to evaluate the anti-tumor efficacy of dual-drug containing NPs at optimized ratio [289]. 
Synergistic anti-cancer effect was further determined via protein based mechanistic analysis. To our 
knowledge, this is the first time that cisplatin has been reported to be co-encapsulated with another 
hydrophilic drug in the same NPs with precise ratiometric control.    
6.3 Materials and Methods 
6.3.1 Chemicals and Materials 
Cisplatin was purchased from Sigma-Aldrich (Dorset, UK). Gemcitabine monophosphate 
disodium salt (GMP, purity ≥97%) was kindly provided by Qualiber, Inc. (Chapel Hill, NC). Dioleoyl 
phosphatidic acid (DOPA) was purchased from Avanti Polar Lipids, Inc. (Alabaster, AL). tBOC-
PEG3500-NH2.TFA and mPEG3000-NH2.HCl were ordered from JenKem Technology USA Inc. (Allen, 
TX). Acid terminated PLGA was purchased from DURECT Corporation (Cupertino, CA). p-Anisic 
acid, EDC, NHS, DIPEA, dichloromethane, Igepal® CO-520, triton™ X-100, cyclohexane and silver 
nitrate were obtained from Sigma-Aldrich (St Louis, MO) without further purification. 
6.3.2 Cell Culture and Animals 
The human bladder transitional cell line UMUC3, kindly provided by Dr. William Kim 
(University of North Carolina at Chapel Hill, NC), and the mouse embryonic fibroblast cell line 
NIH3T3 (UNC Tissue Culture Facility) were cultured in Dulbecco’s modified Eagle’s Media 
(DMEM) (Invitrogen, Carlsbad, CA) supplemented with penicillin (100 U/mL), streptomycin (100 
µg/mL) (Invitrogen), and 10% fetal bovine serum (Sigma, St. Louis, MO)/10% Bovine calf serum 
(Hyclone, Logan, Utah), respectively. Cells were cultivated in a humidified incubator at 37 ºC with 5% 
CO2 and harvested with 0.05% trypsin-EDTA before subculture. 
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Female athymic nude mice, 6-8 weeks of age and weighting 18-22 g were supplied by the 
University of North Carolina animal facility and used in all studies. Animals were maintained in the 
Center for Experimental Animals (an AAALAC accredited experimental animal facility) at the 
University of North Carolina. All procedures involving experimental animals were performed in 
accordance with the protocols approved by the University of North Carolina Institutional Animal 
Care and Use Committee and conformed to the Guide for the Care and Use of Laboratory Animals 
(NIH publication No. 86-23, revised 1985). 
6.3.3 Synthesis of PLGA-PEG-MBA and PLGA-mPEG 
Briefly, for the synthesis of PLGA-PEG-MBA, tBoc-PEG3000-NH2.HCl (1 eq), Anisic acid (8 
eq) and DIPEA (4 eq) were dissolved in DCM and added with DIC (8 eq) to react for 26 h to obtain 
MBA-PEG-Boc. After purification and structure confirmation by NMR, Boc was removed using a 
TFA/DCM (1:2, v/v) mixture to achieve MBA-PEG-NH2.TFA. Afterwards, MBA-PEG-NH2.TFA 
was conjugated to PLGA (15 kDa, 0.1 mmol) in the presence of DIPEA and DIC for 26 h and 
purified. PLGA-PEG-MBA structure was confirmed by NMR. In the synthesis of PLGA-mPEG, 
mPEG-NH2.TFA (3000, 0.126 mmol), PLGA (15 kDa, 0.1 mmol) and DIPEA (0.5 mmol) were 
dissolved in 6 ml DCM and reacted with DIC (1.0 mmol) for 24 h.  
6.3.4 Preparation of CP cores and GMP cores.  
Preparations of CP cores and GMP cores were described in the previous chapter.  
6.3.5 Preparation of PLGA/PLGA-PEG/PLGA-PEG-MBA (4:4:2) NPs (PLGA NPs) Loaded 
with cores 
Drug encapsulated cores were loaded into PLGA NPs using a single step solvent dispersion 
method. Briefly, the cores and 2 mg of polymers were dissolved in 200 µl of THF and added 
dropwise into 2 ml of water under constant stirring at room temperature. The resulting NPs 
suspension was allowed to stir uncovered for 6 h at room temperature to remove the THF. The NPs 
were further purified by ultrafiltration (15 min, 3000 × g, Amicon Ultra, Ultracel membrane with 
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50,000 NMWL, Millipore, Billerica, MA). Then, the PLGA NPs were re-suspended, washed with 
water, and centrifuged at 14,000 rpm for 20 min to remove free lipids and micelles, re-suspended and 
centrifuged again at 800 rpm to remove nanocore aggregations. 
6.3.6 Characterization of PLGA NPs 
 DL and EE of cisplatin were measured using Inductively Coupled Plasma-Mass 
Spectroscopy (ICP-MS, NexIONTM 300, Perkin Elmer Inc); LE and EE of GMP were measured both 
by Ultraviolet–Visible Spectrometer (UV, DU®800, Beckman Coulter) and 3H labeled cytidine 5’ 
monophosphate (CMP) [5-3H] disodium salt (Moravek Bio Inc, 1 mCi/mL) incorporation using a 
Liquid Scintillation Analyzer (TRI-CARB 2900 TR, Packard Bioscience Co). The size distribution of 
particles was determined using a Malvern ZetaSizer Nano series (Westborough, MA). TEM images of 
NPs were acquired using a JEOL 100CX II TEM (JEOL, Japan). The NPs were negatively stained 
with 2% uranyl acetate. The composition of PLGA combo NPs was studied using Electron Dispersive 
Spectroscopy (EDS) (Oxford instruments, INCA PentaFET -x3) and X-ray photoelectron 
spectroscopy (XPS) (Kratos Axis Ultra DLD X-ray Photoelectron Spectrometer). 
6.3.7 Cellular Uptake Study in UMUC3 Cell Lines 
UMUC3 cells were seeded into a 12-well plate (1.5 x 105 cells/well) containing 1 ml of media. 
Twenty-four hours later, 1 ml of the free drug combination, targeted PLGA Combo NPs, targeted 
PLGA Sepa NPs, 20%-targeted PLGA Combo NPs and non-targeted PLGA Combo at a 
concentration of 20 μM GMP and 3.8 μM cisplatin were incubated with cells in a serum-free medium. 
Four hours later, cells were treated with RIPA buffer (Sigma-Aldrich). The concentration of cisplatin 
was measured using ICP-MS and GMP was measured as 3H-CMP using a scintillation counter as 
previously mentioned. 
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6.3.8 In Vitro Release and Intracellular Release of cisplatin and GMP from PLGA NPs 
The dialysis technique was employed to study the in vitro release of GMP and cisplatin from 
PLGA in phosphate buffered saline (PBS) (pH 7.4) at 37 °C.  Five hundred μL PLGA NPs loaded 
with 100 μg/mL GMP and cisplatin separately or co-loaded with 100 μg/mL GMP and cisplatin at a 
ratio of 5.33:1 were added into the dialysis tube with a molecular weight cut off of 3000 Da and 
dialyzed against 15 mL PBS (pH 7.4) in a thermo-controlled shaker with a stirring speed of 200 rpm 
at 37 °C for 96 h. In the preparation of GMP cores, a trace amount of radioactive 3H-CMP was mixed 
with GMP to serve as a marker for the entrapped GMP. At each predetermined time point, 400 μL 
samples were withdrawn and replaced with fresh media. Platinum and GMP concentrations were then 
determined by ICP-MS and scintillation analyzer respectively at specified times. All experiments 
were performed in triplicate and the data were reported as the mean ± SD of the three individual 
experiments. Intracellular release of free drugs from the cargos was carried out according to a 
previous protocol. A twelve-well plate of UMUC3 cells was prepared as is mentioned in the uptake 
study and incubated with 20 μM GMP and 3.8 μM cisplatin encapsulated into PLGA Combo NPs. 
After 1, 4, and 16 hours, the cells were treated with 50 μL RIPA buffer (Sigma-Aldrich) at 4°C for 10 
min and the cell lysate was centrifuged at 14,000 rpm for 20 min at 4°C to separate nanoparticle and 
cell lysate from free drugs. Free Drugs and Nanoparticles were measured using ICP-MS and 3H-
labeled scintillation. All experiments were performed in four replicates and the data reported as the 
mean ± SD of three. 
6.3.9 In vitro Cell Viability on UMUC3 Cells and Analysis of Synergistic Effects of Drug 
Combinations 
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay was conducted to 
evaluate in vitro viability of free GMP, cisplatin and their combinations as well as PLGA GMP NPs, 
PLGA cisplatin NPs and PLGA Combo NPs. In Brief, cells were seeded in 96-well plates at a density 
of 3,000 cells per well 24 h prior to drug treatment. Subsequently, cells were treated with free drugs 
and the drug combination with various molar ratios at a series of dilutions in full medium. Following 
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48 h of treatment, 20 μL MTT (5 mg/mL) reagent was added for an additional 4 h incubation period 
at 37 °C. The medium was discarded, the formed formazan salt was dissolved in 150 μL of DMSO 
and absorbance was read at 570 nm using a multidetection microplate reader (Plate CHAMELEON™ 
V-Hidex). Cell survival rates were calculated as normalized to untreated control wells. Each 
concentration was tested in five wells and data presented as mean ± SD. The mean drug concentration 
required for 50% growth inhibition (IC50) was determined with CompuSyn software (Version 1.0, 
Combo-Syn Inc., U.S.) using the median effect equation: Fa=[1+(IC50/D)m]−1, where Fa is the fraction 
of affected cells, D is drug concentration and m is the Hill slope. 
Combination Index (CI) Analysis of free drug combination based on the Chou and Talalay 
method[290] was conducted using CompuSyn software. Briefly, for each level of Fa, the CI values 
for GMP and Cisplatin combinations were calculated according to the following equation: 
CI=(D)1/(Dx)1+(D)2/(Dx)2, where (D)1 and (D)2 are the concentrations of each drug in the combination 
resulting in Fa×100% growth inhibition, and (Dx)1 and (Dx)2 are the concentrations of the drugs alone 
resulting in Fa×100% growth inhibition. CI values for drug combinations were plotted as a function 
of Fa. CI values less than 1 or more than 1 demonstrate synergism or antagonism of drug 
combinations, respectively. Notably, CI values between Fa 0.2 to 0.8 are considered validate.[291]  
6.3.10 Tumor Accumulation of GMP and Cisplatin in Stroma-rich Xenograft Bladder Tumor 
Model 
A stroma-rich subcutaneous xenograft bladder tumor model was established previously in our 
lab (ref). Briefly, UMUC3 (5×106) and NIH3T3 cells (2×106) in 100 μL of PBS were subcutaneously 
co-injected into the right flank of mice with Matrigel (BD Biosciences, CA) at a ratio of 3:1 (v/v). 
When the tumor reached 100-150 mm2 in size, animals were randomly divided into three groups (n=8) 
and intravenously injected with free GMP containing a trace fraction of 3H-CMP and cisplatin 
(Combo Free), PLGA Combo NPs and PLGA Sepa NPs at a dose of GMP 12 mg/kg and cisplatin 1.9 
mg/kg respectively. Four mice from each group were sacrificed at each predestined time point, and 
approximately 45 mg of blood was withdrawn using the tail bleeding method. Tumor uptake of GMP 
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and cisplatin was expressed as the percentage of the injected dose per gram tumor. For measurement 
of GMP, 10 to 20 mg of blood was immediately mixed with 10× NCS® II Tissue Solubilizer 
(Amersham Biosciences, Inc) and digested at 60°C overnight. Three hundred μL of hydrogen 
peroxide (30% in water, Fisher) was added to the samples and vortexed to bleach the blood color, and 
the sample was then mixed with 4 mL scintillation cocktail (Fisher Inc). The 3H radioactivity in the 
blood samples was counted using a liquid scintillation analyzer (TRI-CARB 2900 TR, Packard 
Bioscience Co.). For the measurement of cisplatin, 25 to 35 mg of blood was digested with 400 μL 60% 
nitric acid (Acros Organic) at 70°C overnight and measured by ICP-MS. 
6.3.11 Biodistribution of Dual Drug in Major Organs 
Mice were administered a single dose of Combo Free, PLGA Sepa NPs and PLGA Combo 
NPs respectively at the dose of 1.9 mg/kg cisplatin and 12 mg/kg GMP. Each group contained four 
mice, which were sacrificed 10 h following injection. Tissue samples were digested as previously 
mentioned in the tumor accumulation study and proceeded to quantify cisplatin via ICP-MS and GMP 
via scintillation counter.  
6.3.12 Anti-tumor Efficacy in Desmoplastic Bladder Cancer Xenografts 
On day seven after tumor implantation (tumor size 100-150 mm2), mice were randomized 
into eight groups (n=5) as follows: Untreated Control (PBS), free GMP (GMP free), free cisplatin 
(Cisplatin Free), combination of free GMP and cisplatin (Combo free), PLGA GMP NPs, PLGA 
cisplatin NPs, GMP and cisplatin PLGA NPs mixtures (PLGA Sepa NPs) as well as PLGA Combo 
NPs. IV injections were performed every three days for a total of three injections with a GMP dose of 
12 mg/kg and a cisplatin dose of 1.9 mg/kg. Tumor volume was measured every day. Body weight 
was also recorded. Mice were sacrificed two days after the last injection by CO2 asphyxiation and 
tumors were excised.  
 202 
 
6.3.13 TUNEL Assay 
TUNEL Assay was described in the previous chapter. 
6.3.14 PCNA Assay 
Proliferation of tumor cells after the aforementioned treatments and dosing schedule was 
detected by immunohistochemistry, using an antibody against proliferating cell nuclear antigen 
(PCNA) (1:200 dilution, Santa Cruz). The immuno-histochemistry was performed using a mouse-
specific HRP/DAB detection IHC kit as recommended by the manufacturer (Abcam, Cambridge, 
MA). The percentage of proliferative cells was obtained by dividing the number of PCNA positive 
cells (shown as brown dots) from the number of total cells (blue nuclei stained by hematoxylin) in 
each microscopic field. Ten representative microscopic fields were randomly selected in each 
treatment group for counting. 
6.3.15 Platinum Adduct staining 
The platinum-DNA adducts were detected using anti-cisplatin modified DNA antibodies 
[CP9/19] (Abcam, Cambridge, MA). The sections were incubated with a 1:250 dilution of anti-
cisplatin modified DNA antibody [CP9/19] at 4°C overnight followed by incubation with FITC-
labeled goat anti-rat Ig antibody (1:200,Santa Cruz, CA) for 1 h at room temperature. The sections 
were also stained by DAPI and coverslipped. The sections were observed using a Nikon light 
microscope (Nikon Corp., Tokyo, Japan). 
6.3.16 Western-blot Analysis 
Twenty-four hours after three daily IV injections, UMUC3 bearing mice were sacrificed and 
tumor lysates were prepared. Mouse monoclonal poly(ADP-ribose) polymerase-1 (PARP-1) 
antibodies, mouse monoclonal ERCC1, mouse monoclonal XPA (12F5) and rabbit polyclonal SMA 
antibodies (1:500 dilution; Santa Cruz biotechnology, Inc.) were used as primary antibodies. β-actin 
antibody (1:4000 dilution; Santa Cruz biotechnology, Inc.) was probed as the loading control.   
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6.3.17 Serum biochemical value analysis and hematology assay 
After three injections, blood was collected directly from heart and centrifuged at 4000 rpm 
for 5 min. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea 
nitrogen (BUN) and creatinine levels were assayed as indicators of hepatic and renal function. Whole 
blood was collected from healthy nude mice after three repeated treatments. Red blood cells (RBC), 
white blood cells (WBC), platelets (PLT), hemoglobin (HGB) and hematocrits (HCT) were counted 
for the detection of myelosuppression. Organs (heart, liver, spleen, lung, kidney) were fixed and 
sectioned for H&E staining. 
6.3.18 Statistical Analysis 
Quantitative data were expressed as mean ± SD. The analysis of variance was completed using 
a one-way ANOVA. P < 0.05 was considered statistically significant. 
6.4 Results 
6.4.1 Preparation and Characterization of Single Drug Loaded PLGA NPs  
GMP cores and CP cores were prepared as previously mentioned[177, 287] and characterized 
as 8-12 nm in diameter as determined by transmission electron microscopy (TEM) (Figure 6.2). 
Encapsulation efficiency (EE) of GMP in the GMP core was 60.6 ± 4.3% as measured by absorbance 
of GMP at 273 nm. CP cores were also prepared with an EE of 40.4 ± 1.4% as measured by 
inductively coupled plasma mass spectrometry (ICP-MS). Both GMP cores and CP cores could be 
well dispersed into organic solvent, such as tetrahydrofuran (THF). The above results indicated that 
hydrophilic GMP and cisplatin have been successfully loaded into hydrophobic cores respectively 
and these cores were ready to be further incorporated into PLGA NPs. 
High and comparable encapsulation efficiency of each component is a prerequisite for 
controlled loading of several modalities in the same nanoparticle. Therefore, single drug loaded 
PLGA NPs were initially investigated and characterized. PLGA NPs were originally conjugated with 
polyethylene glycol (PEG) to prolong systemic circulation time and then self-assembled with PLGA 
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and DOPA coated cores into PLGA NPs via single step solvent displacement (Figure 6.1). Briefly, 
polymer and drug containing cores were dissolved in THF, a water-miscible solvent, and poured drop 
wise into water. NPs was formed instantaneously during this rapid solvent diffusion process. AA, an 
agonist of the Sigma R, was also introduced into PLGA NPs as a ligand to enhance internalization in 
epithelium-derived cancer cells, which overexpress the Sigma R [292, 293]. Results in Figure 6.3 
indicate that both GMP and cisplatin in DOPA coated core structures can be encapsulated into PLGA 
NPs separately with high EE (70.6 ± 2.5% and 74.0 ± 10.1%, respectively) at drug loading (DL) of up 
to approximately 5 wt%. This is the first time that GMP and cisplatin have been engineered into 
PLGA NPs using solvent displacement method. This method proved much more efficient than 
loading free gemcitabine and cisplatin into PLGA NPs via the double emulsion method, whose 
maximum loading is only around 1 wt% [294, 295]. Notably, free cisplatin and GMP are quite polar 
and cannot be loaded into PLGA NPs using the solvent displacement method; and thus, DOPA coated 
cores not only provide an approach to load different types of drugs, especially hydrophilic drugs, into 
PLGA NPs using solvent displacement, but also facilitate hydrophilic drugs to be loaded into PLGA 
NPs with higher DL and EE. More importantly, the EE for single free drugs in PLGA NPs using this 
novel preparation method is quite comparable to each other, suggesting the possibility of loading 
different drug moieties simultaneously into the same NPs at similar EE but different dual-drug ratios，
which is one indispensable parameter for ratiometric loading.  
6.4.2 Precise Ratiometric Control over Dual-Drug Loading in Combo NPs 
The success of loading GMP cores and CP cores into PLGA NPs provides us with the 
possibility to encapsulate two different drug-containing cores into a single NPs in a ratiometric 
manner. To confirm that CP cores and GMP cores can be ratiometrically co-loaded into PLGA NPs 
(Combo NPs), several further studies were investigated. Firstly, total feed loading of GMP and 
cisplatin in Combo NPs was fixed at 6 wt% while the feed molar ratio between GMP and cisplatin 
was altered from 0.5:1 to 5:1 (Figure 6.4A). Results indicated that the measured molar ratio between 
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the two drugs in Combo NPs was almost the same as the feed molar ratio (0.52 vs 0.5; 0.97 vs 1; 3.3 
vs 3, 5.3 vs 5) and the EE of both drugs, which all remained above 70% with subtle fluctuation, was 
almost identical as well. Next, the feed molar ratio of GMP to cisplatin was set at 5 (Figure 6.4B). It 
was found that the measured molar ratio of GMP to cisplatin in Combo NPs was approximately 5 
when the total loading of the two drugs was below 6 wt%. Additionally, greater than 80% EE was 
achieved. In both experiments, particle size measured by dynamic light scattering (DLS) was under 
120 nm and polydispersity of the dual drug particles was around 0.2 (Figure 6.5). Thus, these results 
demonstrated that ratiometric loading of distinct types of drugs in DOPA coated cores could be 
achieved over a wide dual drug ratio range and loading efficiency.   
6.4.3 Characterization of Dual-Drug Loaded Combo NPs using TEM and XPS 
To demonstrate that GMP cores and CP cores are homogenously distributed in each Combo 
NPs, we further characterized the Combo NPs with total drug feeding ratio of 6 wt% and feed 
GMP/cisplatin ratio of 5, whose determined loading was 5.5 ± 0.8 wt% and molar ratio between GMP 
and cisplatin was 5.3. TEM revealed Combo NPs as spherical and mono-dispersed with a diameter of 
approximately 90-120 nm (Figure 6.4C), which is consistent with the value measured by DLS 
(average 120 nm) (Figure 6.6). In addition, large quantities of well-dispersed cores were clearly 
clustered in each NPs, further confirming the hypothesis of a nanocapsule-like structure with high and 
efficient drug loading. Notably, each NPs contained a similar amount of cores. However, TEM result 
alone cannot show the homogeneous distribution of cores in NPs. Therefore, we further characterized 
the Combo NPs using high resolution TEM with energy dispersive spectroscopy (EDS) analysis and 
x-ray photoelectron spectroscopy (XPS). Chemical element analysis using EDS indicated that both 
fluorine (characteristic element of GMP) and platinum (characteristic element of cisplatin) were 
present in single NPs (Figure 6.4D). Over 20 particles were analyzed to determine the average molar 
ratio of GMP and cisplatin inside each NPs. The ratio of fluorine to platinum, representing the ratio of 
GMP to cisplatin, was approximately 4.9 ± 1.9, which is comparable to the feed ratio of 5 and the 
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determined ratio in bulk solution of 5.3. This result demonstrated that the two distinct cores were 
present in single NPs and their ratio was precisely controlled. To avoid disturbance of neighboring 
oxygen on fluorine quantification, XPS was carried out to further confirm the ratiometric distribution 
of the two drugs. Combo NPs was dissolved in THF, and a 5 nm layer of particle lysates were 
analyzed by XPS. The spectrum in Figure 6.4E indicates that fluorine could be separated well from 
oxygen, and the calculated molar ratio of GMP to cisplatin was approximately 5.6, similar to the 
results determined using other techniques. Therefore, quantifications from the single particle nano-
layer of particle lysate as well as the bulk solution strongly suggest the fact that the dual-drug 
combination has been successfully, homogenously loaded into single Combo NPs with relatively 
precise ratiometric control. 
6.4.4 In Vitro Ratiometric Control over Dual-drug Cellular Uptake 
In vitro synergy studies of free cisplatin and GMP (Combo free) using Chou-Talalay method 
[290] indicated that Combo free exhibited the strongest synergy at a GMP/cisplatin ratio of 5 in 
human urinary bladder carcinoma UMUC3 cell line [289]. We incorporated 3H-labeled CMP 
(cytidine monophosphate) into single GMP cores in PLGA NPs (GMP NPs) as a marker to detect the 
concentration of GMP. In vitro cellular uptake (Figure 6.6) of free GMP and free cisplatin indicated 
that UMUC3 cells exhibited an equivalent uptake of GMP and cisplatin, suggesting that the feed ratio 
and the actual intracellular ratio of the drug combination was almost identical in the in vitro assay 
(Figure 6.7A). However, the uptake of drugs in the tumor cells in vivo will be much different due to 
differing PK profiles and the complicated tumor microenvironment. In order to maintain the ratio of 
drugs in vivo and utilize the strongest synergy of Combo free at a GMP/cisplatin ratio of 5, PLGA 
NPs with a total drug loading of 5.5 ± 0.8 wt% and molar ratio between GMP and cisplatin of 5.3 
were further investigated in the following studies. Single drug PLGA NPs with a feed ratio of 6 wt% 
was used for comparison (Table 6.1). Notably, the size of CP cores in single PLGA NPs (cisplatin 
NPs) was smaller (approximately 60 nm) than that of GMP NPs and Combo NPs. This is not 
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surprising considering that CP cores are denser than GMP cores which are mainly composed of 
calcium phosphate.  
Ratiometric cellular uptake of both GMP and cisplatin by UMUC3 cells is a prerequisite to 
evaluating synergistic effects. Cellular uptake of GMP and cisplatin in separate NPs was compared 
with that of the dual-drug combination in Combo NPs (Figure 6.7A). Results indicated that Combo 
NPs ratiometrically transported drugs into cells, which is consistent with the results from Combo free, 
while a mixture of separate NPs (Sepa NPs) cannot maintain the predetermined ratio of drugs because 
smaller cisplatin NPs deliver their cargo into cells more efficiently than the larger GMP NPs. This 
ratiometric uptake of Combo NPs was also observed over a longer incubation of NPs with cells 
(Figure 6.7B).  
6.4.5 In Vitro Ratiometric Control over Dual-drug Release from PLGA NPs 
After verifying that Combo NPs can ratiometrically transport the drugs into cells, we then 
studied the extracellular and intracellular release of Combo NPs. The in vitro release kinetics of 
cisplatin and GMP from Combo NPs, cisplatin NPs and GMP NPs were first investigated via dialysis 
in PBS (pH=7.4) at 37 °C for 96 h. The amount of platinum released from NPs was measured by ICP-
MS, while 3H-labeled CMP served as a marker for the measurement of GMP. It is notable that only 
negligible burst release was observed when the drugs inside DOPA-coated cores were encapsulated in 
PLGA NPs (Figure 6.7C), although burst release phenomenon is well known and commonly 
observed for hydrophilic drugs in PLGA nanoparticulate formulation [294-296]. For example, 
cisplatin incorporated PLGA15K-PEG5000 NPs have shown a burst release in the initial 4 h with a 
release fraction of approximately 50% and gemcitabine encapsulated PLGA NPs have shown 60% 
liberated drug in the initial 6 h [294, 297]. This suggests that the DOPA layer prevents burst release 
of GMP and cisplatin from PLGA NPs. Release kinetics of these two drugs in combination was 
further analyzed by grouped t-tests, which showed that there was no significant difference between 
these two drugs (P = 0.78). This observation suggests that dual drugs in Combo NPs followed a 
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ratiometric release profile. The subtle difference in release rate may be due to the different 
composition of CP cores and GMP cores, yet the difference can be neglected when compared to the 
release rate of drugs from PLGA NPs, which is a key rate-limiting step of the procedure. This 
indicates that release of cisplatin and GMP can be controlled at a similar rate and in a ratiometric 
manner when co-encapsulated into single PLGA NPs.   
Intracellular release of drugs from Combo NPs was then studied. UMUC3 Cells were first 
incubated with Combo NPs for 1, 4, or 16 h and subsequently washed. At each time points, cells were 
lysed with RIPA buffer, followed by separation of NPs and free drugs via centrifugation at 16,000 g 
for 20 min. We found this method can extract more than 98% of NPs and free drugs from cells with 
little destruction of NPs. Results in Figure 6.7D indicated that a controlled and ratiometric release of 
cisplatin and GMP were also observed in the UMUC3 at the cellular level.   
6.4.6 In Vitro Synergistic Effect of Combo NPs 
The in vitro cytotoxicity of free drugs and drug-loaded PLGA NPs were evaluated by using 
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Results showed that 
although subtle differences between the half-maximal inhibitory concentration (IC50) of free cisplatin 
and cisplatin NPs existed, GMP NPs resulted in a much lower IC50 of 17.8 μM compared with GMP 
free drug (IC50 of 34.8 μM), indicating that targeted NPs delivery can maintain or enhance the 
cytotoxicity in vitro (Figure 6.7E). In addition, data revealed blank PLGA NPs containing CaP core 
with negligible toxicity (data not shown). To validate the in vitro synergistic effect of Combo NPs 
with dual-drug molar ratio of 5.3:1 (GMP:cisplatin), the combination index (CI) was further 
determined using the isobologram equation of Chou–Talalay [290]. As shown in Figure 6.7F, Combo 
NPs displayed an overall CI value < 1 when Fa value was in the validated range of 0.2 to 0.8, 
indicating the pronounced and clear synergy of PLGA combo therapy in vitro. 
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6.4.7 In Vivo Anti-cancer Efficacy of Combo NPs on Stroma-riched Bladder Xenograft 
Tumor Model 
As previously mentioned, one of the most fundamental principles behind this formulation is 
to controllably deliver dual drugs into the tumor with an optimized ratio so as to achieve an enhanced 
anti-tumor efficacy in vivo. Therefore, different treatments were evaluated in an aggressive stroma-
rich bladder cancer model, which was established by subcutaneously co-inoculating UMUC3 cells 
along with fibroblast NIH3T3 cells in matrigel. Tumors were allowed to develop until their volume 
reached 100~150 mm3. Tumor bearing mice were then treated with a total of 3 injections at a dose of 
12 mg/kg GMP and 1.9 mg/kg cisplatin in Combo NPs. Cisplatin and GMP prepared in separate 
PLGA NPs (Sepa NPs) were administrated simultaneously in a mixture for comparison. Previous 
study in our lab has shown that blank PLGA NPs have no tumor inhibition effect [298]. As shown in 
Figure 6.8A, free drugs showed little inhibitory effect at the same dose and dose schedule, possibly 
due to low tumor accumulation; while single drugs in PLGA NPs demonstrated an enhanced 
therapeutic efficacy compared with free drugs. This is due to the EPR effect and receptor mediated 
endocytosis mentioned earlier. Dual drugs in Combo NPs inhibited the growth of UMUC3 tumors 
most significantly (Figure 6.8) without reducing the body weight (data not shown), indicating the 
enhanced anti-cancer effect and the safety of cisplatin and GMP in combination compared to single 
drugs. However, when the dual drugs were dosed together in a mixture (i.e., Sepa NPs), tumor 
inhibition seemed to be compromised and the tumor weight on the last day of measurement was 
significantly higher than that of the Combo NPs (Figure 6.8A). To further confirm the potent anti-
cancer efficacy of Combo NPs in the aggressive UMUC3 tumor model, a single injection of high dose 
Combo NPs was administered and compared with low dose at regular dosing intervals. Results 
indicated that GMP and cisplatin in single high dose Combo NPs showed potent efficacy, which is 
comparable to the effect of low dose at regular dosing intervals. Thus, only single injection could 
inhibit tumor growth in the aggressive stroma-rich tumor model (Figure 6.8C). 
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6.4.8 In Vivo Ratiometric Control over Dual-drug Tumor Accumulation in Xenograft Tumor 
Model  
We postulated that Combo NPs were more efficient in inhibiting growth of the tumor than 
Sepa NPs due to the fact that Combo NPs may deliver cisplatin and GMP into the tumor at the 
predetermined optimized synergistic ratio and dose. Tumor accumulation data indicated ratiometric 
accumulation of GMP and cisplatin from Combo NPs over 10 h post injection (Figure 6.8B). 
However, higher uptake of cisplatin NPs and lower uptake of GMP NPs was observed after dosing 
with Sepa NPs. On one hand, smaller particle size (around 60 nm) can account for higher tumor 
accumulation of cisplatin in single PLGA NPs, while on the other hand, compared with 5.5 wt% 
loading of dual drugs in single PLGA NPs, the same dose of 4.4 wt% cisplatin and 4.2 wt% GMP in 
separate PLGA NPs doubles the amount of injected AA modified PLGA NPs, which can result in 
saturation of Sigma Rs and subsequently reduce the accumulation of GMP in tumors. This 
observation suggests advantages in controlling the ratio of drugs in DOPA coated cores in single 
PLGA NPs over a mixture of separate NPs, which have variant physicochemical properties and 
distinct pharmacokinetics. Variations in the loaded ratio and actual amount of drug taken up by tumor 
tissues can directly affect the anti-tumor efficacy induced by synergy. In addition, nanoparticles also 
increased the tumor accumulation of free drugs from 2% ID/g to more than 10% ID/g due to the EPR 
effect and enhanced internalization into tumor cells through a receptor mediated pathway.  
6.4.9 Combo NPs Triggered Significant Tumor Cell Apoptosis and Inhibited Tumor Cell 
Proliferation Effectively In Vivo in Stroma-rich UMUC3 Xenografts. 
Enhanced antitumor efficacy of Combo NPs was confirmed via analysis of apoptosis and 
proliferation. Tumor tissues after treatment were further sectioned for TUNEL (terminal 
deoxynucleotidyl transferase dUTP nick end labeling) assay and PCNA (proliferating cell nuclear 
antigen) immunohistochemistry (Figure 6.9A and B). Results indicated that Combo NPs induced 
apoptosis in 28.8% of cells in UMUC3 xenograft tumors. Dual drugs in Sepa NPs caused more cell 
apoptosis compared with cisplatin NPs and GMP NPs treatment, but were still significantly less 
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efficient in inducing apoptosis than Combo NPs. Free drugs induced few apoptotic cells in vivo, 
probably because the majority of the free drugs were metabolized and cleared before they 
accumulated in the tumor. In addition, the inhibition of tumor cell proliferation was investigated using 
PCNA assay. PCNA is expressed in the cell nuclei during DNA synthesis and can be used as a marker 
for cell proliferation. PCNA results were consistent with those of TUNEL assay. Combo NPs showed 
minimal amounts of PCNA positive cells. These data further illustrated that combined drugs in a 
single NPs inhibited the growth of the tumor through enhanced induction of apoptosis and reduced 
cell proliferation. 
6.4.10 Mechanism of Synergistic Effect of the Dual-Drug Combo NPs 
In order to validate the observed enhanced antitumor effect of Combo NPs is a synergistic 
effect imposed by GMP and cisplatin in the NPs, subsequent studies were designed accordingly from 
a mechanistic basis. It is reported that gemcitabine potentiates the accumulation of cisplatin damage 
by suppressing the expression of key proteins involved in nucleotide excision repair (NER) and 
mismatch repair (MMR), leading to a decreased repair of Pt-DNA adducts, and thereby suppressed 
repair of cisplatin-induced DNA lesions [286, 299, 300]. Therefore, intensified inhibition of DNA 
repair and Pt-DNA adduct removal are two signs of synergistic interaction. The effect of combination 
therapy on ERCC1 and XPA [286], two major proteins with key roles in NER was first examined by 
western blotting and showed that down-regulation of ERCC1 and XPA was induced by GMP free 
drug and enhanced by GMP NPs treatment (Figure 6.9C). Combo NPs almost completely depleted 
the expression of ERCC1 and XPA and was more efficient than Sepa NPs. To study the effect of 
down-regulation of ERCC1 and XPA on Pt-DNA repair, Pt-DNA adducts were stained with FITC-
labeled anti Pt-DNA adduct antibody. As shown in Figure 6.9D, a significant increase in the amount 
of Pt-DNA adducts was observed when tumors were treated with Combo NPs, compared with that of 
Sepa NPs.   
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The level of cleaved PARP and Caspase-3 were observed in order to further investigate the 
relationship of the suppressed DNA repair proteins and apoptosis. During the execution phase of 
apoptosis, intact PARP is mainly cleaved by caspase-3 or caspase-7 to a larger fragment and a smaller 
fragment. Therefore, PARP cleavage serves as a reliable marker of apoptosis [287, 301]. Figure 6.10 
indicated that cleaved PARP was significantly elevated after treatment with Combo NPs, which is 
consistent with the results of the DNA repair proteins and Pt-DNA adduct formation. Caspase-3 was 
also elevated after Combo NPs treatment. Conclusively, Combo NPs exhibited greater efficacy in 
inhibiting DNA repair and suppressing the removal of Pt-DNA adducts, leading to intensified 
apoptosis compared to dual drugs in separate NPs in vivo. These results further verify that Combo 
NPs acted in a synergistic fashion rather than only additive fashion to induce the enhanced anti-cancer 
effect in the stroma-rich bladder cancer xenograft model. 
6.4.11 Evaluation of Systemic Toxicity of Combo NPs 
Another important issue involved with combination therapy is the dual-drug distribution and 
ratio in major organs, as well as, the association of synergistic effects with toxicity in these organs. 
Quantitative bio-distribution analyses of GMP and cisplatin in Combo NPs indicated that the ratio of 
dual drugs remained constant in almost all organs (Figure 6.11). Similar to other nano-platforms, the 
major particle uptake organs were the liver (approximately 20% ID/g tissue) and the spleen 
(approximately 40% ID/g tissue) 10 h post injection. However, free drugs were eliminated rapidly 
from the body leaving the kidney as the major accumulation organ, which also explains the common 
nephrotoxicity of free cisplatin. Due to different particle size, cisplatin and GMP in separate 
nanoparticles presented very different distribution behaviors in vivo. Notably, cisplatin NPs showed 
significantly higher accumulation in spleen, which might be a potential factor for inducing spleen 
toxicity.  
Since the major side effect of GMP is myelosuppression and cisplatin can also induce an 
accumulated decrease in hematopoietic cell counts, a blood routine test was performed on healthy 
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nude mice with three dosages of the 8 treatment groups. Both free GMP and cisplatin significantly 
reduced the levels of red blood cells (RBC), platelets (PLT) and white blood cells (WBC) compared 
to untreated control (Figure 6.13). Combination of these free drugs slightly potentiates the toxicity. 
Although there was an inevitable amount of accumulation of NPs in the liver and kidney, blood 
biochemistry tests showed that NPs coating can slightly alleviate the chemo-drug induced 
myelosuppression. There is no noticeable aggravation of blood toxicity in Combo NPs. WBC, RBC, 
hematocrit (HCT), hemoglobin (HGB) of Combo NPs were all close to the value of the untreated 
control (Figure 6.13).  
Other hematological parameters showed that no detectable damage was caused; aspartate 
aminotransferase (AST), alanine aminotransferase (ALT) and blood urea nitrogen (BUN) analyses 
were all within the normal range (Table 6.2). No noticeable histological changes were seen in H&E-
stained tissue sections of the liver, kidney and spleen (Figure 6.12). These studies demonstrated that 
Combo NPs, with the most significant synergistic therapeutic efficacy, have elevated tumor uptake 
and low spleen accumulation, and as well exhibited no significant toxicity to major organs and tissues. 
Therefore, ratiometric synergistic combination therapy with non-overlapping toxicity is a promising 
strategy in overcoming drug resistance while enhancing anti-cancer effect.  
6.5 Discussion and Conclusion 
Developing NPs to simultaneously encapsulate drugs with different physicochemical properties 
with precise ratiometric loading and delivery is extremely important in the combination 
chemotherapy of malignant diseases. In the present study, we have successfully developed single 
nanocapsule-like PLGA particles with payloads of GMP cores and cisplatin cores. These dual-drug 
loaded NPs exhibited precise ratiometric control over drug loading, cellular uptake, in vitro release 
and in vivo tumor accumulation. Furthermore, this single NPs with well-controlled optimal dual-drug 
ratio exhibited a more significant antitumor efficacy compared with dual drugs in a mixture of 
separate NPs. Overall, our studies provide a solution to the problems of formulating cisplatin and 
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other groups of hydrophilic drugs for ratiometric combination therapy and have therefore 
distinguished this single nanoparticulate delivery platform as an efficient and relatively safe candidate 
in the treatment of human bladder cancer.  
This nanomaterial-system with spatially separated modalities prevents functional interference 
between individual molecules.  Also, this system provides a possible well controlled platform for co-
delivery chemotherapy with other hydrophobic ligand coated inorganic NPs (e.g. ion oxide NPs, gold 
NPs, quantum dots and upconversion NPs) for photothermal and theranostic purposes.  
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Table 6.1 Characteristic features of the optimized single drug PLGA NP and dual Drug PLGA 
Combo NP 
Optimal CDDP PLGA NP GMP PLGA 
NP 
GMP & CDDP PLGA 
Combo NP 
DL (wt%) 4.4 ± 0.6 4.2 ± 0.3 5.5 ± 0.8 
EE (%) 74.0 ± 10.0 69.5 ± 1.6 86.6 ± 1.9 & 92.4 ± 1.6 
 
 
Table 6.2 Effect of different treatments on serum ALT, AST, BUN and creatinine levels 
Treatment BUN mg/dL Creatinine mg/dL AST U/L ALT U/L 
PBS 19 ± 1 0.2 228 ± 13 60 ± 14 
Cisplatin free 25 ± 1 0.2 216 ± 15 59 ± 1 
GMP free 24 ± 2 0.2 122 ± 20 47 ± 3 
Combo free 22 ± 5 0.2 116 ± 18 60 ± 4 
Cisplatin NPs 28 ± 3 0.2 245 ± 22 58 ± 11 
GMP NPs 21 ± 1 0.2 86 ± 6 42 ± 2 
Sepa NPs 29 ± 2 0.3 238 ± 10 55 ± 8 
Combo NPs 18 ± 3 0.2 122 ± 12 52 ± 12 
Normal Range 12 - 33 0.2 - 0.9 54 - 298 17 - 132 
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Figure 6.1 Diagram of PLGA NPs and mechanism of combination therapy.  
A. Fabrication of PLGA-PEG-AA NP (PLGA NPs) containing CP cores and GMP cores via a single 
step solvent displacement method. B. Cisplatin and GMP, which are ratiometrically encapsulated in 
PLGA NPs, are ratiometrically delivered into the tumor and exhibit strong synergistic anti-tumor 
efficacy  
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Figure 6.2 TEM image of GMP cores (A) and CP cores (B).  
GMP and CP cores have similar size and morphology. 
 
  
 
Figure 6.3  EE of GMP in GMP NPs and cisplatin in cisplatin NPs while changing the feed 
loading of single drug cores in PLGA NPs. 
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Figure 6.4 Dual-drug ratiometric loading in Combo NPs.  
A. EE and DL of GMP and cisplatin in Combo NP while the total loading of drugs was fixed at 6 
wt%. B. EE and DL of GMP and cisplatin in Combo NPs while the feed molar ratio of GMP to 
cisplatin was fixed at 5:1. C. TEM image of 5.5 wt% total drug loading of Combo NP with molar 
ratio of GMP and cisplatin of 5.3:1. D. EDS spectra of Combo NP. Both platinum from CP cores 
and fluorine from GMP cores were observed in a single NP indicating actual loading of dual drugs 
in single NP. E. XPS spectrum of Combo NP. Molar ratio of GMP and cisplatin was also 
quantified using atomic ratio of fluorine and platinum. Spectrum of Pt 4F and spectrum of F 1S, 
from which, area of peaks are integrated for atom quantification. 
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Figure 6.5 EE and LD of NPs 
Size and PDI of Combo NPs with total feed loading fixed at 6 wt% (left) or feed molar ratio of 
GMP/cisplatin fixed at 5:1 (right). 
 
 
 
Figure 6.6 Size of PDI of NPs 
Size and PDI of 4.4 wt% cisplatin NPs, 4.2 wt% GMP NPs and 5.5 wt % Combo NPs with molar 
ratio of GMP and cisplatin 5.3:1 were measured by DLS. 
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Figure 6.7 Ratiometric cellular uptake and release of dual drugs from Combo NP.  
A. Uptake of cisplatin and GMP in Combo NPs, Sepa NPs, and free drugs at 37 °C for 4 h in UMUC3 
cells. B. Accumulative uptake of Combo NPs loaded with cisplatin and GMP in UMUC3 Cells. C. In 
vitro release kinetics of cisplatin and GMP from Combo NPs and single NPs in PBS at 37 °C. D. 
Intracellular release of cisplatin and GMP from Combo NPs. E. IC50 of free GMP, cisplatin, and 
Combo free at molar ratio 5.3:1, as well as single drug NPs and Combo NPs at molar ratio 5.3:1. X-
axis indicated the total concentration of dual drugs or single drug formulations. The corresponding CI 
vs Fa plots of Combo NPs and Combo free were shown (F). DL of cisplatin and GMP in Combo NPs 
is 0.8 wt% and 4.6 wt% respectively, while DL of cisplatin and GMP in single NP is 4.4 wt% and 4.2 
wt% respectively. n.s.: no significant difference; * P < 0.05; ** P < 0.01. 
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Figure 6.8 Tumor inhibition effects of free drugs, Combo free, cisplatin NPs, GMP NPs, Sepa 
NPs and Combo NPs on a desmoplastic bladder cancer xenograft (UMUC3/3T3) 
A. Red arrows in panel A indicate time of injection. The tumors were treated with 3 intravenous 
injections at a dose of 1.9 mg/kg cisplatin and 12 mg/kg GMP in all the treatment groups. B. Tumor 
accumulation of cisplatin and GMP was calculated 10 h post injection of Combo NPs, Sepa NPs and 
Combo free at the injection dose of 1.9 mg/kg cisplatin and 12 mg/kg GMP into nude mice bearing 
desmoplastic bladder cancer xenograft tumors. C. Anti-tumor effects of multiple low dosing schedule 
and single high dosing schedule were compared. n = 5; * P < 0.05; ## P > 0.5; n.s: non-significant 
difference. ID/g: injected dose per gram tissue (tumor) D. Representative photo images of mice 
bearing tumors after indicated treatments. 
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Figure 6.9 Mechanistic studies of the combination therapy. 
Apoptosis (A) and proliferation (B) of tumor cells in vivo after administration of different treatments. 
C. Expression of XPA and ERCC-1, common in nucleotide excision repair (NER) systems, after three 
dosage systemic treatments. D. The formation of Pt-DNA adduct (green) in tumor cells detected by 
anti-Pt-DNA adduct antibody after systemic treatment. Bar chart in D is a quantitative analysis of % 
of Pt-DNA adduct in tissue sections. Five randomly selected microscopic fields were quantitatively 
analyzed on Image J. * P < 0.05; ** P < 0.01. 
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Figure 6.10 Western blot of PARP, cleaved PARP, caspase-3 and GAPDH in the tumor lysates 
after 3-dose treatment. 
 
  
 
Figure 6.11 Biodistribution of Combo NPs, Sepa NPs, and Combo free in major organs 10 h 
post intravenous injection into desmoplastic UMUC3/3T3 bearing nude mice.  
(% ID/g tissue: percentage of injected dose per gram tissue) 
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Figure 6.12 HE staining of major drug accumulating organs after three injections of 
treatments. 
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Figure 6.13 Hematological test of whole blood collected from healthy nude mice treated with 3 
doses of free drugs and NPs as indicated 
WBC, white blood cell; HCT, hematocrit; PLT, platelet; HGB, hemoglobin; RBC, red blood cell. If 
not indicated, no significant difference between PBS group and the treatment group. * P < 0.05; ** P 
< 0.01, n = 4) 
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 CHAPTER 7: SUMMARY AND FUTURE STUDIES 
7.1 Summary of Current Work 
In this dissertation, the stroma barriers in desmoplastic tumors and the current strategies to 
overcome the barriers were discussed extensively. In summary, the stroma barriers for nanoparticle 
(NP) delivery and therapy can be classified into two categories, a physical barrier due to dense ECM 
and high interstitial fluidic pressure (IFP); and the stroma cells. Current strategies focus on depleting 
both the ECM and stromal cells to improve the NP perfusion and efficacy. This is particularly for the 
treatment of desmoplastic tumors, where stroma constitute the majority of the tumor mass. Different 
from other types of tumors, tumor associated fibroblasts (TAFs) play an important role in 
desmoplasia. TAFs, on one end, synthesize and secrete major ECM proteins, constituting the physical 
barriers against therapeutic agents’ insult; on the other end, orchestrate an immunosuppressive 
crosstalk among immune cells and tumor cells, escaping immune surveillance. And also, TAFs 
directly facilitate tumor growth, resistance and metastasis through paracrine secretion of growth 
factors and cytokines. Herein, focusing on a stroma-rich desmoplastic bladder cancer xenograft as a 
model of tumor desmoplasia, we investigated the rule of TAFs in modulating the delivery and 
therapeutic outcomes of chemotherapeutic NPs. The data demonstrated that the majority of 
desmoplastic tumors have a stroma-vessel architecture, where TAFs localize in between tumor nests 
and immature tumor vasculatures. This geometrical feature of TAFs causes them as a major binding 
site barrier (BSB) for therapeutic NPs. More than 60% of NPs, in regardless of size and the presence 
of the targeting ligand, are trapped in TAFs after rapid systemic circulation.  
  
227 
 
These off-target distribution of NPs are detrimental to those NPs designed specifically for 
targeting tumor cells. For example, VEGF receptor antibodies designed for blocking the receptors in 
tumor cells failed to respond to the therapy due to internalizations by the less sensitive TAFs. 
Moreover, TAFs would be very likely to generate unexpected off-target effects. Indeed, in a follow-
up study, we found that chronic exposure of fibroblasts to cisplatin NPs activated the synthesis of a 
major survival factor, Wnt16, paradoxically supporting tumor growth and metastasis. Cisplatin has 
been used as a first line therapy for the treatment of bladder cancer. Lipid coated cisplatin NPs (LPC) 
developed previously in our lab have shown promising anticancer effect in various types of tumor 
xenografts, including bladder cancers. However, consistent with cases in clinical trials, resistance 
occurs after chronic exposure and ultimately leads to tumor relapse and treatment failure. Thus, in the 
current dissertation, focusing on the aforementioned observation of TAFs as both a BSB and a 
resistant niche, cisplatin NPs was utilized as a model therapeutic agent to evaluate the combinatory 
strategies relating desmoplasia modulation.  
Since the damage-induced secretion of Wnt16 in TAFs facilitate tumor growth, the first 
strategy we proposed was to knock down the in situ generation of Wnt16. The BSB feature of TAFs 
can be conversely utilized to deliver NPs specifically for TAFs. Therefore, we proposed systemic NP 
delivery of siRNA against Wnt16 for Wnt16 knockdown in TAFs. Indeed, we found the 
downregulation of Wnt16 in vivo in a dose dependent manner. As a result, the neighboring effects 
exposed by Wnt16 to adjacent naïve fibroblasts, blood vessels and tumor cells were abolished. 
Combination of siRNA with cisplatin NPs prolonged the anti-cancer effect and also remodeled the 
tumor supportive TME.       
A more potent strategy of reverting TAFs from tumor supportive to tumor suppressive was also 
proposed utilizing the in situ engineering strategy. In brief, we delivered a gene encoding secretable 
TRAIL to TAFs. The TRAIL-resistant TAFs then became a sTRAIL producing depot, inducing the 
apoptosis of neighboring TRAIL-sensitive tumor cells. The sTRAIL plasmid monotherapy already 
showed promising therapeutic outcome in both desmoplastic bladder cancer and an orthotopic 
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pancreatic cancer. We also unexpectedly found that the TRAIL-producing TAFs were reverted to a 
quiescent state, likely due to the insufficient activation from neighboring apoptotic tumor cells. The 
fibroblasts with a quiescent phenotype further suppressed tumor growth and remodeled the TME. As 
a proof of concept, we observed that the remodeled TAFs and TME facilitated the accumulation and 
anti-cancer efficacy of a second-wave cisplatin NPs, providing a new paradigm for the treatment of 
desmoplasia.      
Another alternative strategy of desmoplasia modulation is stroma depletion. Potent deletion 
agents for both fibroblasts and tumor cells would overcome the damage-induced resistance. We found 
that combination of gemcitabine and cisplatin was more effective in killing both tumor cells and 
fibroblasts compared to monotherapy of each. The combined cisplatin NPs and gemcitabine NPs (in 
separate formulation) induced a prolonged and efficient stroma depletion within 7 days after single 
injection, resulting in prolonged survival. The ratio of combined regimens is crucial to induce 
synergistic rather than antagonist effect. So, in order to improve the combination effect, we designed 
a capsule-like nano-formulation available to ratiometrically co-load and co-deliver cisplatin and 
gemcitabine. As expected, this formulation has shown potent anti-tumor effect compared to those 
being encapsulated separately. Note that, this is the first formulation capable of simultaneously and 
ratiometrically load a hydrophilic drug with a hydrophobic drug.    
7.2 Significance and Novelty of Current Studies 
Overall, the proposed desmoplasia modulating strategies have following advantages:  
(1) The off-target capture of NPs in stroma cells have been originally thought of as a barrier for NP 
delivery, but was utilized herein to its advantage to induce efficient killing of neighboring tumors 
cells or benefit the penetration of a second wave chemotherapy.  
(2) Cytokines play vital rules in regulating the crosstalk between tumor cells and the stromal cells, 
and thus having been used as potent anticancer agents for decades [302]. However, the clinical 
applications of cytokine drugs are usually suffered from severe systemic toxicity. The strategy we 
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proposed here to engineer TAFs into a depot of protein production, allows locally and transient 
expression of cytokines, circumventing the systemic toxicities, inducing potent local modulating of 
the tumor microenvironment.  
(3) The capsule-like PLGA NPs provide a platform of encapsulating hydrophilic drugs with 
hydrophobic moieties with precise ratiometric control. This combination therapy with strong synergy 
would also be a potent stroma depleting agent that improve the therapeutic outcome of desmoplastic 
cancers. 
7.3 Future Expectations 
The idea of in situ engineering of fibroblasts have many other applications. For example, 
engineering the fibroblasts to generate a fusion protein consisting of ligands especially for receptors 
overexpressing on malignant cells, i.e. EGFR, together with toxins, to specifically improve the 
necrosis or apoptosis of neighboring tumor cells. At the same time, the apoptotic cells are capable to 
generate antigen in situ. This, in combined with an antigen presenting cell (APC) stimulation agent, 
would be very likely to facilitate a tumor-specific immune response with a potent memory. Such 
robust host immune responses are considered as a strategy to prolong the tumor inhibition effect, with 
potential of reverting cancers from lethal to chronic disease [303]. 
However, the success of cancer vaccination is strongly hampered by the suppressive tumor 
microenvironment. In situ engineering of fibroblasts also allows the fibroblasts to secrete cytokines or 
antibodies, orchestrating cytokine-mediated crosstalk between infiltrating lymphocytes and the 
resident malignant cells, facilitating potent immune response. For example, future work can also 
investigate the engineering of TAFs to produce Th-1 cytokines, such as IL-12, GM-CSF to boost 
APC stimulation, or to produce antibodies against chemokines or Th-2 cytokines (i.e. IL-6, IL-10) to  
prevent the infiltration of suppressive leucocytes, such as regulatory T cells (Treg) and myeloid-
derived suppressor cells (MDSC). In all the above mentioned strategies, intratumoral penetration of 
NPs would not be a limitation for the therapeutic outcome, which is very beneficial for the treatment 
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of desmoplastic cancers. Besides focusing on TAFs, NPs with tunable size, smart materials and 
effective targeting ligands can be designed to target different cell populations within the tumor mass. 
Multiple NPs with different targets and therapeutic purposes would become another promising 
combination approach for the treatment of desmoplastic cancer in the near future. 
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APPENDIX I TABLE OF ANTIBODIES USED IN THE STUDY 
Antibodies Company Catalog Application 
Anti-αSMA  Abcam Ab5694 WB, IF, IHC, flow 
cyt 
Anti-CD31 Abcam Ab28364 IF, IHC 
Anti-Fibronectin Abcam Ab2413 WB 
Anti-HGF Abcam Ab83760 WB 
Anti-FAPα Abcam Ab53066 WB 
Phosphor-SMAD2 (Ser 465/467) Cell Signaling 3101 IHC 
APC Rat Anti-mouse CD45 BD 
PharmingenTM 
561018 flow cyt 
APC Rat IgG2b, ҝ Isotype Control BD 
PharmingenTM 
553991 flow cyt 
Anti-Rabbit IgG (Alex Fluor® 647 
Conjugate) 
Cell Signaling 4414 IF, flow cyt 
Goat anti-rabbit IgG-HRP Santa Cruz Sc-2030 WB 
Anti-RFP  Invitrogen R10367 WB 
Anti-E cadherin Abcam   
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Anti-N cadherin Abcam   
mouse monoclonal poly(ADP-ribose) 
antibody (PARP, 
Santa Cruz   
rabbit polyclonal anti-Wnt16 
antibodies 
Santa 
cruz/abcam 
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APPENDIX II PRIMERS USED IN THE STUDY 
Primer Species Sequence or 
Applied Biosystems/Ref 
Amplicon 
Length 
Assay 
Locatio
n 
Company Note 
sTRAIL Human Forward: 
GAGGAAATCCTGTCCA
AG 
Reverse: 
GGTTTCCTCAGAGGTG 
98 580 of 
sTRAIL 
Bio-rad, 
Custom Primer 
Assay 
located 
in cover 
of ILZ 
and 
extracell
ular 
domain 
of 
TRAIL, 
exclusive
ly for 
sTRAIL 
TRAIL  Human Hs00234355_m1 93 433 of 
full 
length 
TRAIL 
Invitrogen, 
Taqman®primer 
 
Assay 
located 
to the 
part 
encoding 
extracell
ular 
TRAIL 
domain, 
detecting 
both 
TRAIL 
and 
sTRAIL 
αSMA 
(ACTA2) 
mouse Mm00725412_S1 95 1403 Invitrogen, 
Taqman®primer 
 
Markers 
of TAFs, 
used on 
the 
sorted 
fibroblast
s to 
evaluate 
the state 
of 
fibroblast
s 
Col1a1 mouse Mm00801666_g1 89 4071 Invitrogen, 
Taqman®primer 
Markers 
of TAFs 
PaI-1 mouse Mn00435858_m1 87 1044 Invitrogen, 
Taqman®primer 
Markers 
of TAFs, 
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(Serpine1) 
GAPDH Human Hs02758991_g1 93 728 Invitrogen, 
Taqman®primer 
 
GAPDH mouse Mm99999915_g1 109 117 Invitrogen, 
Taqman®primer 
 
GAPDH Human qHsaCID0015464 - - Bio-rad, 
PrimePCRTM 
SYBR® Green 
Assay 
 
APPENDIX 2  
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